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ABSTRACT 
INTRODUCTION: The magnetic resonance (MR) relaxation parameter T2* is used for non-
invasive assessment of cardiac iron, with low cardiac T2* being associated with left 
ventricular (LV) impairment and the development of heart failure. However, there is very 
little data calibrating cardiac T2* and other MR relaxation parameters to human cardiac iron 
concentration, and the effects of cardiac iron on the right ventricle (RV) are little known. 
METHODS AND RESULTS: We studied the distribution of cardiac iron in a series of post-
mortem hearts from transfusion-dependent patients using mass spectrometry derived iron 
concentration, and compared the results against the MR relaxation parameters T1, T2 and 
T2*. We found variable iron loading between cardiac tissues, but a mainly homogeneous 
deposition of iron in the LV myocardium, apart from a transmural gradient. We established a 
calibration equation for cardiac iron using T2*. Septal iron and T2* were very representative 
of whole-heart values. Cardiac iron was also measurable using T2, but T1 measurement was 
unreliable. Clinical studies of the RV showed a progressive fall in ejection fraction (EF) as 
iron loading increased and we established normal ranges for RV volumes and EF in patients 
with beta thalassaemia major (TM). Finally, a worldwide survey of the clinical use of T2* in 
over 3000 TM patients showed a high prevalence of cardiac iron loading with large regional 
variation, and confirmed that low T2* values are associated with heart failure and death. 
CONCLUSION: In transfusion dependent patients, cardiac iron is deposited variably in the 
cardiac tissues, but is mainly homogenous in the myocardium and can be calculated from 
cardiac T2* using the obtained calibration equation. There is similarity in myocardial 
response to iron loading between the RV and LV. Worldwide data shows a high prevalence 
of cardiac iron loading, but significant variation suggests that undetermined factors may 
influence the loading, of which genetic modulation is a prime candidate. 
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CHAPTER 1: SUMMARY AND OBJECTIVES 
 
For patients with transfusion-dependent anaemias, excess iron from transfused blood 
accumulates in organs and tissues throughout the body, most importantly in the heart, the 
liver and the endocrine organs. Although the greatest concentration of iron is seen in the 
liver, the heart is the most important organ affected, with up to two-thirds of beta 
thalassaemia major (TM) patients dying as a direct result of heart failure due to cardiac iron 
overload [Borgna-Pignatti 1998]. Cardiovascular complications are a late manifestation of 
severe iron loading but once cardiac failure occurs the prognosis is poor [Felker 2000]. 
 
Traditionally, the techniques available to clinicians for monitoring chelation therapy have 
relied either on serial measurement of serum ferritin or liver iron concentration from biopsy, 
neither of which is predictive of the level of cardiac iron [Anderson 2001]. Endomyocardial 
biopsy is difficult to use clinically because of the risk of complications, expense, and 
sampling error from the tiny biopsies [Fitchett 1980, Elliott 2009]. The assessment of left 
ventricular (LV) function by transthroracic echocardiography or multi-gated radionuclide 
angiography (MUGA) is limited by the latency of the effects of iron on the myocardium, with 
typically a long pre-clinical period of severe iron loading before changes in ventricular 
parameters become apparent [Nienhuis 1980, Davis 2004]. Liver iron can be accurately and 
non-invasively determined using a superconducting quantum interference device (SQUID) 
but this technique has very limited availability and cannot measure cardiac iron [Fischer 
2003]. 
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The key to the prevention and successful management of cardiovascular complications lies 
with the early detection of myocardial siderosis and effective therapy with iron chelation. 
Anderson et al [2001] described a cardiovascular magnetic resonance (CMR) method which, 
for the first time, was able to give a reliable non-invasive assessment of myocardial iron. This 
technique uses the measurement of the magnetic relaxation parameter, T2* which is 
progressively shortened by increasing concentration of particulate iron (haemosiderin) in the 
myocardium. Refinements to the original technique have resulted in a robust method for 
measuring cardiac iron which can be performed in a single breath-hold [Westwood 2003, He 
2007]. The measurement of T2* has been shown to be highly reliable and reproducible and 
has rapidly been adopted as part of routine clinical management worldwide [Yardumian 
2008, Cappellini 2007, Tanner 2006, Westwood 2005]. This thesis examines the calibration 
and distribution of iron loading in the heart, with the aim of adding further validation for 
application of the T2* technique. We also explore the effects of iron on the right ventricle, 
and perform a worldwide survey of T2* measurement to examine for regional variations and 
association with clinical outcomes in a large sample size. 
 
Measurement of myocardial T2* depends on the selection of a region of interest in the 
septum of a mid-ventricular slice. The decision to choose this region for the calculation of 
T2* decay was based on the observation of significant susceptibility artefacts arising in other 
areas of the heart. Apart from previous reports which have found that there is a transmural 
gradient of iron from epicardium to endocardium, there is little published data regarding the 
global distribution of iron within the heart and it remains unknown as to whether a surrogate 
measure of iron in the septum is truly representative of the global cardiac iron concentration. 
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Chapter 5 describes a comprehensive study of iron distribution throughout all cardiac tissues 
with data from 12 post-mortem hearts from TM patients. 
 
For the last 10 years, normal and abnormal cardiac T2* ranges have been based on clinical 
observations and outcomes data. The cut-offs have been based on the measurement of T2* in 
healthy volunteers and the observation that patients with cardiovascular complications such 
as heart failure due to cardiac iron overload have very short myocardial T2* values. An 
absolute calibration for cardiac iron has been lacking. Chapter 6 presents the calibration of 
T2* versus absolute iron concentration in post-mortem formalin-fixed cardiac tissue, and 
Chapter 7 extends this investigation to T2 and T1 measurements.  
 
Since 1999, over 600 UK patients with TM have been scanned at the Royal Brompton CMR 
unit. It is known that progressive myocardial iron loading (as measured by T2*) leads to 
worsening LV systolic function and that T2* is highly predictive for the development of 
symptomatic cardiac failure [Anderson 2001, Kirk 2009]. However, there is a paucity of data 
regarding the effects of myocardial iron loading on the right ventricle (RV). As well as this, 
the normal expected ranges for RV volumes and ejection fraction in TM patients with no 
evidence of iron loading are unknown. Previous work has shown that the LV parameters in 
the TM patient cohort are different to normal healthy volunteers. Chapters 8 and 9 describe 
the relationship between T2* and RV parameters as well as documenting the normal expected 
ranges for RV volumes and ejection fraction in TM patients. 
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Since the regular use of T2* for the monitoring of chelation in UK patients, there has been a 
71% fall in numbers of deaths from cardiac iron overload [Modell 2008]. This suggested that 
there had previously been a significant unmet need for monitoring of iron chelation and if this 
level of cardiac iron overload existed in other countries, that there was potential for a 
significant improvement in survival for these patients worldwide. Over 60 international 
centres are now performing regular cardiac T2* assessment for their TM patients. Chapter 
10 presents the results of a survey of the worldwide centres which are routinely performing 
cardiac T2* as part of clinical management. 
 
This thesis is therefore organised into three main parts, namely the study of iron loading and 
its effects on MR relaxation parameters, the effect of iron on right ventricular performance 
and the application of the T2* technique worldwide (figure 1.1). 
 
Figure 1.1. Study organisation. The diagram is an overview of this thesis with main 
subheadings (red) and results chapters (green). 
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In summary, these investigations provide further understanding of how iron loading affects 
the heart and aim to validate a technique which has already made a significant impact on a 
global scale.  
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CHAPTER 2: MYOCARDIAL SIDEROSIS 
2.1 EPIDEMIOLOGY OF TRANSFUSION-DEPENDENT ANAEMIAS 
Inherited disorders of haemoglobin pose a major global health problem with over 300,000 
affected births per year [Modell 2003]. The majority have a sickle-cell disorder but over 
50,000 newborn babies have a major thalassaemia (including at least 30,000 who need 
regular transfusions to survive). Thalassaemia was originally described by Cooley, an 
American paediatrician, in a group of children of Mediterranean descent with severe anaemia, 
splenomegaly and bony deformity [Cooley 1925]. The term thalassaemia is derived from two 
Greek words (θάλασσα, thalassa or ‘sea’ and αίμα, haema or ‘blood’), relating to its original 
description in patients of Mediterranean origin [Whipple 1932] but its endemic distribution 
stretches far beyond the Mediterranean in a broad belt across the Middle East, into India and 
South-East Asia. Due to population migration, thalassaemia is now becoming more common 
in countries where it was once almost absent. In the United Kingdom, according to the UK 
Thalassaemia Register which was last updated at the end of 2003, there are just over 1000 
patients with a transfusion-dependent major thalassaemia, with the largest groups of patients 
originating from Cyprus, India, Pakistan and Bangladesh [Modell 2001, Modell 2008a]. 
Although regular transfusions are life-saving for patients with beta thalassaemia major (TM), 
this benefit is tempered by the harmful effects of iron overload.   
 
2.2 THALASSAEMIA 
The thalassaemias are the commonest single gene disorders and are characterised by a 
reduction or absence of the globin chains of haemoglobin [Weatherall 1997a]. Inheritance is 
autosomal recessive (with rare exceptions) and while there are over 200 documented globin 
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chain mutations, thalassaemia is classified according to the globin chain which is affected. α 
and β thalassaemia are the most important forms but there are also δβ and γδβ subtypes. 
Structural haemoglobin variants are also common in regions where thalassaemia is prevalent 
and it is not uncommon to encounter compound heterozygotes with a thalassaemia gene from 
one parent and a haemoglobin variant from the other, such as haemoglobin E (HbE) / beta 
thalassaemia, or sickle-cell thalassaemia. 
 
Haemoglobin consists of a tetramer of 4 globin chains which combine with a haem moiety, 
responsible for the reversible binding of oxygen. Adult haemoglobin (HbA) has two α chains 
and two β chains (α2β2) whereas foetal haemoglobin (HbF) has two α chains and two γ 
chains (α2γ2). In adults, there is also a small amount of haemoglobin A2 (α2δ2). The genes 
which control globin chain production are located in the globin gene clusters on 
chromosomes 16 and 11. There are multiple mutations which, in general terms, either cause a 
change in the amino acid sequence (leading to a structural change in the haemoglobin 
molecule, as in sickle-cell disease) or a reduced or absent level of globin synthesis (typical of 
thalassaemia). Most haemoglobin variants are rare but some are common in populations from 
regions where malaria is (or was) endemic probably because carrier status provides some 
protection from falciparum malaria.  
 
2.2.1 Beta thalassaemia 
Normal haemoglobin synthesis relies on a balanced production of α and β globin chains but 
in β thalassaemia, there is either an absence of β globin chains (β° thalassaemia) or reduced 
production (β+ thalassaemia). The pathophysiology of β-thalassaemia is related to the 
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imbalance between α and β chains of haemoglobin and the anaemia is a direct result of the 
excess alpha chains which cause the destruction of red cells and their precursors [Nathan 
1966]. Excess α chains precipitate in the immature red blood cells, leading to intravascular 
haemolysis or their destruction in the bone marrow [Clegg 1968]. 
 
With β-thalassaemia, there is marked phenotypic heterogeneity. The spectrum of disorders 
varies from completely asymptomatic conditions with only a minor reduction in β globin 
which are only identified by chance to severe anaemia where lifelong blood transfusion is 
essential for survival. In β-thalassaemia major (TM), haemoglobin production is so reduced 
that normal growth and survival can only be achieved with regular transfusions from infancy.  
Death at an early age is inevitable unless transfusions are given. In β-thalassaemia intermedia 
(TI), an intermediate amount of haemoglobin synthesis occurs which is sufficient for growth 
and development without absolute requirement for regular transfusions, although transfusion 
may be required to prevent later complications such as pulmonary hypertension. 
Thalassaemia trait refers to the asymptomatic heterozygous carrier state which causes mild 
hypochromic microcytic anaemia and is often only diagnosed on routine full blood count. 
 
TM children are asymptomatic at birth but the disease becomes clinically apparent at 4-6 
months onwards due to the physiological switch from foetal (HbF) to adult haemoglobin 
(HbA). Symptoms such as poor feeding, failure to thrive, pallor and infections are common 
manifestations. The profound anaemia causes intense proliferation in the spleen, extensive 
bone marrow expansion and extramedullary haematopoiesis with ineffective erythropoiesis 
leading to worsening of the anaemia and skeletal deformities. Growth retardation and 
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developmental delay result from the anaemia and the energy expenditure required by the 
massive haematopoietic drive. Children who do not receive transfusion die in infancy as a 
result of high output cardiac failure or infection. Regular blood transfusion to maintain 
haemoglobin above 9g/dl suppresses the haematopoietic drive, allowing normal growth and 
development as well as avoiding high-output cardiac failure, skull-bossing and other bony 
deformities that accompany the bone marrow expansion [Piomelli 1969, Pootrakul 1981]. 
 
Transfusion alone has a major impact on survival but without iron chelation, the combination 
of transfused iron (approximately 250mg in each unit of blood) and an inappropriate increase 
in intestinal iron absorption [Brittenham 1994] leads to progressive iron accumulation in 
body tissues and organs. No physiological iron excretory mechanism exists and inexorable 
iron-induced damage occurs in the heart, liver and endocrine organs. However, if the severe 
iron accumulation in the myocardium and endocrine glands can be prevented by iron 
chelation, these complications can be largely avoided. 
 
2.2.2 Alpha thalassaemia 
There are four α-globin genes and α-thalassaemia is caused by the deletion (or less 
commonly, a non-deletional mutation causing inactivation) of 3 or 4 of these genes. 
Haemoglobin H disease, which is due to deletion of 3 out of the 4 α globin genes is a 
clinically mild condition with chronic haemolytic anaemia but deletion of all 4 genes results 
in severe foetal anaemia and, unless intrauterine transfusion can be given, death in utero 
(hydrops fetalis) occurs as α globin chains are an absolute requirement for the production of 
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foetal haemoglobin. As a direct result, α-thalassaemia does not have the same worldwide 
impact as TM. 
 
2.3 OTHER TRANSFUSION-DEPENDENT ANAEMIAS 
Apart from thalassaemia, there are a number of other conditions which require regular 
transfusions and where patients are at risk of iron overload [Weatherall 1997b]. These can be 
divided into hereditary anaemias (sickle cell disorders, red cell enzyme defects, Diamond-
Blackfan anaemia and congenital dyserythropoietic anaemias) and non-hereditary anaemias 
(such as the myelodysplastic syndromes and aplastic anaemia). 
 
2.3.1 Sickle cell disorders 
Sickling disorders result from mutation in the β globin chain which causes a structural 
haemoglobin variant. Inheritance is autosomal recessive. Those with only one copy of the 
HbS gene (sickle cell trait) are generally asymptomatic and only tend to encounter problems 
under conditions of severe hypoxia. Affected patients can be homozygous for the sickle cell 
gene (HbSS), compound heterozygotes with HbS and HbC (HbSC disease) or can have 
inherited a sickle cell gene from one parent and β-thalassaemia from the other (sickle β-
thalassaemia). When red cells are deoxygenated, the amino acid substitution causes 
deformation or ‘sickling’ which leads to aggregation in the microcirculation and vascular 
occlusive or sequestration ‘crises’. There is a chronic background haemolytic anaemia with a 
Hb concentration of 6-10g/dl which is usually well tolerated but painful crises can be 
debilitating and sickling of red cells in the cerebral circulation can lead to the devastating 
complication of ischaemic stroke. Some 24% of sickle cell patients have a stroke by the age 
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of 45 years and as a result, many are now regularly transfused to reduce the amount of sickle 
haemoglobin and prevent this serious complication as well as reducing the likelihood of acute 
chest syndrome, painful crises and growth failure [Verduzco 2009, Walter 2009]. Elevated 
transcranial Doppler velocities are associated with increased stroke risk [Adams 1997] and 
effective primary prevention can be achieved by transfusing those patients at highest risk 
[Adams 1998]. Although most patients with sickle cell disease do not need routine 
transfusion to sustain life, 20% of children are now transfused to reduce potential 
complications. Cardiac dysfunction does occur but it is rarely associated with detectable 
cardiac iron [Wood 2004]. This may be due to the later introduction of regular transfusion 
and the total transfusion burden may be lower than TM. The pathophysiology of the cardiac 
dysfunction is poorly understood and is not solely attributable to either cardiac fibrosis or 
chronic anaemia [Wood 2008a, Raman 2006]. Pulmonary hypertension due to repeated 
pulmonary vascular occlusion may however play a role. 
 
2.3.2 Myelodysplastic syndromes 
Patients with myelodysplastic syndromes may require the same intensity of transfusion as 
those with TM but total transfusion burden is likely to be far lower due to the later initiation 
of regular transfusions [Wood 2008]. Evidence suggests that cardiac iron overload can occur 
after as few as 75 units of blood have been transfused if no chelation therapy is given [Jensen 
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2.3.3 Other rare anaemias 
Patients with pure red cell aplasia (for instance Diamond-Blackfan anaemia), congenital 
dyserythroblastic anaemias and enzyme deficiencies (such as Pyruvate Kinase deficiency) 
can require lifelong transfusion in the same way as TM patients. These anaemias are rare but 
the consequences in terms of the prevalence and severity of cardiac iron loading and cardiac 
dysfunction are similar to those seen in TM patients [Wood 2008, Glanville 2006]. In 
untransfused patients, iron overload may still occur due to the increased iron demand 
associated with ineffective erythropoiesis and increased erythroid activity, stimulating 
excessive gastrointestinal iron absorption [Gordeuk 1987]. 
 
2.4 PATHOPHYSIOLOGY OF MYOCARDIAL SIDEROSIS 
2.4.1 Iron Homeostasis and Overload 
The human body normally contains 40-50mg/kg of iron, most of which (30mg/kg) is present 
in circulating red blood cells as haemoglobin [Gordeuk 1987]. 5-6mg/kg is contained in other 
haem-containing compounds such as myoglobin and iron-dependent enzymes. The rest is 
stored as ferritin and haemosiderin in the bone marrow, liver, spleen and muscle. Only a 
small amount (about 3mg/kg) circulates in plasma, bound to transferrin. Normal iron balance 
involves a turnover of iron recovered from old erythrocytes which is then reused for the 
production of new red blood cells. This efficient cycle involves approximately 0.7mg/kg iron 
per day with only a minimal contribution from intestinal absorption [Cook 1970]. However, 
the ineffective erythropoiesis in TM patients results in a massive increase in iron turnover 
[Hershko 1998]. Iron overload occurs not only as a result of transfused blood but due to 
inappropriate gastrointestinal absorption caused by the downregulation of hepcidin and 
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upregulation of ferroportin [Gardenghi 2007, Origa 2007]. Each unit of red cells contains 
200-250mg of iron and most TM patients require 200-300ml/kg/year of blood [Gordeuk 
1987]. Typically, a regularly transfused TM patient will accumulate 0.3-0.5mg/kg of excess 
iron per day and the clinical effects of iron toxicity usually become apparent when 12-24g 
has accumulated [Gabutti 1994]. Under conditions of iron overload, iron can be found in 
almost all tissues, however this predominantly occurs in either reticuloendothelial cells (bone 
marrow, spleen and liver) or parenchymal cells (in the liver, heart and endocrine organs). 
Whilst accumulation of iron in the reticuloendothelial system is relatively benign, it is the 
accumulation of iron in hepatocytes, myocytes and endocrine cells which results in 
significant organ complications. 
 
Iron is transported in the plasma by transferrin but its capacity is limited such that in severe 
iron overload, transferrin becomes saturated and excess iron appears in the form of non-
transferrin bound plasma iron (NTBI). Transferrin iron is closely regulated by transferrin 
receptor uptake but free iron requires reduction from its ferric (Fe
3+
) to the ferrous (Fe
2+
) 
form before it crosses the cell membrane via membrane-bound ion channels (such as the L-
type calcium channel) acting as divalent cation transporters [Oudit 2003].  It is the toxicity of 
the unbound iron that is responsible for the pathophysiology of tissue and organ damage. This 
labile iron may be present in the plasma as NTBI or as labile iron within cells. It promotes the 
generation of free hydroxyl radicals (the formation of which is catalysed by free iron through 
the Haber-Weiss reaction) and causes damage to cell membrane lipids and proteins by 





 ATPase and 5’-nucleotidase) are the primary targets of iron toxicity and, due to their 
key role in maintaining the cell membrane potential, damage causes functional cellular 
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abnormalities (with impaired contractility and arrhythmias in cultured cardiac cells) [Link 
1994a]. Labile iron also causes impaired mitochondrial respiration [Bacon 1985, Link 1998] 
and increased lysosomal fragility in myocytes [Link 1993]. Disruption of lysosomal 
membrane integrity releases hydrolytic enzymes such as β-hexosaminidase which cause 
damage to other cellular organelles and may result in cell death with loss of myofibres [Weir 
1984, Kolnagou 2008]. Cardiolipin, a major phospholipid component of the inner 
mitochondrial membrane is particularly sensitive to peroxidative injury and damage to this 
also leads to the inactivation of key enzymes in the mitochondrial respiratory chain [Hershko 
1996]. The rate of uptake of low molecular weight iron into cultured rat myocytes is over 300 
times greater than transferrin-bound iron [Link 1985]. Where there is a high tissue iron 
content, transferrin-mediated uptake is inhibited by downregulation of transferrin receptors 
but low molecular weight iron uptake is paradoxically increased in a maladaptive positive 
feedback loop [Randell 1994]. Iron has been implicated in the aetiology of many different 
vascular and inflammatory disorders [Kell 2009], but it is the myocardial toxicity that plays 
the major role in TM patients. 
 
2.4.2 Intracellular iron 
Intracellular iron is stored as ferritin and haemosiderin in the cytosol. Each molecule of 
ferritin has the ability to sequester up to 4500 atoms of iron. Ferritin consists of a spherical 
protein shell of 24 subunits and iron is stored in a hydrous ferric oxide mineral ferrihydrite 
core [Harrison 1996]. At low levels of intracellular iron, ferritin is relatively dispersed within 
the cytosol but as iron concentration increases, small clusters of ferritin appear. Further 
increase in cytosolic iron concentration triggers ferritin accumulation within lysosomes. 
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Ferritin is then degraded within the lysosomes, resulting in aggregation of the iron cores and 
the formation of insoluble haemosiderin, which has a much slower turnover than ferritin.  
 
Iron which is in transit between transferrin and ferritin exists in a weakly bound low 
molecular weight complex as part of a labile iron pool. The concentration of intracellular 
labile iron is usually 0.3 to 0.5μM but massive iron overload results in an uncontrolled 
expansion which cannot be matched by the sequestrating ability of ferritin. The labile iron 
pool is the target for chelating agents which are able to cross the cell membrane. This 
metabolically active cytosolic iron is in rapid equilibrium with ferritin which can be removed 
quickly with intensive iron chelation but exchange with haemosiderin aggregates takes much 
longer. Myocardial toxicity due to iron overload remains the leading cause of mortality in 
TM patients but is fortunately reversible and preventable by effective iron chelation therapy. 
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Figure 2.1. Cellular uptake of iron and consequences of iron overload. Under normal 
conditions, iron bound to transferrin is taken up into cells via transferrin receptors. Under 
conditions of iron overload, non-transferrin bound iron enters cells via cell membrane 
channels (such as the voltage-dependent calcium channel – VDCC). The iron enters a labile 
pool which can induce free radical formation and cellular damage. Iron is stored as ferritin 
and haemosiderin [Britton 2002 and Porter 2007]. 
 
2.4.3 Myocardial iron deposition and distribution 
Deposition of excess iron occurs throughout the heart [Schellhammer 1967, Buja 1971]. 
Within the myocytes, accumulation of iron occurs mainly in lysosomes which combine to 
form iron-laden secondary lysosomes or ‘siderosomes’ [Kyriacou 2000, Kolnagou 2008]. 
Within the lysosomes, cardiac iron deposits appear as granules containing masses of electron-
dense ferritin particles measuring approximately 60 Å in diameter [Buja 1971]. Initially, 
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deposition occurs in a perinuclear distribution but as iron loading becomes more severe, it 
spreads to involve the whole cytoplasm and progressive ultrastructural changes occur within 
the myocyte [Kyriacou 2000]. 
 
Despite a marked variation in the quantity of iron found in biopsy samples in individual 
hearts [Fitchett 1980, Olson 1989], there is an overall consistent pattern of iron deposition. 
The concentration is greater in ventricular myocardium than in the atria, and higher in the left  
ventricle than the right. Within the ventricular wall, there is a transmural gradient of iron with 
the highest concentration in the subepicardial layer, an intermediate level in the 
subendocardium and the lowest concentration in the mid wall [Buja 1971, Capell 1957, 
Sonakul 1984, Olson 1987, Ghugre 2006]. Iron is also found in conducting tissue [James 
1964, Schellhammer 1967].  The degree of cardiac iron loading is linked to the presence of 
cardiac failure [Buja 1971, Olson 1989] and varies with different types of thalassaemia (such 
as HbE thalassaemia patients who tend to have less myocardial iron despite similar levels of 
transfusion) [Sonakul 1988]. The amount of iron present in the heart is also directly related to 
the degree of ventricular dysfunction and the future risk of developing heart failure 
[Anderson 2001, Kirk 2009]. 
 
2.5 MYOCARDIAL SIDEROSIS AND CARDIOVASCULAR COMPLICATIONS 
2.5.1 Cardiotoxicity and Cardiac failure 
Untreated transfusional iron overload causes cardiac dilatation at around the age of 10 years 
associated with a pattern of left ventricular hypertrophy on the surface 12-lead ECG. A 
substantial proportion of patients also develop pericarditis which may be recurrent [Engle 
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1964]. First degree heart block and atrial ectopics precede the onset of heart failure which is 
reported to occur at a mean age of 16 years and, without chelation, only a minority live 
beyond the age of 20. With the onset of heart failure, worsening atrioventricular block and 
bundle branch block occurs together with more serious cardiac rhythm disturbances. 
Arrhythmias become common with atrial arrhythmias (such as supraventricular tachycardia, 
atrial fibrillation and flutter) more frequent than ventricular arrhythmias (such as sustained 
ventricular tachycardia). Historically, in over half the patients, life expectancy after the onset 
of heart failure was less than 3 months [Engle 1964].  Effective treatment with iron chelation, 
especially when started in early childhood, improves survival and can reduce cardiac 
complications [Olivieri 1994, Brittenham 1994]. However, even in the modern chelation era, 
heart failure is still a leading cause of premature deaths in TM [Zurlo 1989, Borgna-Pignatti 
2004, Modell 2008] and although it can be reversible with intensive iron chelation, once heart 
failure develops, the prognosis is poor [Felker 2000].  
 
2.5.2 Pulmonary hypertension 
Complex abnormalities of pulmonary function can exist in patients with thalassaemia 
including reduced lung volumes, reduced diffusion and hypoxaemia [Grisaru 1990]. The 
prevalence of pulmonary hypertension in thalassaemia major patients varies between reports 
but may be prevented by regular chelation [Aessopos 2004, Du 1997, Derchi 1999, Aessopos 
2005a]. In contrast, it is a prominent finding in patients with thalassaemia intermedia, being 
present in nearly 60%, causing RV failure in approximately 5% [Aessopos 2001, Aessopos 
2005b]. Possible causes of pulmonary hypertension include left ventricular dysfunction, iron-
related damage to the pulmonary vessels, chronic endothelial dysfunction due to nitric oxide 
scavenging effects of free haemoglobin from haemolysis, or thrombotic occlusion of the 
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pulmonary arterioles due to a hypercoagulable state. Although pulmonary hypertension can 
affect right ventricular function, RV dysfunction in TM is more likely to be related to iron 
overload than the result of cor pulmonale [Hahalis 2002]. 
 
2.6 NON-CARDIOVASCULAR COMPLICATIONS OF IRON OVERLOAD  
2.6.1 Endocrine complications 
In TM, endocrine complications (due to iron-induced damage to the endocrine organs) are 
common but potentially avoidable with good attention to chelation therapy [Bronspiegel-
Weintrob 1990]. The commonest problems include secondary amenorrhoea (50%), 
hypogonadotrophic hypogonadism (43%), short stature (34%), diabetes mellitus (18.8%), 
primary hypothyroidism (9%) and hypoparathyroidism (5%) [De Sanctis 2002]. In addition, 
endocrine abnormalities can impact on cardiac assessment in TM as patients are frequently of 
short stature with low body surface area. This causes difficultly when directly comparing 
cardiac volumes and indexation for body surface area is therefore mandatory [Westwood 
2007]. 
 
2.6.2 Liver complications 
Liver disease due to iron toxicity, viral hepatitis, gallstones or drug toxicity is a frequent 
problem in TM and the second commonest cause of death in adults [Zurlo 1989]. 
Transfusion-acquired hepatitis C is one of the most important problems affecting TM 
patients, mainly due to transfusions received prior to 1990 [Cunningham 2004]. Liver iron 
loading and hepatitis C results in increased rates of progression to fibrosis and cirrhosis is 
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present in 10% of patients [Angelucci 2002]. Hepatocellular carcinoma is seen predominantly 
in adult patients with concomitant hepatitis C infection and this is likely to cause more of a 
problem as survival improves and the cohort of TM patients ages [Borgna-Pignatti 2004]. 
 
2.6.3 Bone complications 
If TM patients are inadequately transfused, erythroid marrow expansion causes characteristic 
deformity of the face and skull. These skeletal problems are preventable with adequate 
transfusion [Weatherall 2001] but symptoms from bone disease are frequent in adult TM 
patients. Extramedullary haematopoietic masses, more prominent in thalassaemia intermedia 
patients or under-transfused TM patients, may cause back pain or even spinal cord 
compression [Tantawy 2009]. Very high rates of osteoporosis and osteopenia are observed 
and regular bisphosphonate therapy may be required [Jensen 1998, Voskaridou 2003]. 
 
2.7 CHELATION THERAPY 
Iron chelation therapy is essential to address the potentially devastating consequences of 
transfusion-related iron overload. The ideal iron chelating agent should be orally active, free 
from toxic or teratogenic effects and be able to both prevent and treat the adverse clinical 
effects of iron loading. It should be able to remove toxic NTBI, as well as removing 
intracellular iron from the heart, liver and endocrine organs [Hider 2005]. There are currently 
three licensed agents in clinical use but no single chelator possesses all of these 
characteristics. 
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2.7.1 Deferoxamine 
Deferoxamine mesylate is a naturally occurring iron chelator, produced and purified from 
Streptomyces pilosus. It was first introduced in short-term studies in the early 1960s but 
gained slow acceptance as standard therapy in TM and was limited to countries able to 
support the high cost of treatment [Bannerman 1962]. Since the 1970s, it has revolutionised 
the treatment of TM patients, preventing the iron accumulation and iron-related organ 
damage with a consistent decrease in morbidity and mortality [Olivieri 1997]. Its major 
drawback arises from poor oral bioavailability and rapid metabolism in the plasma that 
mandates parenteral administration of the drug [Callender 1980]. Initially, chronic 
intramuscular injections were used but the development of portable ambulatory pumps 
allowed the necessarily prolonged subcutaneous or intravenous infusions to be given at night 
[Weatherall 1983, Porter 1996]. Deferoxamine is a hexadentate chelating agent with a high 
affinity for iron which is rendered virtually inactive once bound. Free radical formation and 
lipid peroxidation is therefore prevented [Moorhouse 1984]. An early prospective trial 
confirmed a significant reduction in liver iron and fibrosis in patients on chelation when 
compared to controls [Barry 1974] and this was accompanied by improved hepatic function 
[Hoffbrand 1979]. Since the 1980s, observational studies have established the ability of 
deferoxamine to prevent cardiac complications associated with iron overload (including two 
studies of over 10 years’ duration), highlighting the importance of adherence to chelation 
therapy [Wolfe 1985, Olivieri 1994, Brittenham 1994]. Early improvement in cardiac 
function was seen (using techniques such as exercise radionuclide angiography) in patients 
with symptomless cardiac dysfunction taking deferoxamine when compared to controls 
[Freeman 1983] and intensive therapy is able to reverse severe iron-overload cardiomyopathy 
with significant improvement in LV ejection fraction [Marcus 1984, Rahko 1986, Aldouri 
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1990, Davis 2000, Miskin 2003, Anderson 2004]. This has translated into a direct reduction 
in morbidity and mortality with improved long-term survival [Modell 1982, Weatherall 1983, 
Zurlo 1989], including evidence from a small randomised trial of deferoxamine versus a 
control regimen not including the drug [Modell 1982]. 
 
Drug toxicity is however a limiting factor, particularly in patients without iron loading or 
those on renal dialysis [Porter 1989a]. High doses can lead to severe ocular and neurotoxic 
effects [Davies 1983], in particular otoxicity and deafness [Porter 1989b]. Rapid intravenous 
injection may cause anaphylaxis requiring desensitisation therapy [Miller 1981] and long-
term use may result in growth defects due to cartilaginous dysplasia of the long bones and 
spine [Olivieri 1997]. Perhaps the greatest problem with deferoxamine is the cumbersome, 
arduous nature of the drug delivery regime and this has a major impact on patient compliance 
and therefore the effectiveness of treatment [Porter 2001, Caro 2002, Porter 2007]. 
 
2.7.2 Deferiprone 
The development of the first orally active chelator, deferiprone (L1, Ferriprox®) was a major 
advance and was the result of an extensive search for new therapeutic chelation agents. It was 
first licensed in India in 1995 and subsequently as a second-line therapy in Europe in 1999. It 
is a bidentate chelating agent which is more lipid soluble and has a much lower molecular 
weight than deferoxamine. It is therefore rapidly absorbed when given orally but has a 
relatively short half-life which necessitates three divided daily doses [Al-Refaie 1995]. Doses 
of 75mg/kg/day are required to produce a negative iron balance [Olivieri 1990], which 
equates to about 60% of that seen with a 12-hour infusion of deferoxamine at 50mg/kg 
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[Collins 1994]. Deferiprone suppresses the redox activity of labile plasma iron [Esposito 
2003], as well as reversing the iron-induced peroxidative damage to sarcolemmal enzymes 
[Link 2004b]. It lowers serum ferritin and liver iron but there is limited data from randomised 
trials and some patients do not achieve a net negative iron balance [Hoffbrand 2003, Maggio 
2002]. Observational studies in patients treated with deferiprone showed lower cardiac iron 
levels, better ventricular function and a lower rate of cardiac complications in comparison 
with those taking deferoxamine [Piga 2003, Anderson 2002, Peng 2003, Pepe 2006a]. These 
findings were confirmed in a prospective randomised controlled trial comparing deferiprone 
with deferoxamine which showed an improvement in cardiac iron and ventricular function 
over the course of a year [Pennell 2006]. The lower incidence of cardiac complications and 
number of deaths from cardiac causes has suggested that deferiprone has a powerful 
cardioprotective role [Piga 2003, Borgna-Pignatti 2006]. However, the drug is not without its 
problems. Agranulocytosis is the most serious side effect but GI disturbance, arthralgia and 
liver enzyme abnormalities may also occur [Cohen 2000, 2003]. Initial concerns about 
hepatic fibrosis [Olivieri 1998] have been discounted [Wanless 2002] but this is a 
controversial issue and deferiprone is still unlicensed in North America. Due to the 
uncertainties surrounding the safety and effectiveness of the drug, opinion remains divided as 
to its use [Hoffbrand 2003, Cunningham 2005]. 
 
2.7.3 Deferasirox 
Deferasirox (ICL670, Exjade®) is a new, orally active tridentate chelator with a high 
specificity for iron [Hershko 2001]. Safety and efficacy have been proven [Piga 2006, 
Galanello 2006, Taher 2009] and the drug is as effective as deferoxamine at removing iron 
[Cappellini 2006]. Due to a plasma half-life of 11-19 hours, it can be given in a once daily 
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dosing regimen. Many patients prefer oral medication to deferoxamine and this has a 
beneficial impact on patient-reported outcomes and compliance [Cappellini 2007b, 
Garbowski 2008]. It is well tolerated with the most common side effects being 
gastrointestinal disturbances and rash, although some patients may have a mild elevation in 
creatinine or liver enzymes [Cappellini 2008]. The most recent evidence suggests that 
deferasirox is not only effective at preventing cardiac iron accumulation but also removing 
cardiac iron in iron-loaded patients [Pennell 2010, Wood 2008b, Pathare 2009]. Whilst 
monotherapy is able to remove iron in patients with mild-to-moderate iron stores, it may not 
be adequate to lower cardiac iron in patients with a severe hepatic iron burden [Wood 2010]. 
Further large-scale prospective clinical trials are underway and results are awaited. 
 
Table 2.1. Summary of currently available chelation agents with typical doses. 
 
Deferoxamine Deferiprone Deferasirox 






over 8-12 hours, 
5-7 days/week 
75-100mg/kg daily in 
three divided doses 
20-40mg/kg/day once 
daily 










elevated liver enzymes 
GI disturbance, rash, 
elevated creatinine, 
elevated liver enzymes, 
ocular and auditory 
abnormalities 
Route of excretion Urinary and faecal Urinary Faecal 
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2.7.4 Combination therapy with deferoxamine and deferiprone 
Each of the iron chelators has its own merits and there are important differences in the 
mechanisms of action. The combination of subcutaneous deferoxamine with deferiprone has 
therefore been tried with an initial small-scale non-randomised study [Wonke 1998] and 
proven in a larger, randomised controlled trial [Tanner 2007]. This combination is considered 
to be the most effective method for removing both heart and liver iron [Tanner 2007, 
Berdoukas 2009]. Sequential therapy with 3 or 4 days of one drug followed by the other has 
been shown to be safe but controversy exists as to whether alternating therapy is superior 
than either deferoxamine or deferiprone alone [Galanello 2006, Maggio 2009a and 2009b]. 
Combination therapy has also been shown to be safe and effective in those patients with 
severe iron overload [Tanner 2008] and established heart failure [Wu 2004, Tsironi 2005, 
Tavecchia 2006]. Combined therapy allows a synergistic action between the chelating agents 
with the ability of one chelator to remove iron from the other in an exchange or ‘shuttling’ 
mechanism [Link 2001]. Although deferoxamine crosses the cell membrane, its large size, a 
conformational change on binding iron, and net charge significantly hinder its exit from 
myocardial cells. In the liver, an active transport mechanism ensures that the chelated 
complex can be excreted effectively, but this is absent in the heart.  Deferiprone is a much 
smaller, more lipophilic molecule which readily enters and exits cells and therefore accesses 
and mobilizes intracellular cardiac iron. Deferoxamine has a much higher affinity for iron and 
once iron has been removed from cells by deferiprone, transfer of mobilised iron to 
deferoxamine occurs, resulting in an efficient chelating mechanism [Kattamis 2005]. 
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2.7.5 Other combinations 
While safety has not been proven, daily alternating regimes of deferoxamine and deferasirox 
have been tried and this combination has been reported in small numbers of patients unable to 
tolerate full doses of the chelators [Balocco 2010]. Two year data (again in small numbers of 
patients) is available on the use of unlicensed therapy with the combination of deferoxamine 
and deferasirox [Jetsrisuparb 2010]. In vitro studies have confirmed a shuttling mechanism 
when deferoxamine and deferasirox are co-administered, similar to that observed between 
deferoxamine and deferiprone, indicating considerable iron exchange between the two 
chelators [Hershko 2001].  
 
2.8 TECHNIQUES FOR ASSESSING TISSUE IRON 
The aim of chelation therapy is to ensure that iron loading from transfusions is kept to a 
minimum in order to prevent tissue damage, organ dysfunction and adverse outcomes. As 
mentioned above, detectable ventricular impairment is a late manifestation of severe cardiac 
iron loading and therefore, early detection of cardiac siderosis is essential [Nienhuis 1980, 
Pennell 2005]. Traditional monitoring techniques used for the assessment of cardiac iron all 
have significant shortcomings and will be discussed in turn. 
 
2.8.1 Serum ferritin 
Serum ferritin is still regularly measured in clinical practice but can be misleading. It only 
represents 1% of the total body iron and is an imprecise assessment of total iron storage 
[Brittenham 1993]. Among other factors, it is an acute phase protein which makes it an 
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unreliable marker in the context of acute illness or infection [Olivieri 1997]. Even when 
average ferritin levels over the course of a year are considered, there is no clinically useful 
relationship to myocardial iron although a weak correlation exists [Anderson 2001]. 
 
2.8.2 Liver iron concentration 
Direct measurement of liver iron concentration (LIC) by biopsy is an invasive procedure with 
non-negligible risk. Although LIC levels are affected by fibrosis and heterogeneous iron 
loading, liver biopsy can be used for monitoring of chelation therapy in clinical practice 
[Crisponi 2000]. In longitudinal studies, LIC has been shown to be associated with clinical 
end-points of death and cardiac failure [Brittenham 1994, Telfer 2000] but on cross-sectional 
evaluation, the myocardial iron concentration cannot be predicted by LIC [Anderson 2001, 
Noetzli 2008]. In fact, some patients may have severe liver iron loading with no myocardial 
iron while others have severe cardiac siderosis and minimal iron in the liver [Anderson 
2001]. The LIC can also be measured using techniques which rely on biomagnetic 
susceptometry (such as iron measurement by superconducting quantum interference device or 
‘SQUID’). A SQUID is a very sensitive magnetometer which can measure weak magnetic 
fields (such as the magnetic field induced by movement of a patient with an iron-overloaded 
liver). This technique can be useful for guiding chelation therapy regimens based on liver 
iron but there is a very limited availability and it cannot be used to measure iron in the heart 
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2.8.3 Direct myocardial iron measurement 
Endomyocardial biopsy (EMB) is an invasive procedure (once again with associated risks) 
which may be affected by the heterogeneity of iron loading in the septum with very small 
samples, and there is limited access to experienced operators [Fitchett 1980, Elliott 2009]. 
Therefore, even though this technique is a direct measurement of myocardial iron, it may not 
be representative of whole-heart iron loading. 
 
2.8.4 Ventricular function 
In comparison to non-anaemic subjects, patients with chronic anaemia have different normal 
ranges for left ventricular parameters with a higher indexed end-diastolic volume, LV stroke 
volume and LV ejection fraction [Westwood 2007]. This has an important impact on the 
interpretation of such parameters when monitoring TM patients, as a low ejection fraction 
may signify the onset of LV impairment even though it is still within the accepted range for 
normal individuals. Ventricular function can be monitored using radionuclide, 
echocardiographic or magnetic resonance techniques: 
 
2.8.4.1 Radionuclide measurement of ventricular function 
This technique uses radionuclide ventriculography with multi-gated (MUGA) acquisition to 
derive end-diastolic and end-systolic LV volumes and hence ejection fraction. It was 
previously used routinely for serial assessment of left ventricular function [Marcus 1984, 
Davis 2004] due to the highly reproducible quantification of LVEF. However, its use has 
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declined due to the routine application of magnetic resonance for measurement of the 
myocardial relaxation parameter T2* in conjunction with ventricular volumes and function. 
 
2.8.4.2 Transthoracic echocardiography 
Although echocardiography is widely available and provides a good measurement of left 
ventricular function, changes in ejection fraction or diastolic parameters do not become 
apparent until there has been a prolonged period of severe cardiac iron loading [Vogel 2003, 
Hui 2003]. Tissue Doppler and strain imaging can detect abnormal parameters early but it is 
not clear how this relates to clinical outcomes [Magri 2008]. In a study looking at specific 
tissue Doppler indices, echocardiographic diastolic function parameters were poorly 
correlated with ejection fraction and myocardial T2* and were therefore deemed to be not 
well-suited for risk stratification [Leonardi 2008 and Pennell 2008]. More recent data using 
speckle tracking suggest that this advanced technique can identify a uniform decrease in 
longitudinal and circumferential strain in patients with T2* below 20ms [Garceau 2011]. 
 
2.8.4.3 Cardiovascular magnetic resonance 
The measurement of left and right ventricular volumes and function with CMR is highly 
reproducible and is now considered to be the ‘gold standard’ method for ventricular 
assessment [Maceira 2006a, 2006b], forming an important part of the assessment and 
longitudinal follow-up for patients at risk of myocardial iron overload. 
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2.8.5 Cardiovascular magnetic resonance relaxometry 
Measurement of the decay parameter T2* is a non-invasive procedure which can be 
performed in a single breath-hold. The myocardial T2* value (measured in milliseconds) is 
inversely related to the degree of cardiac iron loading. Studies have shown this to be a robust, 
reproducible and reliable technique for the assessment of myocardial iron [Anderson 2001, 
Westwood 2003a and 2003b, Tanner 2006b, He 2007]. T2* (which is assumed to be 
measuring myocardial iron) shows a consistent relationship to ventricular function. When 
T2* is above 20ms, the majority of TM patients have an LV ejection fraction within the 
normal range. As T2* falls below 20ms, LV ejection fraction also falls with the most marked 
decline seen in those with T2* less than 10ms [Anderson 2001]. Most patients who develop 
cardiac failure have T2* values of less than 10ms [Tanner 2005] and cardiac T2* has been 
shown to be a strong prognostic indicator for the development of heart failure [Kirk 2009]. A 
T2* value >20ms indicates a low risk, 10-20ms intermediate risk and <10ms a high risk of 
cardiovascular events. 
 
Magnetic resonance T2 techniques are useful for measuring liver iron [St Pierre 2004, 2005] 
and in a similar way to myocardial T2*, liver T2* decay can be measured using a single 
breath-hold scan but it requires shorter echo times as the higher iron concentration can lead to 
very short T2* values. A calibration curve has been derived for T2* versus LIC both in 
humans [Anderson 2001] and in animal models [Wood 2005a]. Updated scanner hardware 
with stronger and faster gradients has allowed the echo times to be shortened and this is likely 
to allow more accurate measurement of T2*, especially at higher levels of liver iron loading 
[Garbowski 2009]. These techniques will be further discussed in Chapter 4 ‘Methods’. 
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2.9 SURVIVAL IN BETA-THALASSAEMIA MAJOR 
The introduction of regular transfusion and subsequently chelation therapy has had a 
profound effect on complication-free survival and longevity in TM. However, most children 
born with TM are in low-income countries and transfusion is only available for a fraction of 
those who actually need it. An estimated 100,000 TM patients worldwide are currently 
transfused although almost 90% of patients born with transfusion-dependent TM do not have 
access to regular blood transfusions. Less than half of those transfused obtain adequate 
chelation therapy and at least 3000 people per year die as a result of uncontrolled iron 
overload in their teens or early 20s [Modell 2008b]. 
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Table 2.2. Estimated burden of disease and reach of treatment for beta thalassaemia. World 
Health Organisation data, reproduced with permission from Modell and Darlison, Bulletin o f 
the World Health Organization 2008; 86(6): 417-96. All figures are minimum estimates. 













Total 1386 341 9914 1019 20420 7538 40618 
Transfusion 
dependent 
























- 58 27 91 19 44 39 
No. with 
chelation 






- 1146 28882 1476 28879 1946 59764 
Annual deaths 
due to iron 
overload 
- 57 1444 74 1444 97 2988 
 
 
In developed countries, survival has consistently improved over the last 30 years [Modell 
1982 and 2000, Borgna-Pignatti 1998 and 2004, Kremastinos 2001, Telfer 2006, Chouliaras 
2009]. However, even until recently, mortality statistics were disappointing with only 50% 
survival beyond the age of 35 years [Modell 2000]. Heart failure due to myocardial siderosis 
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was by far the commonest cause of death [Borgna-Pignatti 1998, Li 2002]. Difficulty in 
assessing myocardial iron together with poor compliance with chelation regimes and lack of 
access to specialist centres with expertise in managing TM may all have been contributory 
factors. As mentioned, traditional measures of iron such as serum ferritin and liver iron 
concentration are unable to predict cardiac iron loading [Anderson 2001] and when 
cardiovascular magnetic resonance was first introduced as a non-invasive measurement of 
cardiac iron, a high prevalence of myocardial siderosis and LV dysfunction was found in TM 
patients [Tanner 2006a]. Over the last decade, newer chelation regimes allowing better 
compliance, improved clinical management, guidelines and standards for clinical care 
[Coligandro 2008, Yardumian 2008], regular monitoring using T2* CMR and patient 
involvement have combined to produce a dramatic reduction in deaths from cardiac 
complications [Modell 2008a]. 
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Figure 2.2. Number of deaths of UK patients with Thalassaemia major showing a significant 
fall in the most recent time period. Reproduced with permission from the author (Modell et 
al. J Cardiovasc Magn Reson 2008: 10: 42). 
 
 
Although iron is an essential component of haemoglobin and required for energy generation 
in the mitochondrial respiratory chain, the overload state can have disastrous consequences, 
particularly on cardiac function. Myocardial T2* is being increasingly used as part of clinical 
management and as a primary endpoint (as a surrogate marker for change in myocardial 
siderosis) in many clinical trials. However, it has not been proven that T2* relates directly to 
iron content and controversy remains as to the optimal region of the heart in which to perform 
the T2* measurement. The technique will be further discussed in Chapter 4 ‘Methods’ and 
this thesis will concentrate on the application of CMR T2* in myocardial siderosis. 
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CHAPTER 3: CARDIOVASCULAR MAGNETIC RESONANCE 
3.1 GENERAL PRINCIPLES OF CARDIOVASCULAR MAGNETIC RESONANCE  
3.1.1  Introduction and History 
Cardiovascular magnetic resonance (CMR) is the application of magnetic resonance imaging 
techniques to provide detailed anatomical and functional assessment of the cardiovascular 
system [Pennell 1999]. Nuclear magnetic resonance (NMR) was first used for clinical 
purposes in the late 1970’s and it became widely accepted as a useful imaging modality in the 
1980’s, undergoing a name change to magnetic resonance imaging (MRI) to remove any 
misunderstanding of the word ‘nuclear’. Its application to the cardiovascular system has only 
become possible with the development of ECG gating and rapid imaging techniques which 
allow acquisitions to be made in a single breath-hold. Respiratory-gated techniques also now 
allow the acquisition of high resolution images during free breathing. This chapter will 
describe the components and basic physics associated with CMR [Lee 2006]. 
 
3.1.2  Hardware and Software requirements 
The magnetic properties of hydrogen protons are manipulated, detected and measured to 
produce images and several different components are required in a clinical CMR scanner to 
achieve this (Figure 3.1): 
1. Superconducting magnet. A coil of niobium-titanium wire is wound around a large 
cylindrical core to form a solenoid or electro-magnet. When a constant current is 
passed through the coil, a longitudinal magnetic field (B0) is induced along the axis of 
the magnet bore (referred to as the ‘z’ axis). At liquid helium temperatures (4.2 
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Kelvin), the niobium-titanium becomes superconducting (i.e. there is no resistance 
within the wires and current continues to flow without the need for further energy to 
be added). Once ‘ramped-up’, a superconducting magnet within a clinical MR scanner 
is always on and safety precautions with respect to ferromagnetic objects need to be 
observed at all times. Most modern clinical scanners operate at 1.5 Tesla, 
approximately 50,000 times the strength of the earth’s magnetic field at the equator. 
2. Shim coils. Shim coils are smaller electromagnets within the magnet bore. Current is 
passed through these coils to modify the static magnetic field to ensure that it is as 
homogeneous as possible for imaging purposes. 
3. Transmit coils. Image formation requires the deflection of protons using 
radiofrequency (RF) excitation. These radiofrequency pulses are generated by the 
transmit coils. 
4. Receiver coils. Following an RF pulse of the appropriate frequency, the hydrogen 
nuclei induce a current in receiver coils placed over the body. A variety of coils can 
be used to receive signals and for cardiovascular imaging, these usually have several 
small coil elements (phased array coils) that can receive signal simultaneously. 
5. Gradient coils. For spatial localisation of the signals in order to form an image, the 
main magnetic field needs to be manipulated during the data acquisition. Gradient 
coils vary the strength of the field in three orthogonal directions (x, y and z) to enable 
slice selection and spatial localization of signals in any desired image plane. 
6. Computer hardware and software. All of the above components are connected to one 
or more main scanner computers. A user interface allows the operator to control the 
parameters for acquisition and reconstruction of clinical images.  
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Figure 3.1. The main components of a CMR system. 
 
3.1.3 Basic physics of CMR 
3.1.3.1 Hydrogen nuclei 
Each hydrogen nucleus consists of a single spinning proton (H
1
) with a positive charge and 
can be considered as a small magnet. Outside a CMR scanner, the magnetic moments of 
hydrogen nuclei are randomly aligned and the net magnetisation is zero but when a subject is 
placed within the strong magnetic field in bore of the magnet (termed B0), the nuclei align so 
that there is a net  magnetization, ‘M’ in the direction of the field. Most protons align with the 
field but some are aligned in a higher energy state in the opposite direction, as dictated by 
quantum mechanics (Figure 3.2). The net magnetisation vector (M) is manipulated to 
generate MR images. While other elements such as phosphorous, sodium or fluorine can be 
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used for magnetic resonance, the abundance of hydrogen in the body makes it particularly 
suitable for imaging applications given that 95% of the human body is water (H2O). 
 
Figure 3.2. Precession. Each proton (H
+
) spins (precesses) about the axis of the B0 field. 
When protons are placed within a strong magnetic field, they align themselves so that there is 
a net magnetisation, M in the direction of the field. 
 
3.1.3.2 Precession 
When placed inside a magnetic field, each of the protons is induced to rotate around the 
direction of the field, as shown in the figure above. This motion is known as precession. The 
frequency of precession (f) depends on the strength of the external field (Bo) as described by 
the Larmor equation: 
f  =  γ B0 
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where γ is the gyromagnetic ratio of the nucleus being imaged. For hydrogen nuclei, γ is 
approximately 42.6MHz/Tesla and therefore, for a 1.5 Tesla magnet, the precessional 
frequency of protons is in the region of 64MHz (f = 42.6 x 1.5). 
 
3.1.3.3 Phase and frequency 
The individual nuclei making up the net magnetization vector have a frequency (or angular 
rotation rate) and a phase (which describes their angular position relative to a fixed point). If 
two protons start at the same position but are spinning at slightly different frequencies, they 
will become out of phase, with the phase shift increasing over time. Before the application of 
a radiofrequency pulse, protons within the tissues in the magnet bore lack phase coherence, 
the direction of the spins is completely random and the sum of the transverse magnetisation is 
zero (i.e. aligned with the B0 field along the z axis).  
 
3.1.3.4 Radiofrequency excitation and resonance 
Radiofrequency excitation is used to deflect the net magnetization vector from its equilibrium 
position along the z axis of the main magnetic field (B0) into the transverse plane (x y axis). 
In addition, an RF pulse induces phase coherence such that all protons are spinning together 
at 64MHz around the z axis. However, for any excitation to occur, the RF pulse must also 
precisely match the precessional (Larmor) frequency so that ‘resonance’ occurs. Any B0 
inhomogeneity will affect this resonance and protons which are not spinning at the same 
frequency as the RF pulse will not be excited. This can be used to advantage in certain 
circumstances. For instance, magnetic field gradients can be superimposed on the main 
magnetic field in a given direction using the gradient coils. This causes precessional 
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frequencies to vary in a predictable way and is used to spatially localise the signal and enable 
image formation. Ferromagnetic objects or iron within the tissues will also affect the 
homogeneity of B0, leading either to artefact or properties that can be exploited to measure 
iron concentration. 
 
An RF pulse will deflect the net magnetisation vector from the z axis (Mz) into the transverse 
plane (Mxy) in proportion to the strength and duration of the pulse. The flip angle (α) 
describes the degree of displacement from the direction of the main field. 
 
Figure 3.3 Flip angle. The RF pulse deflects the net magnetisation ‘M’ away from the main 
magnetic field direction along B0 (z axis) towards the transverse (xy) plane. The flip angle is 
used to define how far the net magnetisation is flipped. A: M is aligned along the z axis. B: 
The net magnetisation vector M consists of an Mz component and an Mxy component 
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3.1.4 Relaxation and Recovery 
Following an RF pulse, the magnetisation returns to its original equilibrium state with net 
magnetisation vector M pointing along z and with no transverse magnetisation (Mxy = 0). 
This occurs by two independent processes:  
 
1. Decay of transverse magnetization: Mxy decays to zero through loss of phase 
coherence of the spins (T2* relaxation or decay) and 
2. Recovery of longitudinal magnetisation: Mz returns to its original equilibrium value 
through spin lattice relaxation (T1 recovery). 
 
When the RF pulse is turned off, an induced current can be detected in the receiver coil due 
to the oscillating magnetic field caused by protons spinning in phase with each other. 
Differences in precessional frequencies (caused by (a) field inhomogeneities and (b) random 
time-varying fluctuations in the field caused by proximity of individual nuclei to others) 
mean that the phase coherence of the spins is lost relatively quickly and the measured signal 
rapidly declines. The signal decays to zero when all the protons’ spins are once again 
randomly distributed. The decay is affected two properties, namely the intrinsic properties 
(T2) of the tissue in question and the effect of local magnetic field inhomogeneity (T2 prime 
or T2’). The combination of these two factors is termed T2* decay and is described by the 
equation: 1/T2* = 1/T2 + 1/T2’. The behaviour of the transverse magnetisation after the RF 
pulse is described as ‘free induction decay’. The time constants (T2, T2’ and T2*) of the 
decay curves are defined as the time taken for 63% of the original signal to have decayed. In 
most tissues, except fluids, T2 is in the region of 100ms. 
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Figure 3.3. Free induction decay. An RF pulse flips the magnetisation into the transverse 
plane. The spinning protons induce an alternating current in a detector coil which decays 
exponentially as the phase coherence is lost. 
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Figure 3.4. T2 decay. As protons lose phase coherence, transverse magnetisation decays. 
Assuming there is no field inhomogeneity, the time constant, T2 is defined as the time taken 
for 63% of the original signal to have decayed. 
 
 
The longitudinal magnetisation recovers more slowly than the loss of phase coherence. T1 
recovery is typically 500-1500ms (for tissues other than water) and also follows an 
exponential curve. The recovery occurs due to an energy exchange between the nuclei 
making up the magnetisation vector and the surrounding environment (historically referred to 
as the lattice). The time constant, T1 relates to recovery of 63% of the original transverse 
magnetisation (see figure 3.5). 
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Figure 3.5. T1 recovery. T1 represents the rate of recovery of longitudinal magnetisation. 
The T1 is the time taken for 63% of the original magnetisation to recover. The recovery of 
the longitudinal magnetisation is independent of transverse magnetisation decay. 
 
3.1.5 Spatial localisation and Image Formation 
The challenge of MR imaging lies in spatial localisation, determining which parts of the 
signal arise from which regions of the body to generate a voxel-by-voxel map of signal 
intensity. For 2D imaging, a slice is selected by applying magnetic field gradients such that 
only the protons within a chosen slice are precessing at the Larmor frequency. To achieve 
slice-selection, a ‘slice-select’ gradient is superimposed onto the static magnetic field at the 
same time that an RF pulse is transmitted. This changes the precessional frequency of the 
protons along the gradient and when the RF pulse is applied, only those protons in a slice 
where the precessional frequencies match the frequency content of the RF pulse are excited.  
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Once the slice has been excited, signals from that slice are detected in the receiver coils. To 
localise the origin of the signals generated within the slice, further gradients are applied. 
Localisation in the x direction of the slice is achieved using a frequency encoding gradient. 
Whereas slice select gradients are applied during the RF pulse, the frequency encode gradient 
is applied during sampling of the signal (known as read-out). This gradient causes protons on 
one side of the slice to precess faster than those at the other side, according to the Larmor 
equation and effectively encodes the location of a proton by the frequency of its signal. The 
detected signal will be a composite from all locations within the slice and will have a range of 
frequencies. By applying a Fourier transform, a histogram of the different frequency 
components is generated, giving a map of the signal intensity from each location along the x 
axis. 
 
The final step required is to localise signals from the y direction of the slice. This is achieved 
by applying a short duration gradient along the y axis which changes the phase of proton 
spins. This phase encode gradient is applied at some stage in the pulse sequence after the RF 
pulse but before the echo sampling. When the gradient is switched on, protons at the top of 
the slice will precess at a different speed to those at the bottom of the slice and this difference 
in precessional frequency leads to a difference in phase. The stronger the gradient, the faster 
the dephasing and when the gradient is turned off, protons return to spinning at the Larmor 
frequency but will be out of phase with each other. This process needs to be repeated multiple 
times to achieve different phase shifts in order to localise the signals along the y axis. The 
number of voxels in the y direction of the slice determines the number of times this process 
has to be repeated (number of phase-encoding steps, NPE) for spatial localisation in the y 
direction. 
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3.1.6 Data acquisition and k-space 
Each detected signal or ‘echo’ contains frequency and phase information. This raw data is 
spatially encoded in terms of its frequency and phase (see previous section) and is referred to 
as k-space data. Each phase encoding step generates one line of data which is used to fill k-
space. The central line of k-space contains the data from the echo when the phase encode 
gradient is zero and as there is no proton dephasing, this has the highest amplitude. With the 
highest phase encode gradients, stored at the periphery of k-space, there is significant 
dephasing and the net signal is low because magnetic moments which are out of phase cancel 
each other out. At high phase encode gradients, signal will therefore only be detected at 
sharply defined edges or where there is fine variation in signal (such as blood vessel walls). 
Thus, the periphery of k-space contains high spatial frequency data that is most sensitive to 
fine detail whereas the centre of k-space consists of the low spatial frequency data which 
contains the information about the overall image contrast. The Fourier transform of the k-
space data recreates an image representation of the original slice which can be viewed on a 
computer monitor and saved in a universally recognised format (Digital Imaging and 
Communications in Medicine or ‘DICOM’). Each DICOM file contains an embedded 
‘header’ with an extensive array of information including patient details and all the imaging 
parameters used to acquire the image. The way that k-space is filled during image acquisition 
can be varied by the application of different gradients and certain short-cuts can be used to 
speed up the process (e.g linear versus centric or spiral k-space filling). For example, a rapid, 
single-shot image can be acquired using a technique known as HASTE (Half-Fourier 
acquisition single-shot turbo spin echo) where only just over half of the k-space data is 
collected. The rest of k-space is filled numerically using Hermitian conjugate symmetry, a 
property of k-space that enables computational approximations to substitute for collected 
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data. The consequence of speeding up the process usually means that a compromise is made 
and HASTE images are typically low resolution. 
 
3.2 CMR PULSE SEQUENCES 
There are two main types of sequence used for clinical MR imaging, namely gradient or spin 
echo. These will be discussed in turn. 
 
3.2.1. Spin echo 
After an initial RF pulse with a 90° flip angle, protons are flipped into the transverse plane 
and free induction decay occurs with loss of phase coherence. To generate a spin echo, a 
second 180° RF pulse is applied. This has the effect of refocusing the dephased magnetic 
moments which regain phase coherence and produce a spin echo. The 180° flip angle 
eliminates the effects of magnetic field inhomogeneity (T2’) and the peak amplitude of the 
spin echo decays exponentially according to the T2. The echo time is defined as the time 
between the 90° RF pulse and the peak of the echo. The 180° pulse is applied at half the echo 
time (TE/2) and therefore it is possible to manipulate the echo time of the sequence by 
applying the 180° pulse at half the required TE. After the spin echo, longitudinal 
magnetisation recovers according to T1 recovery. Another 90° pulse can then be applied to 
generate another spin echo. The time between 90° pulses is termed the repetition time (TR). It 
is possible to manipulate image acquisition so that intensity differences are based on different 
relaxation times for different tissues. By altering the TE and TR, images will have either T1 
or T2 weighting. A T1-weighted image is produced using a short TE and TR whereas T2-
weighted image is produced using a long TE and long TR. 
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Figure 3.6. Spin echo. Following the initial 90° pulse, free induction decay (FID) occurs 
(T2* decay). A second 180° pulse causes rephasing of the spins resulting in a spin echo. The 
180 pulse is only able to rephase the dephasing caused by field inhomogeneities while that 
due to spin-spin interactions remains. The peak amplitude of the spin echo consequently 
exhibits exponential decay governed by T2 relaxation. 
 
 
With conventional spin echo imaging, a single line of k-space is filled with each echo. To 
speed up the acquisition, a series of repeated refocusing 180° RF pulses can be used to 
generate a train of echoes which decay according to T2 relaxation. This technique is known 
as fast spin or turbo-spin echo imaging and improves the efficiency of spin echo imaging by a 
factor equal to the number of echoes acquired after each 90° pulse (known as the echo train 
length). 
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For cardiovascular imaging, spin echo sequences are most valuable for studying anatomy and 
the great vessels. 
 
3.2.2 Gradient echo 
A spin echo is formed by two RF pulses, but in a gradient echo sequence, the formation of the 
echo is due to a combination of the RF pulse together with imaging gradients which can be 
switched very rapidly. Following the initial RF pulse, protons precess in the transverse plane 
in phase with each other. Once the RF pulse is switched off, dephasing occurs and the signal 
decays. For gradient echo imaging, a magnetic field gradient is applied which causes 
accelerated dephasing of the protons. A second gradient with opposite polarity is then applied 
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which reverses the dephasing and brings the magnetic moments of the protons back in phase 
at the time of data readout.  
 
The peak of the gradient echo is produced when the phase coherence is at its maximum. The 
time between the RF pulse and the maximum point of the echo is known as the echo time. 
The amplitude of the echo is governed by free induction decay and therefore the MR signals 
from gradient echo are T2* weighted. For gradient echo imaging, a partial flip angle (less 
than 90°) can be used which enables the sequence to be repeated more rapidly as some 
longitudinal magnetisation is left after each sequence repeat. 
 
Figure 3.8. Gradient echo. The echo time (TE) is the time between the RF pulse and the peak 
of the gradient echo which occurs during the application of the rephasing gradient. 
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3.2.2.1 Multiecho gradient echo sequences 
To improve efficiency, multiple gradient echoes can be sampled following each RF pulse. A 
series of gradient reversals are applied to generate a series of echoes that can be used to fill k-
space. The number of echoes that can be generated before free induction decay results in 
complete loss of signal is dictated by the speed of the gradient switching and how fast each 
echo can be sampled. 
 
Figure 3.9. Multiecho gradient echo sequence. Repeated gradient reversals are used to 
generate a series of equally spaced echoes. 
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3.2.2.2 Steady state gradient echo 
Using a series of high flip angle RF pulses of alternating positive and negative sign in quick 
succession with completely rephased imaging gradients, the transverse magnetisation enters a 
steady state with image contrast based on the T2/T1 ratio of the tissues. Blood within the 
heart and blood vessels has high signal intensity and this is useful for cine imaging, especially 
for the heart as the steady-state free precession sequences give excellent blood-myocardial 
border definition.  
 
Figure 3.10. Steady-state free precession. A series of alternating RF pulses allow image 
contrast based on different T2/T1 ratios of the different tissues. This is of particular use for 
cine imaging of the heart. 
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3.2.3 Cine imaging 
For cine imaging, ECG gating is used with the R-R interval divided into a number of cardiac 
phases. Multiple images are acquired at the same slice position to capture different points of 
the cardiac cycle and a video representation of the cardiac function is achieved when these 
are played back in a cine loop. For each temporal phase of the cardiac cycle, an image is built 
up over multiple heart beats with data from each heart beat being used to fill part of k-space. 
This is termed segmented imaging. Prospective, or more commonly, retrospective ECG 
gating is used to assign each ‘packet’ of data to a specific phase of the cardiac cycle. 
 
For prospective ECG gating, the R-wave of the ECG is used as the trigger and data is 
acquired over approximately 90% of the cardiac cycle. The remaining 10% is imaging ‘dead-
time’ where the scanner is waiting for the next ECG trigger to continue the acquisition. In 
retrospective gating, the R-wave of the ECG is detected ‘on the fly’ and the acquired data is 
retrospectively reconstructed into a number of cardiac phases (figure 3.11). 
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Figure 3.11. Cine imaging. The cardiac cycle is divided into phases (typically 25 phases per 
cardiac cycle). A still image from each phase is used to create a cine loop for the assessment 
of cardiac function. 
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Figure 3.12. Segmented cine imaging. For each phase of the cardiac cycle, a still image is 
created. This information required for each image is obtained from the same time point over 
the course of multiple cardiac cycles. 
 
In practice, k-space is covered in an interleaved fashion so as to avoid signal discontinuities 
which result in image artefacts. 
 
3.3 CLINICAL APPLICATIONS OF CMR IMAGING 
Combinations of the sequences described above allow CMR to provide a comprehensive 
assessment of cardiac anatomy and function. Spin echo images (eg. HASTE, T1 or T2 
weighted sequences) are useful for assessing the anatomy of the heart and thorax. Gradient 
echo sequences are used for cine imaging and for assessment of myocardium following 
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gadolinium injection. Cine imaging (with segmented SSFP) is now considered the gold-
standard for the assessment of cardiac volumes and function. Tissue characterisation can be 
performed using T1 and T2 sequences as well as exploiting the paramagnetic properties of 
gadolinium chelates which shorten T1 times. The technique of ‘late enhancement’ uses a T1-
weighted inversion-recovery sequence which can detect scar or fibrosis giving a bright white 
signal where gadolinium accumulates (for instance in scarred myocardium following a 
myocardial infarction). CMR can also quantitatively measure flow through vessels due to the 
phase shift which accumulates in flowing blood when different gradients are applied. Tissue 
iron (which accumulates with repeated blood transfusions) can also be quantified using T2* 
sequences. This will be discussed further in the next chapter. 
 
3.4 CONTRAINDICATIONS AND SAFETY ISSUES 
3.4.1 Magnetic field and RF energy exposure 
There are no known adverse biological effects from short-term exposure to the static 
magnetic fields used for clinical MR scanning however, RF pulses transfer energy into body 
tissues resulting in a rise in temperature. There are strict regulations regarding specific 
absorption rate (SAR) which restrict RF energy transfer to levels that will induce a maximum 
rise in body temperature of 1°C. Clinical MR scanners have in-built control systems to ensure 
SAR is within the safe operating range. Additional risks associated with RF energy are 
related to lengths of wire in which current can be generated, leading to heating and potential 
burns to a patient’s skin. Loops of wire and direct contact with transmit coils should be 
avoided. Specific MR compatible ECG electrodes are required as other types will heat up and 
have the potential to cause skin burns. 
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Rapid gradient switching can cause nerve and muscle tissue stimulation and the operator 
should be aware of this possibility. Acoustic noise within the scanner is also generated by 
rapid gradient switching and ear protection is routinely required. 
 
3.4.2 Implants, ferromagnetic objects and devices 
Ferromagnetic objects are attracted to the bore of the magnet by the strong B0 magnetic field. 
Objects accelerate towards the isocentre of the magnet with both rotational and translational 
effects. Many implanted devices (such as pacemakers or cochlear implants), foreign metallic 
fragments in the eye or cerebral aneurysm clips can be affected and are considered a 
contraindication for MR scanning. RF pulses and gradients also have effects on pacemaker 
wires and electronic devices by inducing currents or excessive heating, leading to adverse 
effects. Therefore, a routine safety screen should be performed for each patient and it is 
essential to ensure that any implanted device is verified as safe prior to the patient entering 
the magnet room (Figure 3.15). Recently, permanent pacemaker systems have been 
developed which are MR compatible and if routinely implanted, may allow many more 
pacemaker patients to have scans in the future. A set of guidelines has been published by the 
European Society of Cardiology for scanning patients with implanted pacing systems 
[Rogiun 2008].  
 
Due to the risks associated with the static magnetic field, no equipment may be brought 
inside the magnet room unless it is designated as MR safe. This includes wheelchairs, 
trolleys, monitoring equipment, oxygen cylinders and furniture. Fatal accidents due to objects 
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accelerating into the magnet bore have occurred where such safety procedures have been 
ignored. 
 
Figure 3.14. Example of a safety checklist which is routinely completed prior to a CMR 
scan. 
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CHAPTER 4: METHODS 
4.1  ASSESSMENT OF IRON OVERLOAD USING CMR 
4.1.1  Introduction 
During the early development of clinical MR imaging, it was noted that iron overload in 
patients with haemochromatosis and thalassaemia caused a reduction in signal intensity in the 
liver (figure 4.1) and this finding prompted research towards a method of quantifying the 
tissue iron concentration [Doyle 1982, Brasch 1984]. In the mid 1980s, a close correlation 
was described between the signal intensity of the liver and chemical determination of iron in 
an animal model of dietary-induced iron overload [Stark 1983]. An ex-vivo study of iron-
loaded livers using magnetic relaxometry found that it was T2 which was predominantly 
affected by iron with only a small effect on T1 relaxation. The reciprocal of T1 and T2 
(namely R1 and R2) showed a linear relationship to hepatic iron levels [Stark 1985]. 
 
Early techniques for iron quantification relied on spin echo imaging, either measuring T2 
decay or comparing signal intensity between the liver or myocardium and a reference tissue 
which is presumed to have no iron loading (such as skeletal muscle) to generate a signal 
intensity ratio (SIR) [Johnston 1989, Jensen 1994, 2001]. A direct correlation was found 
between hepatic tissue iron from biopsy and the SIR measurement [Jensen 1994] and an 
improvement in myocardial iron measured by SIR was shown with deferoxamine chelation 
[Jensen 2003] but the SIR method had a number of inherent problems. Small changes in 
imaging parameters (such as repetition time) and the presence of any degree of liver fibrosis 
had a significant effect on results leading to poor reproducibility and limitations when 
comparing results between different centres [Cohen 2004, Angelucci 1997]. Also, the 
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suggested quantification of iron for myocardial tissue relied on a modified calibration curve 
derived from liver biopsy data [Jensen 2001]. 
 
Figure 4.1. Early axial and sagittal magnetic resonance images from a patient with 
thalassaemia major (left hand panel) and a normal volunteer (right hand panel). Very low 
signal intensity was noted in the liver and vertebral bodies of patients with siderosis. 
Reproduced with permission from Brasch RC et al. Radiology 1984; 150: 767-771 © 
Radiological Society of North America. 
 
 
T2 measurement techniques have been calibrated against dry weight iron concentration from 
liver biopsy [Kaltwasser 1990, St Pierre 2005] and although there is a high degree of 
accuracy, acquisition times are long (approximately 20 minutes) and analysis can be 
complex. T2 sequences for the heart require long breath-hold times, are limited when iron 
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concentration is severe and suffer from motion and breathing artefacts, causing difficulties in 
achieving reliable measurement [Mavrogeni 1998a, Mavrogeni1998b]. However, recent 
developments in T2 sequences may make this a more practical technique for assessment of 
cardiac iron loading [He 2006, Guo 2009, Kim 2009]. Comparison of myocardial T2 against 
endomyocardial biopsy from the right ventricular side of the septum revealed a better 
correlation than with serum ferritin but a formal calibration has not been possible [Mavrogeni 
2005]. A new method using multiple spin echo sequences has recently shown the potential to 
differentiate tissue ferritin from haemosiderin iron [Jensen 2010]. Alternative methods such 
as the measurement of magnetisation transfer rates have not proven of value for clinical use 
[Papanikolaou 2000]. 
 
4.1.2 Gradient echo T2* techniques for tissue iron measurement 
In comparison to the spin echo T1 and T2 techniques, gradient echo images are 
predominantly T2*-weighted and hence are much more susceptible to magnetic field 
inhomogeneity. Recent data has confirmed that while both T2 and T2* are relatively 
insensitive to soluble ferritin iron, T2* is particularly affected by the aggregated particles of 
haemosiderin iron within cells. [Jensen 2010]. T2* decay is dependent on both the intrinsic 
T2 properties of the tissue in question and the loss of phase coherence caused by magnetic 
field inhomogeneity (T2 prime, or T2’). The relationship is represented by the equation: 
1/T2* = 1/T2 + 1/T2’. As a consequence, the gradient echo signal intensity is affected by the 
paramagnetic properties of particulate intracellular iron which causes disturbance in the local 
magnetic field. With increasing concentrations of iron, signal decay occurs faster, leading to 
shorter T2* times. This intrinsic property was noted in the liver of thalassaemia patients at 
0.5 Tesla but initial experiences suggested that the images were too noisy and limited by long 
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echo times [Gomori 1991, Ernst 1997]. T2* was later successfully exploited by Anderson et 
al. who validated a multiple breath-hold technique using gradient echo to measure cardiac 
and hepatic iron at 1.5 Tesla [Anderson 2001]. 
 
4.1.3 Multiple breath-hold gradient echo T2* technique  
The initial technique described by Anderson et al. required a single breath-hold of 
approximately 10 seconds’ duration for each echo time image acquisition. This not only took 
up valuable scanner time but also caused problems with image registration for varying 
breath-hold positions or patient movement between acquisitions. With the development of 
scanner technology and faster gradients, multi-echo sequences became possible. 
 
4.1.4 Multi-echo single breath-hold T2* technique 
The development of single breath-hold sequences for the measurement of cardiac T2* has 
removed some of the disadvantages of the previous single-echo technique, in relation to the 
effects of different breath-hold positions and patient movement as well as reducing the 
number of breath-holds required for a single T2* measurement. There are two different 
sequences which have been validated for routine clinical use. See Figures 4.2 and 4.3. 
 
4.1.5 Bright-blood sequence 
The first of the multi-echo techniques acquires a single short-axis midventricular myocardial 
slice at eight separate echo times (2.6 – 16.74ms, at 2.02ms increments). [Westwood 2003] In 
order to achieve this during a single breath-hold, a multi-echo sequence is repeated many 
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times in succession for each cardiac cycle. With this gradient echo sequence, one RF pulse is 
followed by multiple echoes. A spoiler or ‘crusher’ gradient is then used to remove the 
residual magnetisation before a new RF pulse is applied. If repeated 5 times with a TR of 
20ms between RF pulses, this takes approximately 100ms so that images are taken when the 
heart is still in diastole.  This allows several phase-encoding steps for each R-R interval so 
that multiple lines of k-space data are acquired per cardiac cycle. The acquisition is 
completed over a number of cardiac cycles (‘segmented’ imaging with signals sampled over a 
number of heart beats to fill k-space). This spoiled gradient echo sequence uses a flip angle of 
35°, a matrix of 128 x 256 pixels, a field of view of 40cm, repetition time of 20ms between 
each radiofrequency (RF) pulse and a sampling bandwidth of 810 Hz per pixel. All of echo 
times are acquired immediately after the ECG R wave trigger (delay time of 0ms) in order to 
obtain a high quality image with minimal blood flow and myocardial wall motion artefact. 
 
4.1.6 Black-blood sequence 
The bright-blood sequence can give rise to cardiac motion or blood pool artefacts (with bright 
signal in the septal region of interest) and it can be difficult to delineate the blood-myocardial 
border accurately. These issues give rise to potential inaccuracy in the T2* calculation and as 
a result, a black-blood sequence was developed with a double inversion-recovery pulse on the 
R wave to null the blood signal and acquisition of the multi-echo T2* sequence in late 
diastole when the heart is still. This sequence gives high contrast images with clearly defined 
myocardial borders and is much less sensitive to artefact and background noise. It is therefore 
easier for the operator to delineate the blood-myocardial border [He 2007].  
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Single breath-hold bright 
blood [Westwood 2003] 
Single breath-hold black 
blood [He 2007] 
Number of breath-holds 
required 
9 1 1 
Typical scan time for T2* 
sequence 
Approx 3-4 minutes for 
all breath-holds 
10 seconds 13 seconds 
Trigger delay 
Zero (immediately after 
R-wave) 
Zero (immediately after 
R-wave) 
Set for image acquisition 
in late diastole 
Inversion recovery pulse 
to null blood signal 
No No Yes 
Echo times 5.6 – 17.6ms 2.6 – 16.74ms 2.6 – 16.74ms 
 
Figure 4.2. Single breath-hold multi-echo imaging. For the bright blood sequence, the images 
are acquired immediately after the R-wave. A crusher gradient is applied after each multi-
echo sequence to eliminate any residual transverse magnetisation before the next RF pulse is 
applied. Several multi-echo sequences are performed after each R wave trigger. 
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Figure 4.3. Diagram showing the different timings for T2* sequences. The bright blood 
sequence is acquired with no trigger delay immediately after the R wave. The dark-blood 
acquisition is in late diastole following a double inversion pulse to null the blood signal. 
 
 
4.1.7 Image analysis and Calculation of myocardial T2* 
Calculation of T2* decay requires a series of images at different echo times after the initial 
radiofrequency pulse (figure 4.4). Due to proton dephasing, signal intensity decays over time 
and the more iron present, the faster the signal decay. In vivo measurement of T2* can be 
affected by susceptibility artefacts at tissue borders (such as the myocardial/lung interface), 
by the degree of iron loading in the liver, by deoxygenated blood in the blood vessels in the 
anterior and posterior interventricular grooves and by cardiac motion. Therefore, for analysis 
of T2*, a full-thickness region of interest (ROI) in the interventricular septum is chosen to 
measure mean signal intensity for each echo time. This avoids most sources of artefact but 
care is needed to ensure that blood pool signal or other artefact is excluded from the ROI. 
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Signal intensity is plotted against echo time and a mono-exponential trendline is fitted to the 
decay curve to derive T2* (figure 4.5) which represents the time taken for the signal intensity 
to decay to 37% of its initial value. The signal intensity (SI) at each echo time is given by the 
following equation (where SI0 represents the signal intensity at time zero and TE represents 
the echo time): 




Dedicated software (Thalassaemia tools, a plugin of CMRtools, Cardiovascular Imaging 
Solutions, London) is used for this calculation. 
 
Figure 4.4. Images of a mid-ventricular short-axis slice at increasing echo times (TE) after an 
initial RF pulse. The myocardium becomes progressively darker as T2* decay occurs. Bright-
blood images are shown in the top row with black-blood images in the lower row. 
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Figure 4.5. T2* calculation. An optimal region of interest is chosen in the interventricular 
septum of a mid-ventricular slice (left hand panel). The signal intensity is then plotted for 
each echo time (right hand panel). A mono-exponential trendline is fitted to derive a T2* 
value of 9.72ms which represents severe cardiac iron loading (see text). 
 
 
4.1.8 Measurement of Hepatic T2* 
Hepatic T2* can be measured in a similar way. A multi-echo sequence is acquired during a 
single breath-hold for a transverse slice of the liver. ECG gating is not required but shorter 
echo times are needed due to the higher concentration of iron within the hepatic tissue. An 
ROI is chosen in a homogeneous region of the liver which avoids any blood vessels or 
hepatic sinusoids as these are potential sources of artefact. A similar signal intensity decay 
curve is plotted and T2* calculated in the same way as for the heart. 
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4.1.9 Curve-fitting and background noise correction 
In situations where myocardial iron loading is severe, later echo times are affected by 
background noise, motion and blood pool artefacts. This noise ‘floor’ does not allow signal 
intensity to reach the baseline and consequently may affect the calculation of T2* from the 
exponential decay curve. There are a number of methods which have been proposed to deal 
with this, namely the addition of a constant ‘offset’ to force the baseline of the graph upwards 
to meet the noise floor, truncation of the final data points or a biexponential model. 
 
In an ex-vivo model of iron loading, it has been shown that the most accurate and 
reproducible estimation of T2* is made using the truncation method [He 2008]. T2* 
acquisitions of iron-overloaded myocardium were obtained using a varying number of 
excitations (NEX) to obtain images with a wide range of signal-to-noise ratio (SNR). 
Following noise correction using the truncation algorithm, the T2* curve was the closest to 
the original high SNR images using the highest NEX. 
Chapter 4 Page 69 Methods 
 
Figure 4.6. Truncation model. The graphs show signal intensity plotted against echo time for 
an ex-vivo heart which was used to derive the optimal method for T2*calculation. 
 
The left-hand graph shows that if all original data points are used, a noise floor is reached. 
Using an offset model, the baseline is forced upward to meet this noise floor and the T2* is 
lower (overestimating tissue iron) than a truncation model where only the first 4 points are 
used to draw the decay curve.  
 
The right hand graph shows the effect of increasing the number of excitations (NEX) for the 
same T2* measurement. With the highest signal-to-noise ratio (SNR) with NEX = 32, the 
scan is very long but there is very little noise and the curve closely resembles a truncated 
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4.1.10 Validation and reproducibility of T2* measurements 
From first principles, with the knowledge of the paramagnetic properties of particulate iron, it 
is possible to predict that T2* decay is inversely related to tissue iron but in order to prove 
that T2* truly measures iron in the heart, a number of conditions need to be satisfied.  
 
Both T2 and T2* have been calibrated against liver iron from biopsy data and it is accepted 
that there is an inverse relationship between tissue iron and both of these relaxation 
parameters [Anderson 2001, St. Pierre 2005]. Although it cannot be assumed that myocardial 
T2* will give the same results, a calibration for T2* versus cardiac iron has been published in 
the Mongolian gerbil model of iron overload [Wood 2005a] together with a report of a single 
post-mortem human heart with corresponding chemical iron and T2* measurements [Ghugre 
2006]. In thalassaemia patients, left ventricular ejection fraction is normal when T2* is within 
the normal range (>20ms) but shows a progressive and significant decline when T2* falls 
below 20ms, being most marked when T2* is <10ms. T2* is low in patients presenting with 
heart failure [Tanner 2005], is a strong prognostic indicator for the development of cardiac 
complications (such as cardiac failure and arrhythmia) [Kirk 2009] and has also been shown 
to improve in conjunction with LV ejection fraction with chelation therapy [Anderson 2004, 
Tanner 2007, Pennell 2006]. Despite this, an absolute calibration for myocardial iron is 
lacking. 
 
T2* is a highly robust measurement which has been shown to have a high reproducibility 
between different observers and different studies performed a few hours or days apart. It has 
also been shown to have a high level of agreement between different scanners (proven using 
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different models by the same vendor and across different vendor platforms) and between 
different worldwide centres [Kirk 2010]. See table 4.2. 
 
Table 4.2. Interstudy, intersite and interobserver reproducibility of multi breath-hold, bright 












[Smith 2010, personal 
communication]. N/A – data not available. 
Reproducibility Liver T2* 
Cardiac T2* Bright blood 
sequence 
Cardiac T2* Dark blood 
sequence 













2.9%3 5.8%3 N/A 
Inter-scanner 7.9%4 9.4%4 N/A 
Inter-centre 7.1%5 5.0 %5 N/A 
 
4.1.11 Normal ranges for cardiac T2* 
From initial experience, a lower limit of normal for T2* of 20ms was determined. From the 
original report of clinical T2* use, the mean normal (± SD) of T2* in healthy volunteers was 
52 ± 16ms with 20ms representing the mean minus 1.96 standard deviations [Anderson 
2001]. It should be noted that the distribution of T2* is skewed with a right-hand tail and T2* 
is usually now presented as geometric mean and interquartile range. With increasing iron 
overload, there is increasing risk of left ventricular dysfunction and the development of 
complications such as heart failure and arrhythmias. In a series of patients presenting to our 
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unit with heart failure due to siderotic cardiomyopathy, 89% were found to have T2* values 
less than 10ms [Tanner 2005]. T2* has been found to be strongly prognostic for the 
development of heart failure with values of less than 10ms predicting the onset of heart 
failure [Kirk 2009]. As a result of these clinical observations, T2* ‘risk ranges’ for cardiac 
complications have been proposed with a T2* of <10ms representing high risk, 10-20ms 
intermediate and >20ms low risk. 
 
4.2 EX-VIVO MEASUREMENT OF MYOCARDIAL IRON USING CMR 
4.2.1 Background 
As mentioned above, the measurement of liver iron using CMR has been calibrated against 
biochemically determined iron concentration from biopsy samples for both T2 [St. Pierre 
2005] and T2* sequences [Anderson 2001]. A calibration for myocardial iron versus T2* has 
been published in an animal model [Wood 2005a] but there is limited data available for the 
human heart. This is partly due to unacceptable variation in iron from endomyocardial biopsy 
samples [Fitchett 1980] and there is only one published autopsy report from a single human 
heart [Ghugre 2006]. We used the following methods for our investigation: 
 
4.2.2 Post-mortem specimen fixation and preparation 
Whole human heart specimens from autopsy required fixation using a 1% formaldehyde 
(formalin) solution prior to transfer between centres. Following fixation, the heart can be 
easily dissected with specimens taken from atria, ventricles, conducting tissue or valves. 
Hearts were routinely weighed and examined macroscopically for any gross anatomical 
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abnormalities. For the measurement of CMR parameters, the hearts were cut into a series of 
1cm thick short-axis myocardial slices from base to apex as shown in figure 4.9. 
 
4.2.3 Gradient echo T2* sequences 
For this project, all short axis slices were imaged using the same 1.5 Tesla MR scanner with a 
4-element phased array coil at Royal Brompton Hospital, London (Siemens Sonata, Siemens 
Medical Systems, Erlangen, Germany). Due to the temperature dependency of T2*, all slices 
had to be scanned at a constant 37°C. Each slice was therefore maintained at 37ºC (immersed 
in water in a custom-made holder between two sheets of plexiglass) and positioned at the 
isocentre of the magnet bore. For the measurement of T2*, a multi-echo sequence identical to 
the in-vivo sequence can be used although ECG gating is not required. The range of echo 
times (TEs) was designed to address different ranges of iron loading. Each myocardial slice 
was scanned in the same orientation to ensure that reliable identification of anatomy and wall 
segmentation was achieved for co-localization of T2* and iron concentration. T2* is 
calculated in a similar way as for in-vivo measurement. Endocardial and epicardial borders 
were manually determined and calculation of T2* decay performed using Thalassaemia 
Tools. Each myocardial slice was divided into 18 regions of interest (ROIs) – outer 
(epicardial), inner (endocardial) and intermediate (mesocardial) layers in 6 radial sectors of 
60° each. The attachment of the right ventricular wall to the left ventricle was used to 
separate the septum.  T2* was measured from each of the ROIs separately using 
Thalassaemia tools. A truncation model was used as described above to allow for correction 
of background noise and avoid overestimation of high iron concentrations.  
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4.2.4 T2 sequence acquisition and analysis 
The same method of specimen preparation and positioning was used to measure T2 and T1. 
For T2 measurement, a series of equally spaced 180° refocusing pulses were used to generate 
a train of spin echoes (with 16 echo times (TEs) from 4.8 to 76.8ms). T2 sequence parameters 
were as follows: Slice thickness 5mm, flip angle 90°, matrix 128x128 pixels, sampling 
bandwidth 780 Hz/pixel. A set of images is generated from this sequence which allows 
calculation of T2 from the signal intensity-time decay curve using Thalassaemia tools in a 
similar way to the calculation of T2*. A detailed description of T2 decay and T1 recovery is 
given in chapter 3. 
 
4.2.5 T1 sequence acquisition and analysis 
T1 represents the time taken for the magnetisation to recover to 63% of its equilibrium value 
following a radiofrequency pulse. For the measurement of T1, a series of inversion-recovery 
images was acquired with a range of inversion times. Each inversion recovery sequence 
begins with a 180 inversion pulse. T1 recovery occurs during the delay between the 180 
and the 90 imaging pulse (the inversion time). When the 90 pulse is applied, some of the 
signals may still be negative and phase correction of the magnitude image is required to 
generate an inversion recovery curve. At one time point, the magnitude of the image passes 
through the null point (zero signal intensity) as the T1 magnetisation recovers back towards 
its equilibrium value. 8 different inversion times were used for T1 measurement (64, 128, 
256, 512, 1020, 2040, 4100 and 10000 ms). These values were chosen to allow full relaxation 
following the inversion pulse and each inversion time was acquired separately. 
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The signal intensity (SI) at each inversion time is given by the following equation (where TI 




Signal intensity was plotted against inversion time to generate the T1 recovery curve. To 
calculate T1 using the above equation, curve-fitting was performed using a sum of least 
squares technique.  
 
Figure 4.7. Series of T1 sequences with different inversion times (TI). The myocardium 
appears bright at 64ms, becomes darker at 128ms, passing through the null point before 
becoming progressively brighter with lengthening TI. 
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Figure 4.8. T1 calculation. Signal intensity (SI) is plotted against inversion time (TI) to 
generate a T1 recovery curve. A mono-exponential trendline is fitted using the sum of least 




4.2.6 Specimen Dissection 
Each heart was divided into 6 short axis slices through the ventricles as described prior to 
magnetic resonance scanning (figure 4.8). Due to the variation in thickness and the lack of 
ventricular cavity which had the potential to affect the measurement of CMR relaxation 
parameters, the apical slice in each case was not used for the calibration analysis. Slices were 
sectioned with reference to the CMR images to obtain into 18 myocardial tissue samples in 
the same anatomical location as the regions of interest used for the measurement of T2*, T2 
and T1. At each short axis level, two samples were taken from the right ventricular free wall 
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(anterior and posterior). Additional samples were taken from the right and left atrium 
(anterior, lateral and posterior), the interatrial septum and each of the four valves. 
 
Figure 4.9. Experimental setup and specimen dissection. A: Schematic of short axis slices 
through the ventricles showing endocardial, mesocardial and epicardial regions of interest for 
iron quantification. B: Series of short axis slices from a single heart. C: Custom-designed 
holder within scanner bore. D: T2 image at a single echo time showing regions of interest 
used for calculation of the decay parameters. E: The same myocardial slice as D showing 
dissection with myocardial tissue specimens prepared from identical anatomical sites as the 
ROIs used for T2*, T2 and T1 decay. 
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4.2.7 Measurement of iron concentration in tissue samples 
The wet weight of each piece of myocardial tissue was recorded after discarding excess 
formalin. The tissue blocks were then freeze dried using a Virtis type lyophiliser (SP 
Industries, Inc.) for a minimum of 72 hours.  Dry weights were recorded immediately after 
removal from the lyophilizer. Specimens were then placed into plastic digestion flasks along 
with 10mL of 10M nitric acid (HNO3) and heated at 60°C for 3 hours on an Environmental 
Express™ Hot block. Further heating at 90°C for 3 hours was required before removal to a 
bench to cool for 30 minutes. Addition of 5mL hydrogen peroxide (H2O2) was made at room 
temperature and the solution was then left for an hour to allow bubbling to subside. Samples 
were returned to the heating block at 60°C and allowed to evaporate until nearly dry. Reverse 
osmosis purified water was added to bring the resultant solution to 30mL. Solutions were 
then decanted into test tubes for iron measurement. 
 
Figure 4.10. Virtis type lyophyliser (SP Industries, Inc.) used for freeze-drying the 
myocardial tissue samples. 
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Iron measurement was performed using inductively coupled plasma atomic emission 
spectroscopy (ICP-AES). The ICP-AES analyser is composed of two parts: the ICP ‘torch’ 
and an optical spectrometer. See figure 4.10 for a schematic diagram and further explanation 
of the ICP-AES technique. The iron concentrations in samples of NIST human liver standard 
4352 were used as quality controls for ICP-AES analysis. 
 
ICP-AES uses a very high temperature (7000 – 8000K) excitation source to excite atoms for 
the atomic emission spectroscopy. The sample is nebulised and entrained in the flow of a 
plasma support gas (eg. Argon). The plasma torch is made from a set of concentric quartz 
tubes. An oscillating current within induction coils wrapped around the tubes creates an 
oscillating magnetic field which induces an oscillating current in the ions. As the ions collide 
with each other, the various molecules break up into their respective atoms which then lose 
electrons and recombine repeatedly in the plasma, giving off radiation at the characteristic 
wavelengths of the elements involved. Emitted light enters the optical chamber of the 
spectrometer and is split into different wavelengths. Light intensity is measured and this 
allows the concentrations of the elements in the sample to be calculated. 
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Figure 4.11. Diagram of an ICP ‘torch’ showing sample flow which combines with the 
support gas, argon within concentric quartz tubes. The induction coils generate an oscillating 
magnetic field causing excitation of the iron atoms. The argon gas is ignited leading to a brief 
discharge arc which initiates the ionization process. Concentration of iron is measured using 
an optical spectrometer. 
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4.3  CMR FOR THE ASSESSMENT OF VENTRICULAR VOLUMES AND MASS 
4.3.1 Introduction 
CMR has a number of advantages over previous techniques used for the determination of 
ventricular volumes, mass and ejection fraction. Unlike 2D echocardiography or radionuclide 
ventriculography, it does not make geometric assumptions based on a limited number of 
measurements. There is also no exposure to ionising radiation and the myocardial-blood 
border is clearly defined with steady-state free precession cine imaging. CMR is accurate, 
highly reproducible with low interobserver variability and is now considered to be the ‘gold 
standard’ technique for the measurement of ventricular volumes and mass [Bellenger 2000, 
Maceira 2006a and 2006b]. 
 
4.3.2 Image acquisition 
A series of short axis slices, perpendicular to the long axis of the heart are planned using two-
chamber and four-chamber images of the heart at end diastole. The first slice is taken at the 
level of the atrio-ventricular groove, perpendicular to both pilot images. Contiguous short 
axis slices are then acquired at 10mm intervals (figure 4.11), from base to apex (7mm slice 
thickness with 3mm gap). Retrospective ECG gating allows the whole cardiac cycle to be 
used for the cine acquisition. For normal clinical purposes, 25 frames or phases are acquired 
per cardiac cycle with an approximate temporal resolution of 30-40ms. A high temporal 
resolution sequence (which utilises view-sharing to speed up acquisition) can be used to give 
50 phases per cardiac cycle with a temporal resolution of 16-20ms. 
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Figure 4.12. Short axis scan planning. A series of slices 10mm apart and perpendicular to the 
long axis of the heart are taken (represented by white lines). This generates a set of short axis 





4.3.3 Image analysis 
There are a number of proprietary analysis packages available for CMR. All analysis for this 
project was performed using dedicated PC-based software (CMRtools, Cardiovascular 
Imaging Solutions, London, UK). There are a number of advantages of this software which 
include valve plane tracking, blood pool thresholding and the ability to trace cardiac borders 
throughout all phases of the cardiac cycle. Once the central axis of each ventricle has been 
defined on the short axis series of images, epicardial and endocardial contours are traced 
throughout all phases of the cardiac cycle. Semi-automated blood pool thresholding allows 
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delineation of the papillary muscles in the left ventricle and trabeculations in the right 
ventricle. These are included in the calculation of LV and RV mass but excluded from the 
blood pool. The software then allows the user to define the valve planes from long-axis 
images which ensures that signal from the atria is not included in the ventricular volume. 
 
End-diastolic (EDV) and end-systolic volumes (ESV) are calculated from the sum of the 
blood pool signal from all short axis slices for both RV and LV at end-diastole and end-
systole. The ventricular stroke volume (SV) is defined as the difference between end-diastolic 
and end-systolic volume. Ejection fraction (EF) is then derived from stroke volume and end-
diastolic volume: EF (%) = SV / EDV x 100. The LV mass is calculated from the volume of 
myocardial tissue between the epicardial contours and the blood pool, including the papillary 
muscles in the volume. The RV mass is calculated in a similar way, defined by the difference 
between RV epicardial contours and blood pool, including RV trabeculations and 
myocardium (such as the septomarginal trabeculation) on the RV side of the interventricular 
septum. The total volume of myocardium is then multiplied by the density of normal 
myocardial tissue (1.05g/mL) to derive the myocardial mass. 
 
4.4 STATISTICS 
The relevant statistical methods will be discussed in each of the results chapters. All 
statistical analysis was performed using STATA version 10.1 (StataCorp, Texas, USA). A 
value of P < 0.05 was used to define a significant difference. 
Chapter 4 Page 84 Methods 
 
Figure 4.13. Cardiac volumes and function calculation. The images show RV and LV 
endocardial delineation, valve plane tracking (yellow line) and thresholding in both diastole 
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RESULTS 
CHAPTER 5: THE SEGMENTAL DISTRIBUTION OF CARDIAC IRON LOADING IN PATIENTS 
WITH MYOCARDIAL SIDEROSIS 
5.1 INTRODUCTION 
Despite improvements in chelation therapy, monitoring techniques and patient care which 
have led to improved survival, cardiac failure due to myocardial siderosis remains a major 
cause of morbidity and mortality in patients with transfusion-dependent anaemias, in 
particular those with beta thalassaemia major (TM) [Borgna-Pignatti 1998, Modell 2000, 
Modell 2008a, Borgna-Pignatti 2004]. Therefore, iron remains an area of intense interest in 
decreasing the deaths from cardiac failure in these patients and monitoring of iron overload 
forms an important part of the clinical management. Having said this, little is known about 
the variation in iron loading throughout the heart. Previous post-mortem studies have been 
either limited to reviews of autopsy records or to a small number of post-mortem hearts 
[Capell 1957, James 1964, Schellhammer 1967, Buja 1971, Sanyal 1975, Olson 1987, 
Sonakul 1984, Kyriacou 2000, Ghugre 2006].  A number of reports based on endomyocardial 
biopsy (EMB) have been published [Mavrogeni 2005, Olson 1989, Fitchett 1980] but EMB is 
an invasive procedure with associated risk and has proven unreliable for monitoring cardiac 
iron loading due to sampling error within the small biopsy samples from the right ventricular 
(RV) side of the interventricular septum [Fitchett 1980, Cooper 2007, Elliot 2009]. 
Cardiovascular magnetic resonance (CMR) using the T2* technique has now been accepted 
worldwide as the method of choice for the assessment of myocardial iron loading in 
transfusion-dependent patients [Anderson 2001, Pennell 2005]. Due to imaging artefacts from 
fat surrounding the coronary arteries, deoxygenated blood in the cardiac veins and from the 
myocardium-lung interface [Atalay 2001, Wacker 1999], it is recommended that T2* is 
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measured from a region of interest in a single mid-ventricular slice, giving a single value for 
the representation of the global iron loading in the heart [Anderson 2001]. A recent study has 
shown that the mid-ventricular septal T2* correlates well with the global T2* value, but the 
data is limited and controversy still exists as to whether this single measurement gives an 
accurate representation of the global iron loading in the heart [Pepe 2006b]. 
 
The distribution of iron is therefore highly relevant both to the understanding of the disease 
process and the monitoring of chelation therapy, especially for techniques (such as T2*) 
which measure cardiac iron concentration from a specific region of the heart. No previous 
studies have given a good appreciation of the global distribution of iron loading or 
heterogeneity of iron deposition in different segments of the ventricular myocardium. With 
this in mind, we set about to document comprehensively the distribution of iron loading 
within hearts that were known to have myocardial iron overload using gold standard iron 
quantification in order to ascertain the degree of heterogeneity of iron deposition throughout 
the heart. This is the first comprehensive report of iron analysis in a series of hearts from 
transfusion-dependent patients to look at segmental iron concentration in both ventricles and 
to incorporate results from all cardiac tissues. We report the findings of the tissue iron 
distribution in 12 ex-vivo hearts donated following death or cardiac transplantation. 
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5.2 METHODS 
5.2.1 Patient characteristics 
This project started in 2003 and was completed in 2010, during which time 12 whole human 
hearts were donated from five international centres: University College Hospital (London, 
UK), Ospedale Galleria (Genoa, Italy), Children’s Hospital of Los Angeles (USA), Azienda 
Ospedaliera Brotzu (Cagliari, Italy) and Mahidol University (Bangkok, Thailand). All 
patients were transfusion-dependent (10 beta-thalassaemia major, 1 sideroblastic anaemia, 1 
Diamond Blackfan anaemia), most having required transfusions from early childhood. The 
hearts were donated following death or cardiac transplantation for end-stage heart failure. 
The study protocol was approved by all local research ethics committees, and local consent 
was obtained in all cases. 
 
5.2.2 Quantification of myocardial iron 
All hearts were fixed in formalin. Each heart was subsequently cut into 4-5 slices of 1cm 
thickness in the ventricular short axis according to ventricular size (see Methods, figure 4.9a 
and b). Each of the short axis slices was divided into 6 sectors of 60° each (anterior, 
anterolateral, inferolateral, inferior, inferoseptal and anteroseptal), and then each sector was 
subdivided into 3 transmural layers (figure 4.9e): outer (epicardial), inner (endocardial) and 
intermediate (mesocardial), giving 18 LV samples. The attachment of the right ventricular 
(RV) wall to the left ventricle (LV) was used to define the septum [Cerqueira 2002]. For each 
short axis slice, 2 samples were also taken from the RV free wall (resulting in a total of 20 
myocardial samples per slice). Additional samples were taken from the right atrium (3) and 
left atrium (3), the inter-atrial septum (1) and each of the valves (4). 
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The wet weight of each piece of myocardial tissue was recorded after discarding excess 
formalin. The tissue blocks were then freeze-dried for a minimum of 72 hours using a Virtis-
type lyophilizer (SP Industries Inc) and dry weights were recorded immediately after removal 
from the lyophilizer. Specimens were then placed into plastic digestion flasks along with 
10mL of 10M nitric acid (HNO3) and heated at 60°C for 3 hours on an Environmental 
Express Hot block. Further heating at 90°C for 3 hours was required before removal to a 
bench to cool for 30 minutes. Addition of 5mL hydrogen peroxide (H2O2) was made at room 
temperature and the solution was then left for an hour to allow bubbling to subside. Samples 
were returned to the heating block at 60°C and allowed to evaporate until nearly dry. Reverse 
osmosis purified water was added to bring the resultant solution to 30mL. Solutions were 
then decanted into test tubes for iron measurement using inductively coupled plasma atomic 
emission spectroscopy (ICP-AES). The iron concentrations in samples of NIST (National 
Institute of Standards and Technology, USA) human liver standard 4352 were used as quality 
controls for ICP-AES analysis. 
 
For the segmental analysis of the distribution of myocardial iron, we used the American 
Heart Association / American College of Cardiology (AHA/ACC) 16-segment model 
[Cerqueira 2002]. Three myocardial slices from each heart were used for this analysis: the 
mid-ventricular, the apical and basal slices, as per the AHA/ACC model. Each segment 
comprised the full transmural extent of myocardium. To match the apical slice to 4 segments 
as dictated in the 16 segment model, the 2 apical-septal sectors were analyzed together, and 
the 2 apical-lateral sectors were analyzed together. The apical cap was not included in the 
segmental analysis.  
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5.2.3 Effect of time in formalin fixation on iron concentration 
As the fixed hearts had been stored for varied lengths of time, the effect of formalin on iron 
concentration was studied. Myocardial tissue from an apical slice not included in the 
segmental analysis was used to assess whether there was any leaching of iron from the 
myocardium into formalin over time. This 7.35g sample was preserved in 280mL of 10% 
neutral buffered formalin (pH 7.0). At repeated intervals up to 600 days, small (1mL) aliquots 
of formalin were taken for analysis of the iron content of the solution. The initial iron 
concentration in this tissue sample was estimated from immediately adjacent areas of 
myocardium in the same apical slice. 
 
5.2.4 Statistical analysis 
For each distribution analysis, one region of interest was defined as the reference region, and 
differences in tissue iron content throughout the heart against this region were assessed using 
mixed-model linear regression. The null hypothesis was that there was no difference in iron 
concentration between segments, layers or slices. For each analysis, the regions of interest 
were entered as fixed effects, so that differences between regions could be estimated. Patients 
were entered as random effects, since it was not of interest to test for differences between 
individual patients. To account for the repeated measurements from each heart, all samples 
from each individual heart were nested for analysis. The degree of heterogeneity of iron 
concentration for each heart was evaluated by calculating the coefficient of variation across 
all samples. All data were analysed using STATA version 10.1 (StataCorp, Texas, USA). A 
value of P <0.05 was used to define a significant difference. 
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5.3 RESULTS 
5.3.1 Patient characteristics 
Twelve hearts were donated, 8 following death and 4 from patients undergoing cardiac 
transplantation for end-stage heart failure. End-stage heart failure was the cause of death in 7 
of the 8 patients who died, but one patient died from an ischemic stroke at the age of 46 with 
a history of excellent compliance to chelation therapy and no cardiac complications (apart 
from a transient episode of atrial fibrillation aged 21). Table 5.1 summarises the clinical 
information for each patient. 
 
5.3.2 Loss of iron from stored myocardial samples 
The iron content of the formalin solution in which a piece of myocardial tissue had been 
stored over a period of 600 days is shown in figure 5.1. The average iron concentration of 
adjacent myocardial tissue was 1.21 mg/g wet weight, corresponding to a total of 8.91mg of 
iron in the 7.35g wet weight sample. The iron concentration of the solution increased rapidly 
over the first 30 days after formalin fixation, with a further subsequent rise but thereafter 
stabilised to reach a plateau of approximately 480μg/L after 300 days, equating to a loss of 
135μg (approximately 1.5%) of the total iron from the myocardial tissue. 
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1 M TM Death 46 
Ischemic stroke 
(no cardiac failure) 
0.38  
±0.13 
21.1 1584 6 Excellent 
2 F SA Death 62 Cardiac failure 8.20  
±1.44 
15.9 2000 42 Good 










5 F TM Death 20 Cardiac failure 7.74  
±1.51 
16.4 432 6 Poor 
6 M TM Transplant 23 Cardiac failure 3.63  
±0.82 
18.0 765 10 Not known 
7 M TM Transplant 24 Cardiac failure 3.38  
±0.53 
10.0 528 6 Good 
8 M TM Transplant 21 Cardiac failure 5.87  
±1.0 
9.5 500 4 Not known 
9 F TM Transplant 31 Cardiac failure 8.78  
±1.88 
10.5 624 7 Poor 
10 M TM Death 24 




17.3 660 10 Poor 
11 M TM Death 44 Cardiac failure 3.19  
±1.02 
26.6 1209 18 Poor 
12 M DBA Death 22 




10.1 442 10 Poor 
 
SD = standard deviation, LV = left ventricle, [Fe] = myocardial iron concentration, TM = 
Beta thalassaemia major, SA = Sideroblastic anaemia, DBA = Diamond Blackfan anaemia, 
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Figure 5.1. Iron content of the formalin solution in which a piece of myocardial tissue was 
stored, showing an initial rapid increase in iron which reaches a plateau after the first 300 
days. There appears to be an early and a late plateau, possibly suggesting a two-stage process 
of iron release, however no further iron is lost after the first 300 days. 
 
5.3.3 Myocardial iron samples: overall summary 
The mean (±SD) weight of all samples in the iron analysis was 1001 ±620mg. Iron 
concentration in all samples ranged from 0.09 to 78.64mg/g dry weight (dw). The myocardial 
iron concentration ranged from 0.18 to 53.4mg/g dw. The mean (±SD) ratio of dry to wet iron 
concentration in the myocardium was 5.04 ±0.9 and was independent of iron concentration. 
One heart had exceptionally high levels of iron and in view of the possibility that this could 
bias the results, all further analysis is presented separately for this outlier heart. The 
coefficient of variation of iron for myocardial samples ranged from 9.2% to 26.6% per heart 
with a mean of 15.2% (table 5.1). 
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5.3.4 Distribution of left ventricular iron 
With all hearts considered together (except the most heavily iron-loaded heart, number 4), a 
gradient of iron was found in the transmural layers of the LV myocardium with the greatest 
concentration in the epicardium, an intermediate level in the mesocardium (-1.1%, p=0.63), 
and the lowest level in the endocardium (-7.5%, p=0.001) (figure 5.2 and table 5.2). In order 
to examine for variation in larger regions of the LV, an analysis was also performed of 
variation in iron concentration of whole walls of the LV (inferoseptal, anteroseptal, anterior, 
anterolateral, inferolateral, inferior) encompassing all segments from base to apex, which 
showed no significant systematic variation of mean iron concentration. A further analysis 
comparing the whole basal, mid-ventricular and apical slices also failed to show any 
significant systematic variation in mean iron concentration. No statistically significant 
systematic variations in iron concentration were observed between the different AHA 
segments (table 5.3). The most heavily iron-loaded heart (heart 4) had very high iron 
concentration in the epicardium (36.1mg/g dw) with an intermediate level in the endocardium 
(-28.0%) and the lowest level in the mesocardium (-54.7%) (figure 5.2 and table 5.2). There 
was no systematic variation in mean iron concentration between the different LV segments or 
from base to apex.  
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Table 5.2.  Distribution of iron throughout the left ventricular myocardium. 
  All hearts (excluding heart 4)  Heart 4 alone 
LV Region of interest  [Fe] mg/g 95% CI p value  [Fe] mg/g 
Epicardium (reference)  6.2 4.7 7.7 Ref  36.1 
Mesocardium (Δ)  -0.07 -0.34 0.20 0.63  -19.8 
Endocardium (Δ)  -0.46 -0.73 -0.19 0.001  -10.1 
Global LV (reference)  6.0 4.3 7.7 Ref  26.2 
Anterior (Δ)  -0.07 -0.93 0.78 0.87  3.5 
Anterolateral (Δ)  0.16 -0.70 1.0 0.72  -0.4 
Inferolateral (Δ)  -0.06 -0.91 0.80 0.89  1.6 
Inferior (Δ)  -0.16 -1.0 0.69 0.71  4.4 
Inferoseptal (Δ)  -0.06 -0.92 0.79 0.89  -3.9 
Anteroseptal (Δ)  0.20 -0.66 1.1 0.65  -5.1 
Apical (Δ)  0.27 -0.55 1.1 0.51  2.0 
Mid (Δ)  -0.17 -1.0 0.66 0.69  0.4 
Basal (Δ)  -0.11 -0.93 0.72 0.80  -2.4 
 
For the transmural distribution of iron, the differences in iron concentration (Δ) are compared 
against the epicardial [Fe] dw. Other values are compared against the mean global heart [Fe] 
dw as the reference. Heart 4 is presented separately as it is an extreme outlier with very high 
myocardial iron concentration. 
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Table 5.3.  Distribution of iron according to the AHA/ACC 16-segment model. 
  All hearts (excluding heart 4)  Heart 4 alone 
LV Region of interest  [Fe] mg/g 95% CI p value  [Fe] mg/g 






1 Ant (Δ)  -0.37 -1.3 0.56 0.43  1.1 
2 Ant-sep (Δ)  0.09 -0.84 1.0 0.85  -7.3 
3 Inf-sep (Δ)  -0.27 -1.2 0.66 0.57  -6.6 
4 Inf (Δ)  -0.41 -1.3 0.52 0.39  5.3 
5 Inf-lat (Δ)  -0.14 -1.1 0.79 0.77  -4.1 




7 Ant (Δ)  0.03 -0.90 0.96 0.94  4.4 
8 Ant-sep (Δ)  0.50 -0.43 1.4 0.29  3.1 
9 Inf-sep (Δ)  0.59 -0.34 1.5 0.22  -1.3 
10 Inf (Δ)  -0.01 -0.94 0.92 0.98  -0.7 
11 Inf-lat (Δ)  0.02 -0.91 0.95 0.97  2.2 






13 Ant (Δ)  0.08 -0.85 1.0 0.87  4.9 
14 Sep (Δ)  -0.29 -1.2 0.64 0.54  -4.4 
15 Inf (Δ)  -0.12 -1.05 0.81 0.81  8.6 
16 Lat (Δ)  -0.50 -1.43 0.43 0.29  3.7 
 
AHA segments are numbered and labelled as: ant = anterior; sep = septum; lat = lateral; inf = 
inferior). Differences in iron concentration (Δ) are compared against the mean global heart 
[Fe] dw as the reference. Once again, heart 4 is presented separately as it is an extreme outlier 
with very high myocardial iron concentration. 
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Figure 5.2. Myocardial iron distribution. Histogram showing transmural gradient across the 




5.3.5 Septal iron compared with global cardiac iron 
Iron concentration measured in the mid-septal slice was highly representative of global iron 
(figure 5.3).  Regression analysis showed a slope indistinguishable from 1 (1.06; 95% CI: 
0.83 to 1.29) and an intercept indistinguishable from 0 (0.04; 95% CI: -1.57 to 1.66). The 
mean percentage (±SD) difference between mid-septal and global iron concentration was 
10.5 ±13.4%. 
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Figure 5.3. Graph of mid-septal iron concentration versus mean whole-heart iron 
concentration for each of the 12 hearts (data points are plotted against the line of identity, and 
error bars are ±SD of the septal samples). The double lines across each axis represent a 
discontinuity in the scale between 10 and 25mg/g for illustrative purposes. 
 
 
5.3.6 Distribution of iron in RV, atria and valves 
Excluding the most heavily iron-loaded heart (heart 4), all RV, atrial and valve samples 
showed lower iron levels compared to global LV iron (apart from the anterior left atrial wall 
where only a borderline difference was observed). The RV wall had up to 21.9% less iron 
(p<0.001). Compared to the mean global LV iron concentration, the left atrial iron 
concentration was up to 28.1% lower (p<0.001) and right atrial iron up to 57.0% lower 
(p<0.001). All 4 cardiac valves showed low iron concentrations which were up to 74.4% 
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lower than the LV (p<0.001). Heart 4 showed a consistently higher level of iron in the atrial 
and valve samples but no difference between LV and RV iron (table 5.4). 
 
Table 5.4. Distribution of iron in the right ventricle, atria and valves. The differences in iron 
concentration (Δ) are compared against the mean [Fe] dw for a reference region. 
   All hearts (excluding heart 4)  Heart 4 alone 
 Region of interest  [Fe] mg/g 95% CI p value  [Fe] mg/g 











 RV Posterior (Δ)  -1.3 -1.8 -0.78 <0.001  2.6 
RV Anterior (Δ)  -1.3 -1.8 -0.83 <0.001  10.5 
Apical (Δ)  -1.0 -1.6 -0.39 0.001  6.7 
Mid (Δ)  -1.4 -2.0 -0.84 <0.001  7.2 













LA anterior (Δ)  -0.78 -1.6 0.09 0.080  45.9 
LA posterior (Δ)  -1.7 -2.6 -0.76 <0.001  13.3 
LA lateral (Δ)  -1.1 -2.0 -0.20 0.013  30.8 
Atrial septum (Δ)  -3.0 -3.9 -2.1 <0.001  20.8 
RA anterior (Δ)  -3.3 -4.2 -2.4 <0.001  34.2 
RA posterior (Δ)  -3.4 -4.3 -2.5 <0.001  22.2 
RA lateral (Δ)  -3.1 -4.0 -2.2 <0.001  23.4 
Aortic valve (Δ)  -4.5 -5.6 -3.3 <0.001  42.6 
Mitral valve (Δ)  -4.4 -5.2 -3.5 <0.001  52.5 
Pulmonary valve (Δ)  -4.3 -5.5 -3.2 <0.001  41.1 
Tricuspid valve (Δ)  -4.4 -5.3 -3.5 <0.001  52.4 
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5.4 DISCUSSION 
This is a unique study of a series of human hearts that have undergone comprehensive 
quantitative iron analysis to investigate iron distribution throughout the heart. Apart from a 
higher iron concentration in the epicardium, the results of the distribution analysis show no 
other systematic variation of iron concentration throughout the left ventricular myocardium. 
These findings were consistently observed between all 16 myocardial segments, the 6 
myocardial walls and the 3 short axis slices from base to apex. Of note, the mid-ventricular 
septal iron concentration was highly representative of the global iron concentration. Iron was 
found to be deposited throughout all cardiac tissues, including the right ventricular 
myocardium, both atria and valves, but to a lesser extent than that seen in the left ventricle. 
The hearts in this study had been stored in formalin and there was a concern that this could 
affect the measurement of iron concentration but in agreement with previous work, we found 
only minor leaching of iron from myocardial tissue into the formalin solution over time 
[Chua-anusorn 1997]. The curve of iron concentration over time (figure 5.1) suggests that the 
loss of iron into the formalin solution may be a two-stage process but the mechanism behind 
this remains unclear. 
 
Studies dating from the mid-1950s have assessed myocardial iron loading in post-mortem 
hearts using various techniques including histological grading of iron-positive myocytes, 
electron microscopy and analysis of elemental iron by flameless atomic absorption 
spectroscopy [Engle 1964, James 1964, Schellhammer 1967, Buja 1971, Olson 1987, 
Kyriacou 2000]. Our results are in broad agreement with the previously published studies 
which have observed a similar transmural gradient of myocardial iron. Two autopsy studies 
have attempted to quantify regional variation but no definite pattern has emerged [Olson 
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1987, Ghugre 2006], and this is the first time a comprehensive study of regional variation has 
been made. 
 
The iron values obtained from our study are of considerable interest with regard to the level 
of cardiac iron concentration which is associated with iron-related death and cardiac disease, 
an issue that has hitherto been little explored. One previous study reported the normal 
myocardial iron concentration to be 0.34 (range 0.29-0.47) mg/g dw [Collins 1987]. The one 
heart we studied from a patient who died of a stroke with no evidence of heart disease had a 
global iron concentration of 0.38mg/g dw, which is in good agreement with the previous 
study. Of 10 hearts with similar ranges of myocardial siderosis, the mean global myocardial 
iron causing severe heart failure was 5.98 ±2.42mg/g dw (range 3.19-9.50), but in 1 outlier 
case of heart failure, myocardial iron was 25.9mg/g dw. The values seen in the 10 hearts are 
rather modest in comparison with iron levels commonly seen in the liver in TM, and this 
indicates that the heart is considerably more sensitive to iron loading than the liver in terms of 
functional consequences. The outlier heart had 5 times the iron concentration compared to the 
mean value of the other hearts, which was a totally unexpected finding. This heart was from a 
patient who had died from heart failure at the age of 15 following unopposed iron loading in 
the pre-chelation era. The explanation for this tolerance to myocardial iron can only be 
speculative, but may have been genetically mediated.  
 
Studies using CMR have reported a heterogeneous pattern of cardiac iron distribution in 
some TM patients, as measured by in vivo T2* [Positano 2009, Pepe 2006b], but there is 
debate as to whether this apparent heterogeneity of iron loading might be the result of 
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confounding factors such as artefact, measurement error or the high prevalence of hepatitis C 
in this population. In view of the problems with artefact in vivo, it has been recommended 
that the measurement of T2* is restricted to a full-thickness region of interest in the septum of 
a mid-ventricular slice [Anderson 2001]. Our results suggest that the iron concentration 
measured in the mid-septum is highly representative of the global myocardial value and we 
observed no systematic regional heterogeneity of iron loading.  
 
5.4.1 Limitations 
We have reported findings based on formalin-fixed hearts. This project could not have been 
performed with fresh, unfixed tissue due to regulations on transport of human tissue between 
sites. Although we have shown that there is relatively homogeneous distribution of iron 
throughout the heart, it should be noted that all of the iron-loaded hearts in this study have 
mean iron levels well above the normal range. This is in keeping with the fact that death from 
cardiac failure is almost always restricted to patients with severe cardiac iron loading. The 
findings may therefore only apply in moderate-to-severely iron loaded hearts. Valve tissue 
(especially the leaflets of the aortic and pulmonary valves) is thin and in comparison to the 
ventricular myocardial tissue samples, a much smaller amount of tissue was provided for 
analysis. Therefore, small inherent errors in the weight of these samples may have affected 
the concentration measurements for valvular tissue and the values obtained should be 
interpreted in this light. All of the iron measurements in this study were made on formalin-
fixed specimen samples which had been stored for varied lengths of time. Although 
traditionally, studies looking at the form of iron-oxide deposits and tissue iron concentration 
have been limited to fresh, frozen or freeze-dried tissue samples, the effects of formalin 
fixation have been well studied [Chua-anusorn 1997, Koizumi 1994, Olynyk 1994]. It has 
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previously been shown that iron leaches slowly from formalin-fixed iron-loaded tissue 
samples over the first 60 days until approximately 3% has been lost. Thereafter, no further 
iron is lost and the concentration remains unchanged. Our results concur with these findings, 
with a loss of only 1.5% of the tissue iron content at 600 days following fixation. In addition, 
Mössbauer spectra of formalin-fixed human liver and pancreas show no evidence of chemical 
transformation of the form of iron when compared to freeze-dried samples from the same 
patient [Chua-anusorn 1997]. Accordingly, we have concluded that it is acceptable to quote 
the iron concentration derived from formalin-fixed heart tissue. 
 
5.5 CONCLUSION 
The results of this study show that, apart from a transmural gradient of iron concentration,  
there is no systematic variation in iron loading throughout the left ventricular myocardium. 
These findings have important implications for iron monitoring in patients with transfusion-
dependent anaemias and are of particular importance for techniques (such as myocardial T2*) 
which use septal iron measurement as a surrogate for whole-heart iron. 
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CHAPTER 6: THE CALIBRATION OF MYOCARDIAL T2* VERSUS ABSOLUTE MYOCARDIAL 
IRON CONCENTRATION 
6.1 INTRODUCTION 
Transfusion-dependent patients receive approximately 20 times the normal intake of iron 
leading to iron accumulation and damage in the liver, heart and endocrine organs [Gordeuk 
1987, McLaren 1983]. Such patients are at risk of myocardial siderosis and therefore, clinical 
assessment of myocardial iron is essential to prevent iron overload cardiomyopathy. 
However, conventional non-invasive techniques are less than ideal. Neither serum ferritin nor 
liver iron concentration gives a reliable indication of cardiac iron in cross-sectional studies 
[Anderson 2001]. Monitoring ejection fraction can be useful, but its value is limited by 
difficulty in achieving reproducible longitudinal measurements as well as the masking of 
ventricular dysfunction by the high basal cardiac output seen in chronic anaemia, and its late 
occurrence in the disease process. Even more modern contractile measures such as tissue 
Doppler imaging correlate poorly with cardiac iron [Leonardi 2008]. Endomyocardial biopsy 
is also unreliable for measuring myocardial iron due to sampling errors as discussed in 
Chapter 5 [Fitchett 1980, Olson 1989]. The need for an alternative non-invasive measurement 
of myocardial iron led to the development of an optimized cardiac T2* magnetic resonance 
(MR) technique. Particulate intracellular iron causes shortening of the magnetic resonance 
relaxation parameter T2* due to microscopic magnetic field inhomogeneity. Myocardial T2* 
is an easily quantifiable, clinically robust and highly reproducible measurement technique 
[Westwood 2003a, 2003b, Kirk 2010]. In the liver, T2* correlates well with biopsy iron 
concentration [Anderson 2001, Wood 2005b]. Although the relationship between T2* and 
cardiac iron can be inferred from first principles, animal models [Wood 2005a], and the liver 
data, there is limited direct information on cardiac calibration of T2* in humans [Ghugre 
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2006, Wang 2010], and the inherent limitations associated with endomyocardial biopsy 
prevent in vivo calibration [Mavrogeni 2005]. We therefore initiated a project to calibrate 
cardiac T2* against chemically assayed tissue iron concentration in ex-vivo human hearts. 
 
6.2 METHODS 
6.2.1 Patient characteristics 
The same twelve hearts (as described in Chapter 5) were used for this study. As previously 
mentioned, the hearts were donated following death or cardiac transplantation for end-stage 
heart failure and all were from patients with transfusion-dependent anaemias (10 beta-
thalassaemia major, 1 sideroblastic anaemia, 1 Diamond Blackfan anaemia). The study 
protocol was approved by all local research ethics committees, and local consent was 
obtained in all cases. 
 
6.2.2 Imaging protocol and analysis 
We used scientific convention in quoting R2* to evaluate relaxation and its relation to iron, 
R2* being the reciprocal of T2*. Scans performed on patients pre-mortem are quoted in T2*. 
All hearts were fixed in formalin. Each heart was cut into 4-5 slices of 1cm thickness in the 
ventricular short axis according to ventricular size (see Methods, figure 4.9a and b). The 
apical cap was not analyzed for R2* because of potential for partial volume effects. All slices 
were imaged using a 1.5 Tesla MR scanner (Sonata, Siemens Medical Systems, Germany) 
with a 4-element phased-array coil. Slices were immersed in water in a custom-made 
container between two sheets of plexiglass and maintained at 37ºC throughout imaging 
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(figure 4.9c). A multi-echo gradient echo sequence was used for imaging, and in order to 
cover R2* values from 25 to 500s
-1
 (T2* from 2 to 40ms), 2 sequences were required. For all 
hearts, a high resolution sequence with 16 echoes was used with TEs from 3.1 to 39.1ms. 
Slice thickness was 5mm, flip angle 35°, matrix 128x128 pixels, field of view 160mm, 
number of excitations 2 and sampling bandwidth 815Hz per pixel. An additional lower 
resolution sequence with a lower minimum TE was also performed with 12 echoes ranging 
from 1.21 to 14.9ms. For this sequence, flip angle was 20°, matrix 64x64 pixels and sampling 
bandwidth 1955Hz per pixel. All other parameters were identical. The 2 sequences were 
compared in 6 ex-vivo hearts with a range of R2* from 125 to 278s
-1
 (T2* from 3.6 to 
8.0ms), and found to agree closely with a coefficient of variation of 5.1%. Care was taken to 
orientate each slice, including photography, to ensure reliable identification of anatomy and 
wall segmentation for co-localization of R2* and chemically assayed iron concentration.  
 
For the measurement of R2*, each slice was analyzed with 18 regions of interest (ROIs) of 6 
radial sectors of 60° each, and 3 layers: outer (epicardial), inner (endocardial) and 
intermediate (mesocardial) (figure 6.1a). The attachment of the right ventricular (RV) wall to 
the left ventricle (LV) was used to define the septum [Cerqueira 2002]. R2* was measured 
from each ROI using dedicated software (Thalassaemia Tools, Cardiovascular Imaging 
Solutions, London) using a truncation model to account for background noise, as has been 
previously validated (figure 6.2) [He 2008a]. Analysis of the 12 echo sequence was only 
required for heart 4, which was extremely heavily iron loaded (R2* 500s
-1
, T2* 2.0ms). In all 
other cases, the 16 echo sequence was used for analysis. 
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A) CMR image showing regions of interest used for R2* analysis which correspond to the 
tissue blocks in B) Identical slice sectioned ready for iron analysis. 
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Figure 6.2 Example of ex-vivo cardiac T2* scans. 
 
 
Representative images of two hearts are shown at increasing echo times (TE) from 3ms to 
17.4ms. Heart 1 has normal iron levels and remains bright whereas heart 2 (which has severe 
iron loading) shows progressive darkening with increasing echo time. The graph shows signal 
intensity (arbitrary units) plotted against echo time (ms) for the hearts in upper panel. Heart 1 
has a shallow decay curve with T2* value of >20ms. Heart 2 has a much more rapid decay 
with T2* <10ms. 
Chapter 6 Page 109 Calibration of T2* 
 
6.2.3 Quantification of myocardial iron 
After R2* CMR was completed, each short axis slice was cut into 6 sectors of 60° each, and 
then each sector was subdivided into 3 transmural layers to give 18 left ventricular samples 
per slice (figure 6.1b). The wet weight of each piece of tissue was recorded after discarding 
excess formalin. Samples were then freeze-dried and the dry weight (dw) was recorded 
immediately after removal from the lyophilizer. Following acid digestion, iron measurement 
was performed using inductively coupled plasma atomic emission spectroscopy (ICP-AES) 
as described in Chapter 4, Methods. For the LV myocardial R2* calibration analysis, all LV 
samples were directly compared with the CMR R2* scan. Care was taken to ensure that all 
tissue blocks corresponded as accurately as possible to the ROIs used for R2* analysis (figure 
6.1). 
 
6.2.4 Effect of time in formalin fixation on R2* measurement 
As the fixed hearts had been stored for varied lengths of time, the effect of formalin on MR 
relaxation over time was studied. One myocardial slice was analysed at repeated intervals 
with multiple R2* measurements up to a total of 566 days (12 scans in total). 
 
6.2.5 Pre and post-mortem scans 
Three of the patients had clinical T2* scans shortly before death on the same scanner 
(Sonata) as was used for the ex-vivo scanning. A mid-ventricular short axis slice was imaged 
with a single breath-hold 8-echo T2* sequence as previously described (range of echo times: 
2.6-16.74ms, slice thickness 10mm, flip angle 20°, matrix 128x256 pixels, field of view 
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400mm, sampling bandwidth 815Hz per pixel) [Westwood 2003a]. The anatomical 
appearance of the slice (papillary muscle position, trabecular pattern and distance from apex) 
was used to achieve as precise a correlation as possible between pre- and post-mortem scans, 
allowing direct comparison of T2* values. 
 
6.2.6 Statistics 
R2* was compared with iron concentration using linear regression. To account for the 
repeated measurements from each heart, all samples from each individual heart were nested 
for analysis. The degree of heterogeneity of R2* for each heart was evaluated by calculating 
the coefficient of variation across all samples. All data were analysed using STATA version 
10.1 (StataCorp, Texas, USA). A value of P <0.05 was used to define a significant difference. 
 
6.3 RESULTS 
6.3.1 Patient characteristics 
The same 12 hearts as described in Chapter 5 were studied: 8 donated following death and 4 
from patients undergoing cardiac transplantation for end-stage heart failure. For 7 of the 8 
patients who died, the cause of death was end-stage heart failure but, in one case, a patient 
with a history of excellent compliance to chelation therapy and no cardiac complications 
(apart from a single transient episode of atrial fibrillation aged 21) died from an ischemic 
stroke at the age of 46. A summary of the clinical information together with T2* and R2* 
data for each patient is given in Table 6.1. 
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1 M TM Death 46 
Ischemic stroke 







11.9 1584 6 Excellent 






12.9 2000 42 Good 
























15.9 432 6 Poor 






12.8 765 10 Not known 






15.9 528 6 Good 






14.8 500 4 Not known 






15.1 624 7 Poor 
10 M TM Death 24 








23.0 660 10 Poor 






21.4 1209 18 Poor 
12 M DBA Death 22 








21.9 442 10 Poor 
 
SD = standard deviation, LV = left ventricle, [Fe] = myocardial iron concentration, TM = 
Beta thalassaemia major, SA = Sideroblastic anaemia, DBA = Diamond Blackfan anaemia, 
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6.3.2 Pre and post-mortem scans 
Three patients underwent both pre- and post-mortem T2* scans (figure 6.3). The mean time 
between CMR scan and death was 26 ±13.3 days (range 11-35). Two mid-ventricular short-
axis slices were imaged for each heart, giving 12 myocardial regions of interest for 
comparison (2 slices, 2 septal sectors, 3 transmural layers). There was no significant 
difference in septal T2* between scans (table 6.2 and figure 6.4).  
 
Table 6.2. Comparison of T2* measurement pre- and post-mortem.  
Heart number 2 10 11 
In-vivo T2* pre-mortem  ms 4.9 (1.3) 6.0 (0.8) 10.9 (2.3) 
Ex-vivo T2* post-mortem  ms 5.2 (0.4) 5.9 (0.9) 9.2 (2.2) 
P value 0.28 0.84 0.21 
 
The T2* values are quoted as mean (SD) and refer to measurements from septal ROIs only. 
The P values are given for pairwise comparison of the septal regions of interest pre- and post-
mortem. 
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Figure 6.3. Pre and post-mortem scans. 
 
A) Pre-mortem mid-ventricular slice and B) corresponding post-mortem slice of the same 
heart at the same position. 
 
Figure 6.4. Pre- and post-mortem T2* scan results. 
 
The graph shows the relationship between pre- and post-mortem T2* values measured from 
corresponding ROIs in the mid septum. Error bars represent standard deviation and the line of 
identity is given. 
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6.3.3 Effect of time in formalin on R2* measurement 
For the single short axis slice which was scanned at repeated intervals, there was no 
significant change in R2* value, even after 18 months’ storage in formalin (figure 6.5). Mean 
R2* for all sectors was 198.4 ±21.5s
-1
 at day 6 and 197.7 ±7.3s
-1
 at day 566 (P=0.93). 
 
Figure 6.5. Effect of time in formalin on R2* measurement. 
 
The R2* values measured from a single myocardial slice stored in formalin over a prolonged 
duration are plotted, showing no significant difference in R2*. The dashed line represents 
mean R2* (194.4s
-1
) and error bars are ±SD. 
 
6.3.4 Relation of R2* to tissue iron concentration 
Due to the very high level of iron in the most severely overloaded heart (heart 4), it is 
possible that the measurement of R2* might be underestimated. Therefore, the results of the 
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MR relaxation calibration are presented twice, both including and then excluding this heart. 
A total of 1006 tissue samples and their corresponding ROIs were used for iron and R2* 
assessment, with 84 ROIs (8.3%) being excluded from the R2* analysis due to imaging 
artefact predominantly caused by cuts made at autopsy. A curvilinear relation between R2* 
and cardiac iron concentration was observed (figure 6.6). A similar curvilinear relation was 
shown when mean global whole heart iron was plotted against R2* (figure 6.7). 
 
Figure 6.6. Calibration of CMR versus myocardial iron concentration. 
 
A) R2* plotted against myocardial iron measured from each myocardial ROI. The regression 
(solid line) and 95% confidence bands (dotted lines) are shown and derived from analysis of 
the log-log data shown in figure 6.8.; B) R2* versus myocardial iron excluding heart 4. The 
regression (solid line) and 95% confidence bands (dotted lines) are shown and derived from 
analysis of the log-log data shown in figure 6.8. 
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Figure 6.7. Calibration of CMR versus mean myocardial iron concentration. 
 
A) Mean R2* plotted against mean iron concentration for each heart. The regression (solid 
line) is derived from analysis of the log-log data shown in figure 6.8; B) Mean R2* versus 
mean iron concentration excluding heart 4. The regression (solid line) is derived from 
analysis of the log-log data shown in figure 6.8. 
 
The strongest linear correlation was found (all hearts) by plotting lnR2* and ln[Fe] (R
2
 0.910, 
p <0.001) with a slope of 0.745 [95% CI: 0.729–0.760] and intercept of 3.896 [95% CI: 
3.868–3.924] (figure 6.8). There was almost no difference to this calibration result if heart 4 
was excluded (R
2
 0.898, p <0.001, slope 0.754 [95% CI: 0.737–0.772], intercept 3.884 [95% 
CI: 3.855–3.913]). Using this calibration in all hearts, the relation between R2* and iron is 




[Fe] = 0.00985 • (R2*)1.22 
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Figure 6.8. Relation between Ln(R2*) and Ln([Fe]). 
 
The graph shows ln(R2*) plotted against ln([Fe]) for all ROIs, including heart 4 showing the 
best fit linear regression line. 
 
6.3.5 Relation between septal and whole-heart R2* 
R2* measured in the mid-septal slice was highly representative of whole-heart mean R2* 
(figure 6.9). Regression analysis showed a slope indistinguishable from 1 (0.97; 95% CI: 0.82 
to 1.13) and an intercept indistinguishable from 0 (0.33; 95% CI: -0.73 to 1.38). The mean 
percentage (±SD) difference between mid-septal and global R2* was 2.8 ±7.3%. The relation 
of septal R2* and T2* with whole heart iron concentration is shown in figure 6.10.  
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Figure 6.9. Septal versus whole-heart R2* 
 
Mean mid-septal R2* versus mean whole-heart R2* plotted against the line of identity, 
showing that the septal R2* value is highly representative of the whole-heart R2* (only 11 
hearts are shown because severe artefact prevented analysis of mid-septal T2* in one heart). 
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Figure 6.10. Relation between septal CMR measurements and whole heart iron.  
 
A) Mean septal R2* plotted against mean iron concentration for each heart. Error bars are 
±SD for septal R2* and the regression line is shown based on the log-log data shown in 
figure 6.8. B) Mean septal T2* plotted against mean iron concentration for each heart. These 
two graphs illustrate the difference between T2* and R2* when compared to tissue iron. T2* 
shortens with increased iron concentration and hence its reciprocal R2* rises with tissue iron.  
 
6.4 DISCUSSION 
This is the first report of a series of human hearts that have undergone both magnetic 
resonance relaxometry and quantitative iron studies for calibration purposes. The results of 
the calibration analysis of myocardial MR relaxometry against absolute iron concentration 
are of considerable clinical interest. Heart R2* provided a robust (R
2
=0.910) calibration 
against chemically assayed cardiac iron in the current study. Our statistical analysis 
demonstrated that this relationship was curvilinear. Previous investigators have described a 
linear relationship between R2* and iron concentration, but these studies had fewer 
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observations and a more limited range of measurement [Wood 2005a]. Although R2* 
underestimation may occur at high iron concentrations if initial echo times are too long, a 
minimum echo time of 1.2ms should have been adequate to capture even the most heavily 
loaded samples. In addition, we found little calibration differences if heart 4 was included or 
excluded. For clinical purposes where T2* is typically the result quoted for patients with 
suspected cardiac iron overload the calibration equation can be rewritten using T2* = 




 [Fe] = 45.0 • (T2*)-1.22 
 
Although direct comparison across species should be treated with caution, our results are 
comparable with R2* measurements in a gerbil model of severe iron loading where tissue 
iron concentration was measured from fresh, unfixed tissue [Wood 2005a]. Proton relaxivity 
is known to be temperature dependent and in phantom studies, T2* falls by up to 1.5% per 
degree Celsius [He 2009]. Previous investigators have noted a shortening of cardiac T2* 
post-mortem, but in this case, scans were performed at room temperature on an unfixed 
specimen [Ghugre 2006]. We scanned all hearts at a constant 37C and this may account for 
the consistency of our pre and post-mortem heart measurements. The hearts in this study had 
been stored in formalin and there was a concern that this could affect the measurement of T2* 
and iron concentration. As mentioned in the previous chapter, we found only minor leaching 
of iron from myocardial tissue into the formalin solution which is in agreement with previous 
work [Chua-anusorn 1997]. In addition, we observed very little variation in the measured T2* 
over time. 
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The myocardial T2* values are also of particular interest in relation to the development of 
heart failure and death. Normal myocardial iron concentration derived from a series of 
normal human hearts has been reported to be 0.34 (range 0.29-0.47) mg/g dw [Collins 1987], 
but in contrast to this, previous ranges for T2* in vivo have been derived solely from clinical 
observations. In normal volunteers with no history of blood transfusion or iron overload, 
Anderson’s first paper on myocardial T2* found a mean normal value of 52ms, which yields 
a myocardial iron concentration of 0.36mg/g dw from our calibration. More recently, a 
normal mean value of 40ms has been widely used which equates to 0.50mg/g dw. These 
values accord well with the previously published normal values for myocardial iron, and also 
with the myocardial T2* value of the patient in our study who died of a stroke. This patient 
had no clinical evidence of heart disease, a normal mean global myocardial T2* (44.4ms) and 
a global iron concentration of 0.38mg/g dw. The myocardial T2* values associated with 
being below the normal range are typically those below 20ms (1.1 mg/g dw), and as T2* falls 
below 10ms (2.7mg/g dw), there is a progressive decline in both LV and RV ejection fraction 
[Anderson 2001, Alpendurada 2010]. The vast majority of patients who present with heart 
failure due to cardiac iron overload have T2* <10ms and low T2* values are powerful 
independent predictors of subsequent development of cardiac failure [Kirk 2009]. All but one 
of the hearts in this study were from patients who had either died from or had undergone 
cardiac transplantation for end-stage heart failure. In keeping with clinical experience, the 
mean myocardial T2* for these hearts was 5.9 ±3.0ms (range 2.0-12.3). Much higher levels 
of iron are routinely seen in the liver in patients with TM, giving T2* values which can be 
considerably shorter than those measured in the heart [Anderson 2001, Wood 2005b], once 
again an indication that the heart is considerably more sensitive to iron loading than the liver 
in terms of the functional consequences. 
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CMR studies have reported that some TM patients have a heterogeneous pattern of cardiac 
iron distribution, as measured by in vivo T2*, although this apparent heterogeneity lessened 
with increasing iron concentration [Positano 2009, Pepe 2006b]. Myocardial T2* in vivo may 
however be confounded by a number of factors, including magnetic susceptibility artefact as 
well as measurement error [Wacker 1999, Anderson 2001, He 2008a]. In view of the 
problems with artefact in-vivo, it has been recommended that the measurement of T2* is 
restricted to a full thickness septal region of interest (ROI) [Anderson 2001]. There has been 
recent debate over the use of this septal ROI for predicting whole-heart iron [Pepe 2006b], 
but our results validate this approach given that both iron and R2* measured in the mid-
septum are highly representative of their respective global myocardial value.  
 
6.4.1 Limitations 
This project has required international collaboration between 5 specialist centres and, due to 
international regulations governing transportation of human tissue, could not have been 
performed with fresh, unfixed hearts. Therefore, the calibration findings represent 
measurement of T2* in ex vivo formalin-fixed tissue versus chemically determined iron 
concentration. The fact that death from cardiac failure is almost always restricted to patients 
with severe cardiac iron loading (T2* <10ms) is reflected in the range of T2* values. 
Although there is no guarantee that in-vivo and ex-vivo myocardial T2* are the same, the 
data are supportive with a good agreement between pre- and post-mortem T2* values in 3 
hearts. Some hearts had been stored in formalin over extended periods, but our data suggest 
that there is no significant change in T2* over time and only a small amount of leaching of 
iron into the formalin solution. Although every effort was made to correlate ROIs used for 
R2* measurement with the tissue blocks that were analysed for iron concentration, it is not 
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possible to eliminate disparity completely There are difficulties with R2* measurement in 
heavily iron-loaded tissue where signal decay is rapid, requiring very short echo times. 
Scanner hardware imposes constraints on minimum echo spacing which may be inadequate 
for accurate R2* measurement at very high iron concentrations. However, a minimum echo 
time of 1.2ms should allow reliable measurement of T2* values as low as 1.44ms [Wood 
2005a],
 
which is below the minimum global myocardial value seen in this study. Finally, 
some ROIs were excluded from the calibration due to imaging artefact. The decision to 
exclude an ROI was made by subjective assessment prior to the analysis of R2* and is 
unlikely to have affected the calibration significantly due to the many regions sampled 
throughout the 12 hearts.  
 
6.5 CONCLUSIONS 
The results of this study validate the clinical technique in current use, and provide detailed 
calibration data for CMR measurement of myocardial iron in humans. 
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CHAPTER 7: EX-VIVO MEASUREMENT OF T1 AND T2 IN IRON LOADED HEARTS 
 
7.1 INTRODUCTION 
As discussed in Chapter 6, the magnetic resonance decay parameter T2* which, in vivo, is 
routinely measured from the septum of a mid-ventricular slice, has an inverse relationship 
with tissue iron and correlates well with myocardial iron in post-mortem hearts [Anderson 
2001, Carpenter 2009]. CMR T2* has proved to be the most reliable and clinically useful 
method of measuring cardiac iron loading and predicting cardiac complications [Westwood 
2003a, 2003b, Tanner 2006b, Kirk 2009], being superior to other clinical indices (including 
serum ferritin, liver iron, ventricular ejection fraction, tissue Doppler echocardiographic 
parameters and endomyocardial biopsy) [Anderson 2001, Telfer 2000, Leonardi 2008, 
Fitchett 1980, Olson 1989]. 
 
In the same way that T2* is affected by particulate intracellular iron, the relaxation 
parameters T2 and T1 are also shortened due to local inhomogeneity in the magnetic field 
which causes faster proton dephasing [Wood 2005a]. For the liver, T2 techniques allow 
accurate assessment of iron loading as well as giving an impression of the degree of hepatic 
fibrosis present [St Pierre 2005, Wood 2005b]. However, previous attempts at using spin 
echo techniques to measure cardiac iron have been unreliable [Pennell 2005] and there 
remains very limited data in the heart regarding the relation between either T1 or T2 and 
cardiac iron concentration. To extend our knowledge of the effects of tissue iron on CMR 
parameters, we measured T1 and T2 in post-mortem hearts and compared the findings to 
biochemically derived tissue iron concentration.  
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7.2 METHODS 
7.2.1 Study patients 
This study forms the final part of a project designed to validate CMR measurement of cardiac 
iron which has taken over 7 years to complete. The same 12 hearts (donated from patients 
with transfusion-dependent anaemia either post-mortem or following cardiac transplantation 
for end-stage heart failure, as described in the preceding two chapters) were studied. The 
study protocol was approved by the local research ethics committees. Local consent was 
obtained in all cases. 
 
7.2.2 Study protocol 
All of the hearts were preserved in formalin before being divided into 1cm thick slices 
perpendicular to the long axis of the ventricles (see Methods, figure 4.9a and b). As for the 
T2* calibration (Chapter 6), the most apical slice was not included in the analysis due to the 
variation in thickness which could have affected T1 and T2 measurement. All short axis 
slices were scanned using the same 1.5 Tesla MR scanner at the Royal Brompton Hospital, 
London (Sonata, Siemens Medical Systems, Germany). Each slice was mounted between two 
Perspex sheets, immersed in water and scanned using a 4-element phased-array coil. Slices 
were maintained at a constant 37°C throughout. 
 
For T2 measurement, a series of equally spaced 180° refocusing pulses were used to generate 
a train of spin echoes (with 16 echo times (TEs) from 4.8 to 76.8ms). This multiecho fast spin 
echo T2 sequence had the following parameters: Slice thickness 5mm, flip angle 90°, matrix 
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128x128 pixels, sampling bandwidth 780 Hz/pixel (figure 7.1). For T1 measurement, a series 
of inversion recovery T1 images was acquired with a range of inversion times (64, 128, 256, 
512, 1020, 2040, 4100 and 10000ms), slice thickness 5mm, flip angle 90°, matrix 128x128 
pixels, sampling bandwidth 230 Hz/pixel (figure 7.2). Both sequences were designed to 
address different ranges of iron loading. Each myocardial slice was scanned in the same 
orientation to ensure reliable identification of anatomy and wall segmentation for co-
localization of decay parameters and iron concentration. 
 
To determine the regions of interest (ROIs) for measurement of T2 and T1, a series of steps 
were performed as follows. First, endocardial and epicardial borders were drawn for the left 
ventricle (LV). Then, each myocardial slice was divided into 18 ROIs comprised of outer 
(epicardial), inner (endocardial) and intermediate (mesocardial) layers in 6 equal radial 
sectors. The septum was delineated by the attachment of the right ventricular (RV) wall to the 
LV [Cerqueira 2002]. T2 was measured from each of the ROIs individually using software 
specifically designed to quantify signal intensity decay (Thalassaemia Tools, Cardiovascular 
Imaging Solutions, London). Where necessary, curve truncation was used to correct for 
background noise (figure 7.1) [He 2008a]. A monoexponential decay curve was fitted using 
the following equation (where SI is signal intensity, SI0 is signal intensity at time zero and TE 
is the echo time): 
 
 
Analysis of T1 required correction of the phase prior to curve fitting. A T1 recovery curve 
was then fitted to the signal intensity points at each time point using a least squares fit (figure 
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7.2). The signal intensity (SI) at each inversion time is given by the following equation 
(where TI is the inversion time, M0 is the magnetisation and C is a constant representing 
noise and artefact: 
 
 
Any ROIs which contained artefact with the potential to affect T1 or T2 measurement were 
excluded from the analysis before the measurement was performed. 
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Figure 7.1. T2 decay. A series of images generated from the multiecho T2 sequence showing 
the same heart slice at increasing echo times. The graph shows signal intensity (arbitrary 
units) plotted against echo time. For the calculation of T2, the curve has been truncated, 
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Figure 7.2. T1 recovery. A series of T1 images of the identical heart slice to that shown in 
figure 7.1. Following a 180° inversion pulse, the magnetisation recovers to its original value 
and therefore, different myocardial signal intensities are seen at increasing inversion times 
from 64 ms to 10 seconds. Myocardial signal is initially negative, recovering through the zero 
point (where the myocardium appears black at 128ms) back to its maximal intensity. The 
graph shows a least-squares fit for the calculation of T1, defined as the time taken for 
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7.2.3 Effect of formalin on relaxation 
To assess the effect of time in formalin on the T2 value, a single myocardial slice was 
scanned at repeated intervals up to 566 days. T2 was measured in all 18 ROIs at each time 
point. 
 
7.2.4 Myocardial iron measurement 
Following scanning, each left ventricular short axis slice was cut into 18 samples 
corresponding to the ROIs used for T2 and T1 measurement: 6 sectors of 60° each, 
subdivided into 3 transmural layers. Samples were freeze-dried and acid digested prior to iron 
measurement using inductively coupled plasma atomic emission spectroscopy (ICP-AES) as 
described in Chapter 4, Methods. For both T2 and T1, the iron concentration in the 
myocardial samples was directly compared with the CMR measurements in the 
corresponding ROI. Care was taken to ensure that all tissue blocks corresponded as 
accurately as possible to the ROIs used for T2 and T1 analysis. 
 
7.2.5 Statistics 
The reciprocals of T1 and T2 (namely R1 and R2) were compared with tissue iron 
concentration. Curve fitting was performed by modelling using both linear and non-linear 
regression algorithms of raw and log data to determine the best fit. Comparison was also 
made against previously measured T2* values (as described in Chapter 6) from identical 
ROIs. All data were analysed using STATA version 10.1 (StataCorp, Texas, USA). A value 
of P < 0.05 was used to define significance. 
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7.3 RESULTS 
7.3.1 Patient characteristics 
A total of 12 hearts were donated for this study, of which, 11 were from patients who had 
either died (n=7) or had undergone cardiac transplantation (n=4) as a result of end-stage heart 
failure. The remaining patient had required lifelong transfusions for beta thalassaemia major 
but died aged 46 from an ischaemic stroke with no prior cardiac complications (apart from a 
single short-lived episode of atrial fibrillation at the age of 21). A summary of the clinical 
information is given in table 7.1.  
 
7.3.2 Comparison of ex-vivo CMR imaging parameters with tissue iron 
For 11 of the 12 hearts, mean myocardial iron concentration ranged from 0.38 to 9.5mg/g dw. 
One of the hearts was an extreme outlier with a very high level of iron loading. The mean 
myocardial iron in this heart was 25.9 ±10.3mg/g dw, with iron concentrations of up to 100 
times the upper limit of normal. The T1 and T2 images from this heart suffered from 
substantial artefact caused by sectioning performed at the time of autopsy prior to scanning. 
Due to difficulty in analysis caused by these artefacts, we considered both T2 and T1 
measurements to be unreliable and therefore have excluded this heart from the correlation for 
both parameters. For measurement of T2 and T1, 934 ROIs and their corresponding tissue 
blocks were used. Some of the hearts had been cut longitudinally at the time of autopsy prior 
to scanning leading to image artefact at the cut surfaces and as a result, 41 (4.4%) ROIs were 
excluded from the T2 analysis and 106 (11.3%) ROIs were excluded from the T1 analysis. 
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1 M TM Death 46 
Ischemic stroke 







1584 6 Excellent 






2000 42 Good 





















432 6 Poor 






765 10 Not known 






528 6 Good 






500 4 Not known 






624 7 Poor 
10 M TM Death 24 








660 10 Poor 






1209 18 Poor 
12 M DBA Death 22 








442 10 Poor 
 
SD = standard deviation, LV = left ventricle, [Fe] = myocardial iron concentration, TM = 
Beta thalassaemia major, SA = Sideroblastic anaemia, DBA = Diamond Blackfan anaemia, 
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7.3.3 T1 measurement 
Analysis of T1 proved challenging with a dichotomous distribution of T1 values. Seven of 
the 12 hearts were found to have extremely short T1 recovery with very little variation 
between hearts. The mean ±SD T1 value recorded from these hearts was 72.3 ±25.8ms and 
was independent of tissue iron concentration. This very short T1 recovery was only found in 
hearts which had been stored in formalin for over a year. In the remaining 5 hearts which had 
been stored for a much shorter duration (less than 10 weeks) prior to scanning, comparison of 
R1 and tissue iron revealed a weak positive correlation with marked scatter (R
2
 0.338, P 
<0.001) (figure 7.3a). A log log plot of the data revealed a stronger correlation (R
2
 0.517, P 
<0.001) with a slope of 0.13 [95% CI: 0.12 – 0.14] and intercept of 1.19 [95% CI: 1.17 – 
1.21] (figure 7.3b). 
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Figure 7.3. Relation between R1 and tissue iron. A) R1 plotted against [Fe] for the 5 hearts 
which had been immersed in formalin for less than 10 weeks. The linear regression line is 
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7.3.4 Effect of time in formalin on T2 decay 
For the single myocardial slice which was examined repeatedly, there was a modest decrease 
in T2 with time (figure 7.4). Mean (±SD) T2 at baseline (first measured 13 days after death 
and formalin fixation) was 23.7 ±0.93ms. At day 566, mean T2 was 18.5 ±1.41ms (P 
<0.001). 
 
Figure 7.4. The effect of time in formalin on T2 measurement. 
Mean T2 values are plotted against time for a single myocardial slice stored in formalin over 
an extended duration. There was a shortening of the T2 value over time. Error bars are ±SD. 
 
 
7.3.5 T2 measurement 
There was a direct relationship between 1/T2 (R2) and cardiac iron concentration (figures 7.5 
and 7.6). Using mean R2 for each heart plotted against the mean cardiac iron concentration, a 
straight line initially appeared to be a reasonable fit for the data (R
2
 0.718, P=0.001). 
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Figure 7.5. Mean R2 plotted against mean [Fe] for each whole heart (n=11). The solid line 
denotes the linear regression line. Error bars are ±SD. 
 
When all R2 and iron measurements from all samples were considered (n=893), the strongest 
linear correlation was found by plotting lnR2 versus ln[Fe] (R
2
 0.710, P <0.001) with a slope 
of 0.49 [95% CI: 0.47 – 0.51] and intercept of 3.31 [95% CI: 3.28 – 3.34] (figure 7.7). Using 
different models in an attempt to improve the fit for the data, similar but less good results for 
correlation coefficient were found with non-linear regression algorithms (R
2
 0.593) and 
simple linear regression (R
2
 0.566) (figure 7.6). The best non-linear fit was found using the 
power function (as described by St. Pierre for the calibration of R2 versus liver iron) of the 




 where R2 is in units of s
-1
, x is cardiac iron concentration in mg/g 















 and 0.52 respectively. From the log 
data, the relation between R2, T2 and tissue iron can be expressed by the following equations 
(where R2 is in s
-1
 and T2 is in ms): 
[Fe] = 0.0055 • (R2)1.67    and    [Fe] = 561.4 • (T2)-1.67 
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Figure 7.6 Relation between R2 and tissue iron concentration in all samples (n=893). A) R2 
(s
-1
) is plotted against [Fe] (mg/g dw). The solid line is the best linear fit regression line; B) 
The same data are shown (R2 against [Fe]). The solid black line is the correlation line derived 
from the logged data as described in the text. The dashed lines represent the upper and lower 
95% confidence bands. The red line (arrowed) depicts St. Pierre’s data for R2 calibration 
versus [Fe] in the liver. 
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Figure 7.7. ln(R2) plotted against ln[Fe] with the best fit regression line 
 
Figure 7.8. Comparison of R2 and R2* in identical ROIs.  
 
7.3.6 Comparison of R2 and R2* measurements 
There was a strong linear relationship between R2 and previously determined R2* 
measurements in identical ROIs (R
2
 0.696, P <0.001) as shown in figure 7.8. 
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7.4 DISCUSSION 
These findings provide insight into the effects of iron both on the heart and on magnetic 
resonance relaxation parameters. The normal range for iron concentration in myocardial 
tissue is 0.290-0.470 mg/g dry weight [Collins 1987] and the hearts included in this report 
have provided us with the opportunity to study a wide range of iron loading up to and 
including severe, fatal iron overload. Our results show a clear relation between R2 and iron, 
similar to that found by other groups. Whether this is a straight-line or curvilinear 
relationship remains unclear. Non-linear regression modelling and the log data result in a 
curve which is flatter than that seen for R2 in the liver [St. Pierre 2005], with the potential to 
overestimate iron at higher concentrations. Although a straight line appears a very good fit 
for the data, this may underestimate iron in the crucial range near the cut-off between normal 
and abnormal values. R1 increases with cardiac iron concentration but appears to be 
markedly affected by the duration of specimen storage in formalin and the relationship is 
weaker than that observed with R2 with a much greater variability in R1 measurements. 
 
In a single post-mortem human heart from a patient with beta-thalassemia major, T2 
correlated well with tissue iron concentration [Ghugre 2006]. Our results are in broad 
agreement with these findings but cover a much greater dynamic range. Similarly, in the 
gerbil model of siderotic cardiomyopathy, both T1 and T2 are strongly related to tissue iron 
and show greater variability in T1 measurements than T2 [Wood 2005a]. As already 
mentioned, when compared with R2 measured in human liver biopsy samples, our curve 
appears flatter, but this is consistent with the findings observed in the rodent model and may 
reflect the higher water content of cardiac tissue compared to the liver when samples are 
compared on a dry-weight basis [Wood 2005a, 2005b, St Pierre 2005].  
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In the human heart, an in vivo correlation has been described between the degree of stainable 
iron in myocardial biopsy samples and qualitative T2 measurement [Mavrogeni 2005]. 
Despite this observed correlation, in vivo T2 measurement can be challenging and difficult to 
apply in a clinical setting. More recently, a method for measuring T2 in the human heart has 
been developed which gives reproducible results [He 2006, 2008c]. T1-weighted images have 
previously been used to derive the signal intensity ratio (SIR) between the myocardium and 
skeletal muscle with limited degrees of success but this technique has many potential pitfalls 
and does not measure T1 decay [Jensen 2001]. The normal expected value for T1 in human 
hearts has been determined but there is very little data on the relationship between T1 and 
cardiac iron in transfusion dependent patients [Messroghli 2006], and no previous studies 
have attempted to provide a formal validation for T2 or correlate T1 with tissue iron in 
human hearts. 
 
The major challenge in providing a definitive calibration for T2 or T1 hinges on differences 
which exist between in vivo and ex vivo measurements. It is important to account for 
temperature dependence, as all the relaxation parameters (T1, T2 and T2*) show a positive 
relationship with temperature [Kamman 1988]. Phantom studies have revealed that T2* can 
change by up to 1.5% per degree Celsius [He 2009].  For this reason, all of the hearts were 
scanned at a constant 37C and, with this methodology, we have previously shown that there 
is very little difference between in vivo and ex vivo T2* values (see Chapter 6). Also, in vivo, 
artefact affects T2* measurements but this is less of a problem with T1 and T2. For T2*, 
artefacts are often seen at the myocardial / lung interface, in the inferior wall due to heavy 
iron loading in the liver, as a result of cardiac motion and from veins in the atrioventricular 
groove containing deoxygenated blood. Although blood oxygenation level affects T2* in 
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vivo, T1 and T2 are less affected and this is unlikely to affect post-mortem T1 or T2 values 
[Wacker 1999]. The non iron-loaded heart in the present study had a mean ±SD T1 value of 
351.4 ±37.2 and a mean T2 value of 63.4 ±6.5ms. Normal myocardial T1 measured in vivo is 
much higher (approximately 1100ms) [Krombach 2007] but a previous study looking at T1 of 
infarcted myocardial tissue in formalin fixed autopsy specimens (stored for between 1 and 9 
years) found significantly shorter T1 values with a T1 of 272 ±163ms in non-infarcted tissue 
and 459 ±266ms in infarct tissue [Hsu 1994]. T2 in formalin-fixed myocardium is less 
affected but is also slightly shorter than the normal, in vivo level (which is around 70ms) 
[Hsu 1994, Hosch 2007].  
 
While previous evidence suggests that organ iron concentration is lower after fixation in 
formalin or histological processing, the difference is not significant [Barry 1974, Koizumi 
1994]. In comparison, immersion in saline causes a significant drop in tissue iron levels with 
up to 50% lost in the first hour [Olynyk 1994]. Although very little iron is lost from cardiac 
tissue stored in formalin after the first 60 days [Chua-Anusorn 1997], there appears to be a 
marked change in the T1 properties of the stored samples with prolonged storage. The fact 
that the very short T1 recovery was only found in hearts which had been stored in formalin 
for greater than 10 weeks suggests that the T1 shortening effect was likely to be due to the 
effects of formalin but the reasons for this remain unclear. 
 
The ideal fixative agent would not alter the biological, physical or paramagnetic properties of 
the tissue concerned. Formalin, however, causes initial shrinkage followed by swelling of 
cells over the first hour, which then return to their original size. There is rapid hardening of 
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tissues and also loss of water. T1 is highly dependent on the water content of the tissue, and 
thus, as expected, T1 falls following fixation [Saryan 1974], however, the relationship 
between T2 and water content does not have the same predictable effect [Messroghli 2006]. 
Formalin molecules may form covalent and ionic bonds within tissues, predominantly with 
amino groups. Thus, as changes in structure and proton mobility occur together with 
dehydration and denaturation of proteins, proton relaxivity is affected with consequent 
changes in T1 and T2 [Kamman 1985]. Initial changes in T1 seem to occur more quickly in 
some tissues than in others, possibly due to the effects on phospholipid structure [Tovi 1992]. 
There is conflicting data in rat liver and spleen samples, where a significant decrease in T1 
but initial elevation in T2 has been observed following fixation [Thickman 1983]. 
Mathematical modelling has been used to assess changes in T1 and T2 in the human brain 
after formalin fixation [Yong-Hing 2005]. Relaxation maps confirm progressive T1 and T2 
shortening with time and findings from this model suggest that the brain is not completely 
saturated in formalin until after 14.8 weeks of immersion. Indeed, the changes in T1 and T2 
are not complete until after 5.4 weeks and the effects on fixed myocardial tissue may take 
even longer. The chemical form of iron however, appears to remain constant. Mössbauer 
spectra of freeze-dried tissue in human spleen, liver and pancreas samples reveal no evidence 
of chemical transformation of iron after immersion in formalin for 200 days [Chua-Anusorn 
1997]. For splenic tissue, the ratio between heme iron and non-heme iron has been observed 
to differ between fresh and formalin-fixed samples but this finding was considered to 
represent inhomogeneity of iron loading within the spleen itself rather than a true alteration in 
chemical form [Chua-Anusorn 1997]. 
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7.4.1 Limitations 
The main limitation of this study, namely the relative change in T2 and T1 following 
formalin fixation, has been discussed at length. None of the patients underwent T2 or T1 
measurement pre-mortem and T1 values were not measured over time. Therefore, we have no 
way of confirming whether there are significant changes in T2 or T1 post-mortem following 
formalin fixation compared to their pre-mortem values. Notwithstanding this, the T2 in the 
non iron-loaded heart compares well with the expected in vivo value and although T2 was 
observed to change over time, the effect was small. With sequences which use a train of 
echoes to measure R2 (Carr-Purcell-Meiboom-Gill sequences), the T2 value is dependent on 
the inter-echo spacing and the derived T2 may be higher than that measured using single 
spin-echo sequences [Jensen 2000]. This effect should not be as pronounced with the fast 
spin echo technique we have used. Unfortunately, the difficulty with measurement of T1 
means that we have not been able to produce a meaningful calibration for this parameter. As 
this study has taken many years to complete, it is unlikely to be easily repeated, especially as 
the survival of patients with beta thalassaemia is constantly improving and hence transplant 
or autopsy heart specimens will become less frequently available. Also, we do not have the 
opportunity to go back and rescan hearts to try and minimise artefact (which precluded 
analysis in a number of the ROIs) or to check T1 or T2 as the technique for measurement of 
tissue iron is fully destructive. There is likely to be an imperfect match between the ROIs and 
the cuts made for the tissue iron samples which could affect T1 and T2 but we have tried to 
minimise this as far as possible. 
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7.5 CONCLUSIONS 
From the data which we have presented, myocardial T2 has a good correlation with tissue 
iron concentration and importantly, the T2 measured in a non iron-loaded formalin fixed 
heart compares well with the expected T2 value of normal, healthy myocardium in vivo. T2 
correlates well with T2* and the measurement of T2 may provide additive information to T2* 
for patients with myocardial siderosis. In comparison, ex-vivo T1 measurements are much 
less reliable and further work will be required before a calibration for T1 and iron 
concentration can be produced.  
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CHAPTER 8: RELATION OF MYOCARDIAL T2* TO RIGHT VENTRICULAR FUNCTION IN 
THALASSAEMIA MAJOR 
8.1 INTRODUCTION 
For patients with beta-thalassaemia major, heart failure due to myocardial iron overload 
remains the main cause of mortality. In developed countries until recently [Modell 2008a],  it 
has accounted for up to 71% of all deaths, with up to 50% of these patients dying before 35 
years of age, despite iron-chelating therapy [Modell 2000, Borgna-Pignatti 2004]. 
Fortunately, this form of cardiomyopathy can be reversible if detected early and appropriately 
treated, but once symptoms of heart failure develop, prognosis is poor [Felker 2000].  
 
As already discussed, cardiovascular magnetic resonance (CMR) has emerged as the most 
useful non-invasive tool for evaluating the amount of iron in the heart. It has been shown that 
lower myocardial T2* values are associated with an increased likelihood of left ventricular 
(LV) dysfunction [Anderson 2001], whereas an improvement in myocardial T2* results in 
improvement in LV ejection fraction (EF) [Anderson 2004]. These findings have been 
confirmed in observational, prospective and randomised controlled studies of iron chelation 
in thalassaemia patients [Anderson 2002 and 2004, Tanner 2007 and 2008, Pennell 2006]. 
However, the relation between myocardial iron loading and right ventricular (RV) function 
has not been fully addressed. RV EF is an important predictor of outcome in other forms of 
cardiomyopathy, which is both independent of and incremental to LV EF [Juillière 1997]. 
Accordingly, the effects of myocardial iron loading on RV function may be important in 
thalassaemia patients.  As CMR is considered to be the most accurate and reproducible 
technique for assessing RV volumes and EF [Grothues 2002 and 2004], it provides an ideal 
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opportunity to correlate myocardial iron loading with RV function. Therefore, the aim of this 
study was to evaluate the relationship between myocardial T2* and RVEF in patients with 
thalassaemia major.  
 
8.2 METHODS 
8.2.1 Study population 
We analysed a database of 323 consecutive patients with beta-thalassaemia major who were 
referred for their first myocardial T2* scan from 21 UK haematology centres. All the patients 
included in this analysis were treated with a single iron chelation agent (deferoxamine) at 
presentation. They had all received iron chelation therapy since the mid-to-late 1970s or from 
an early age if born after this. Any patient with suspected pulmonary hypertension (defined as 
tricuspid regurgitant jet velocity of >3.0 m/sec on transthoracic echocardiogram) or any other 
known or potential cause of RV abnormality was excluded (eg. congenital heart disease, 
valve disease, lung disease) [Galie 2009]. Four patients were excluded from the final analysis 
due to cardiac or vascular anomalies (one aortic stenosis, one subaortic shelf, one pulmonary 
artery stenosis, and one repaired tetralogy of Fallot). The residual cohort consisted therefore 
of 319 patients, (144 males and 175 females), with a mean age of 26.5 ±8.9 years (table 8.1). 
At the time of their first CMR scan, 21 of the patients were taking medication for LV 
dysfunction or heart-failure (diuretics, beta-blockers or angiotensin-converting-enzyme 
inhibitors). The data collection and analysis associated with this study was approved by Trent 
NHS Research Ethics Committee. 
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Table 8.1 - Patient demographics and summary of CMR parameters 
Patient demographics 




Body surface area (m2) 
 





T2* (geometric mean ±CV%) 
Cardiac T2* (ms) 




CMR parameters for all patients 
RV ejection fraction (%) 
LV ejection fraction (%) 
RV end systolic volume index (mL/m2) 
RV end diastolic volume index (mL/m2) 








Serum ferritin (μg/L) 
Mean pre-transfusion haemoglobin (g/dL) 




























Data are presented as mean ±SD or number (%), unless otherwise stated. 
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8.2.2 Magnetic resonance 
Patients were scanned with a 1.5T Sonata scanner (Siemens Medical Systems, Erlangen, 
Germany). Each scan included the measurement of heart T2* (mid-septum) together with left 
and right ventricular volumes, ejection fraction and mass using previously published 
techniques [Westwood 2003, Maceira 2006a and 2006b]. T2* measured in the mid-
ventricular septum is known to be a reliable estimation of cardiac iron loading [Ghugre 2006 
and 2006b, Pepe 2006b]. Scan duration was approximately 15-20 minutes. For the 
measurement of myocardial T2*, a single short axis mid-ventricular slice was acquired using 
a single breath-hold ECG-gated multi-echo technique. This T2* sequence generated a series 
of 8 images with a range of echo times (TE = 2.54-17.9 ms).  
 
8.2.3 CMR analysis 
Myocardial T2* was calculated from a full-thickness region of interest in the interventricular 
septum using Thalassaemia-tools as previously described. The T2* value of 20ms is widely 
accepted in clinical practice as a cutoff for normality and was therefore chosen to define the 
lower limit of the normal range in this study [Anderson 2001]. 
 
RV and LV volumes were determined from steady-state free precession cines, with 
contiguous short-axis slices from base to apex as previously described (7mm slice thickness 
with 3mm gap) [Maceira 2006a and 2006b]. Ventricular volumes and ejection fraction were 
analyzed with CMRtools (Cardiovascular Imaging Solutions, London). Three main steps for 
volume analysis were performed. Firstly, both RV and LV endocardial and epicardial borders 
were delineated in all phases of the cardiac cycle in the short-axis slices. Then, valve plane 
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tracking of the tricuspid and mitral valves was used to correct for alteration in volume due to 
descent of the AV ring towards the apex during systole. Finally, blood pool thresholding was 
used to delineate the papillary muscles and RV trabeculations (which were excluded from 
ventricular volume measurements). LV and RV volumes were indexed to body surface area 
(BSA). The normal ranges for LV and RV volumes and function were taken from previously 
published data with the lower limit of normal for RV EF in healthy subjects being 54% and 
the lower limit of normal for LV EF in non-iron overloaded thalassaemia patients being 59% 




8.2.4 Statistical analysis 
All parameters are presented as mean ± standard deviation, except T2* which is shown as 
geometric mean (antilog of the mean of the log data) and percent coefficient of variation (CV 
- equivalent to the variance of the mean in log scale) following log transformation of data to 
normalize the data distribution. Spearman’s rank test was used to assess the correlation 
between myocardial T2*, ferritin, RV volumes and EF. Analysis of variance (ANOVA) was 
used to assess differences across different ranges of myocardial T2*. Two sided statistical 
significance was set at p<0.05. All statistical analysis was performed using Stata 10.1 
software (StataCorp, Texas, USA). 
 
8.3 RESULTS 
In thalassaemia patients with a normal myocardial T2* (>20ms), RV EF was 65.0 ±6.1%, and 
was distributed within the normal range of expected values in 98% of patients. In patients 
with myocardial siderosis (T2* <20ms), there was a progressive and significant decline in RV 
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EF (r=0.43, P<0.001; figure 8.1) and an increase in the RV end-systolic volume (r=-0.33, 
p<0.001; figure 8.2). In contrast to ejection fraction and end-systolic volume index, there was 
no significant correlation of either RV end-diastolic volume index or RV mass index with 
T2*. Of the 165 patients with myocardial siderosis (T2* <20ms), 23 (14%) were found to 
have an RV EF below the lower limit of the normal range. Of the patients with impaired RV 
EF, 82.6% also had an impaired LV EF. There were four patients with T2* <20ms who had 
impaired RV EF but a normal LV EF. None of the patients had documented pulmonary 
hypertension. The mean RV EF for these patients was 49 ±1.6% and the mean LV EF was 
towards the lower limit of the normal range (62 ±3.8%). Both RV mass and the pulmonary 
artery diameter were normal (mean RV mass index 28 ±4.6g/m
2
, mean PA diameter 18 
±3.7mm). No septal flattening or tricuspid valve regurgitation was seen on cine images. All 
four patients had severe myocardial iron loading with T2* ranging from 5.0 to 9.2ms (mean 
T2* 7.0 ±2.1ms). All were on the same transfusion regime (2 units of packed red cells every 
four weeks, mean annual red cell consumption 129mL/kg/year), none had undergone 
previous splenectomy and none had symptoms of heart failure. Apart from 
hypogonadotrophic hypogonadism in one patient and osteoporosis in another, there were no 
other complications. Serum ferritin ranged from 723 to 4673μg/dl (mean ferritin 1772 
±1937μg/dl). 
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Figure 8.1. The relationship between myocardial T2* and right ventricular ejection fraction. 
The vertical broken line shows the lower limit of the normal range for T2* of 20ms. The 
horizontal line shows the lower limit of the normal range for right ventricular ejection 
fraction of 54%. 
 
 
Figure 8.2. The relationship between myocardial T2* and right ventricular end-systolic 
volume indexed to body surface area. The vertical broken line shows the lower limit of the 
normal range for T2* of 20ms. The horizontal line shows the upper limit of the normal range 
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LV EF was 69.5 ±5.2%, and was within normal limits in 99% of thalassaemia patients with a 
normal T2*. Below 20ms, LV EF showed a significant decline with lower T2* values 
(r=0.40, p<0.001; figure 8.3). Of patients with myocardial siderosis (T2* <20ms) 47 (28.4%) 
had reduced LV EF, of which, 19 (40.4%) also had a low RV EF. Linear regression between 
RV EF and LV EF showed a significant relation (r=0.69, p<0.001; figure 8.4). A comparison 
of two representative patients is shown in figure 8.5, one with severe myocardial iron loading 
and poor biventricular function and the other with no evidence of myocardial iron loading 
and normal ventricular function. 
 
A summary of the ventricular and haematological parameters in three different T2* ranges 
(less than 10ms, 10-20ms and more than 20ms) is shown in table 8.2. Differences between 
groups were found for RV and LV EF, RV end-systolic volume index and serum ferritin. No 
difference was found between groups for RV end-diastolic volume index, RV mass index, 
pre-transfusion haemoglobin, yearly transfusion or total units transfused. No correlation was 
found between any of the haematological parameters (including ferritin) and RVEF. There 
was a weak negative correlation between ferritin and myocardial T2* when the whole patient 
cohort was considered (r= -0.22, P<0.001). 
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Figure 8.3. The relationship between myocardial T2* and left ventricular ejection fraction. 
The vertical broken line shows the lower limit of the normal range for T2* of 20ms. The 
horizontal line shows the lower limit of the normal range for left ventricular ejection fraction 
in thalassaemia major patients of 59%. 
 
 
Figure 8.4.  The relationship between RV ejection fraction and LV ejection fraction. 
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Table 8.2 – Breakdown of CMR parameters for different ranges of T2* 
T2* range <10ms 10-20ms >20ms P value 
Number of patients 
Male (%) 
LV ejection fraction (%) 
RV ejection fraction (%) 
RV end systolic volume index (mL/m2) 
RV end diastolic volume index (mL/m
2
) 
RV mass index (g/m2) 
Ferritin (μg/L) 
Pre-transfusion haemoglobin (g/dL) 
Red cell consumption (units/year) 














































Data are presented as mean ±SD. P values given are for analysis of variance (ANOVA) 
between groups. 
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The top row of images (A-C) shows a patient with raised right and left ventricular volumes in 
end-diastole (A) and end-systole (B), poor biventricular ejection fraction (RV EF = 25% and 
LV EF = 22%) and severe iron overload. Myocardial T2* is 5.4ms (C). The lower row shows 
end-diastolic (D) and end-systolic (E) images from a patient with normal biventricular 
ejection fraction (RV EF = 61% and LV EF = 66%) and no myocardial iron loading (T2* is 
29.8ms – panel F). The dotted line in each case denotes the level of the atrio-ventricular 
junction at end-diastole to illustrate the long-axis contraction of the heart in systole. TE = 
Echo time. 
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8.4 DISCUSSION 
Heart failure due to iron-overload cardiomyopathy is the dominant cause of mortality in 
patients with thalassaemia major. Iron overload in thalassaemia major occurs due to a 
combination of repeated blood transfusions, with each unit of blood containing 200-250mg of 
elemental iron, and excessive gastrointestinal absorption. Excess body iron is stored in 
ferritin and its degradation product hemosiderin. In the heart, this results in impaired function 
of the mitochondrial respiratory chain, ventricular dysfunction and the potential for 
progression to heart failure [Hershko 1998]. In this study, we have evaluated the relationship 
between myocardial iron loading and right ventricular function. Our data show mirror effects 
on both LV and RV volumes and ejection fraction. We found a normal RV EF in 98% of 
patients with normal myocardial T2* values, but progressive RV enlargement and 
dysfunction with increasing myocardial siderosis. The RV and LV EF showed significant 
correlation. Aside from myocardial iron loading, we did not identify any clinical factors that 
could explain the observed effects on ventricular function. 
 
In the original validation study by Anderson et al, myocardial T2* values in the normal range 
were associated with normal LVEF values, but when myocardial T2* fell below 20ms, a 
progressive deterioration in LVEF was seen [Anderson 2001], and this finding has been 
reproduced once again in this large cohort. There is limited data examining the relation 
between cardiac T2* and RV function [Pepe 2006a, Hahalis 2002], The importance of the 
right ventricle as an aggravating factor in heart disease and a predictor of adverse cardiac 
outcomes has often been overlooked in the past. Studies have indicated the importance of RV 
function in conditions such as congenital heart disease [Roos-Hesselink 2004, Graham 2000, 
Gatzoulis 1995], dilated cardiomyopathy [Juillière 1997, La Vecchia 2001], chronic systolic 
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dysfunction [Meyer 2010], and ischemic heart failure [Di Salvo 1995, de Groote 1998, Ghio 
2001]. In these studies, RV dysfunction was a strong predictor of mortality and outcomes in 
heart failure, irrespective of etiology, and independent of the LV function, New York Heart 
Association (NYHA) functional class of heart failure, or peak oxygen consumption. This 
suggests that RV function may be a significant contributor to the clinical manifestation of 
heart failure seen in severe myocardial siderosis. The finding of a close correlation between 
LV and RV function suggests that there is diffuse myocardial toxicity due to excess iron and 
that this plays an important role in both left and right ventricular dysfunction in this type of 
cardiomyopathy. This pattern is typical of non-ischemic cardiomyopathy, where RV 
dysfunction is common and more closely parallels LV dysfunction in contrast with the 
predominant LV impairment seen in ischemic heart failure.  
 
The function of the right ventricle may be affected by pulmonary hypertension (PHT) which 
can occur as a complication in patients with thalassaemia [Aessopos 2005a]. Initial reports 
suggested that increased pulmonary systolic pressure was a common finding in thalassaemia 
major patients but some of these early results were based on a cohort of patients who were 
under-transfused and poorly chelated [Grisaru 1990, Du 1997]. Subsequent studies in well-
treated Italian and Greek patients have not confirmed these findings, with PHT being 
practically absent in thalassaemia major patients with a high standard of care [Derchi 1999, 
Aessopos 2004]. In contrast, PHT is a prominent finding in patients with thalassaemia 
intermedia [Aessopos 2005b]. While beta-thalassaemia major is a severe anemia which 
presents within the first years of life and requires lifelong transfusions to prolong survival, 
thalassaemia intermedia is milder with a later clinical onset. In one series of 110 thalassaemia 
intermedia patients, PHT was found in nearly 60%, causing RV failure in approximately 5% 
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although all patients had preserved LV systolic function [Aessopos 2001]. Despite this, a 
recent study has shown that patients with thalassaemia intermedia have a higher RV EF than 
those with TM [Mavrogeni 2008]. The current study included only thalassaemia major 
patients, all of whom had been transfused from an early age and none had evidence of 
pulmonary hypertension on transthoracic echocardiography. In the small number of patients 
where there was isolated RV impairment, all had severe myocardial iron loading with T2* 
values below 10ms and LV EF was at the lower end of the normal range. None of the patients 
had known pulmonary hypertension and there were no CMR features to suggest that the RV 
impairment was related to raised pulmonary artery pressure. It is likely that the RV 
impairment in these four cases is a precursor to LV impairment secondary to severe iron 
loading since T2* values below 10ms are a strong predictor of the development of heart 
failure [Kirk 2009]. 
 
There is limited previous data on RV function in myocardial siderosis. Pepe et al compared 
patients taking different iron chelating agents and found no correlation between myocardial 
T2* and RV EF [Pepe 2006a]. This may be explained by the small study population and the 
small proportion of patients with significant myocardial iron loading. In a study of 26 patients 
with symptomatic heart failure (NYHA class III -IV), LV EF (measured by single plane area-
length echocardiography) was compared with RV EF (measured by first-pass radionuclide 
angiography) [Hahalis 2002]. Our findings not only confirm that RV and LV function are 
often correlated but also provide evidence that both RV and LV impairment are strongly 
related to myocardial iron overload. In addition, we have used CMR which is considered to 
be the gold-standard for the assessment of both right and left ventricular volumes and 
function [Grothues 2002 and 2004].  
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8.4.1 Limitations 
The data was analysed retrospectively from a prospectively accumulated database. RVEF is 
highly dependent on loading conditions and may not adequately reflect RV contractility, 
however it is the most widely available method for assessing RV function. These T2* values 
only apply at a field strength of 1.5T, and the relaxation parameters will be different at higher 
field strengths such as 3T which is becoming more widely available for clinical scanning. We 
measured myocardial T2* in the interventricular septum, using this value to give an 
assessment of global myocardial iron loading. Although this is an indirect measurement of 
RV iron, direct measurement of T2* in the right ventricular free wall is not robust as the 
myocardium is very thin, close to the chest wall and susceptible to artefact. Patients 
underwent regular cardiology assessment which included transthoracic echocardiography. 
We excluded patients with pulmonary hypertension (defined as tricuspid regurgitant jet 
velocity of >3.0 m/sec on transthoracic echocardiography) but echocardiograms were not 
performed at the time of the CMR studies. We did not find any significant increase in RV 
mass index in this cohort (compared with normal reference values for healthy subjects) and 
there was no significant difference in RV mass between those patients with T2* less than 
20ms and those with a T2* of >20ms. In this study, we did not assess biomarkers (such as 
brain natriuretic peptide or BNP) or the presence of late enhancement following gadolinium 
injection, both of which could give further insight into the mechanism of both RV and LV 
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8.5 CONCLUSIONS 
Increasing myocardial siderosis as assessed by T2* CMR is associated with RV dysfunction, 
and this may be a significant contributor to heart failure in thalassaemia major. Further 
studies are required to determine the relative importance of RV function compared with LV 
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CHAPTER 9: RIGHT VENTRICULAR VOLUMES AND FUNCTION IN 
THALASSAEMIA MAJOR PATIENTS IN THE ABSENCE OF MYOCARDIAL IRON OVERLOAD 
9.1 INTRODUCTION 
Patients with beta-thalassaemia major (TM) have a severe hereditary anaemia which requires 
lifelong transfusions to prolong survival and allow normal development [Weatherall 2001]. 
Previously published data have shown that indices of the left ventricle (LV) such as 
ventricular volumes and ejection fraction (EF) differ in non cardiac iron loaded TM patients 
from healthy non-anaemic controls. [Westwood 2007, Maceira 2006a]. These differences in 
the normal range of expected values are most likely due to chronically increased cardiac 
output related to the anaemia and affect the interpretation of measurements of ventricular 
function from echocardiography and cardiovascular magnetic resonance (CMR). This is 
important with regard to the early detection of impaired EF because the use of inappropriate 
reference values may mask the diagnosis of underlying iron-overload cardiomyopathy and 
this can result in delayed treatment or a preventable episode of heart failure, which places the 
patient at high risk [Felker 2000]. Conversely, an apparently dilated heart in a TM patient 
may be within normal limits for the non-iron overloaded TM population. Although it has 
been shown that both RV and LV EF are reduced by iron loading [Anderson 2001, 
Alpendurada 2010], the normal ranges for RV parameters and function in TM patients who 
have no evidence of cardiac iron loading are unknown.
 
The aim of this study therefore was to 
define the normal reference ranges for RV volumes, ejection fraction and mass in non-iron 
overloaded transfusion dependent TM patients in comparison with non-anaemic healthy 
controls. Using a similar approach to chapter 8, CMR was used for this assessment as it is 
regarded as the gold-standard technique for measurement of both LV and RV
 
volumes and 
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function [Grothues 2002 and 2004, Bellenger 2000], and can also measure myocardial iron 
loading using myocardial T2*. 
 
9.2 METHODS 
9.2.1 Study population 
We performed a retrospective analysis of patients with beta-thalassaemia major who were 
referred for their first myocardial T2* scan from 21 UK hematology centres. All patients 
were regularly transfused (every 3-4 weeks) to maintain pre-transfusion haemoglobin levels 
of 9-10 g/dl and all had received iron chelation therapy from an early age or from the mid-to-
late 1970s if born before this time. To remove any possible effects of different iron chelating 
agents, only patients taking deferoxamine as a single iron chelator were included. None of the 
patients had received treatment with either of the oral chelating agents (deferiprone or 
deferasirox). Forty male and forty female patients over the age of 18 years who had no 
myocardial iron loading (defined as having cardiac T2* > 20ms) and no history of any known 
cardiovascular pathology were identified from the initial target population of 323 patients. 
The cut-off value for normal T2* was based on the lower limit of normal observed in a cohort 
of healthy volunteers [Anderson 2001]. Patients with evidence of pulmonary hypertension 
(defined as tricuspid regurgitant velocity > 3.0m/s at rest by transthoracic echocardiography) 
were excluded. Forty age and sex matched healthy non-anaemic volunteers formed a control 
population for comparison. All control subjects were healthy, asymptomatic volunteers with 
no cardiovascular risk factors or history of cardiac disease. Each had a normal 12 lead 
electrocardiogram and no abnormal signs on physical examination. This study was approved 
by the local NHS Research Ethics Committee. Written informed consent was obtained from 
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all of the volunteers. For the TM patients, the Ethics Committee granted permission for 
review of clinical and scan data, waiver of informed consent and anonymous publication. 
 
9.2.2 Cardiovascular Magnetic resonance 
All scans were performed using a 1.5T Sonata scanner (Siemens Medical Systems, Erlangen, 
Germany). After routine localizer images, each scan comprised of a contiguous set of breath-
hold steady state free precession (SSFP) short-axis cines at 10mm intervals from base to apex 
(7mm slice thickness with 3mm gap) using standardised techniques as previously described 
[Maceira 2006a and 2006b]. An ECG gated breath-hold bright blood multi-echo sequence 
was also used to acquire a single short axis mid-ventricular slice for the measurement of 
myocardial T2*. This sequence generated a series of images with a range of equally spaced 
echo times (TE = 2.6–16.7 ms) [Westwood 2003a]. 
 
9.2.3 CMR analysis  
Right ventricular volumes and mass were measured from the SSFP cines as previously 
described [Maceira 2006b, Bellenger 2002], using CMRtools (Cardiovascular Imaging 
Solutions, London). This involved tracing the endocardial and epicardial borders at end-
diastole and end-systole with semi-automated thresholding to delineate the blood pool. RV 
trabeculations were excluded from the blood pool volume but included in the RV mass 
calculation. The tricuspid valve plane was tracked in both systole and diastole to ensure that 
any blood signal from the right atrium was excluded from the ventricular volume calculation. 
Any of the blood pool signal above the pulmonary valve was also excluded from the 
ventricular volume using the endocardial contour definitions. Cardiac output was calculated 
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from the product of right ventricular stroke volume and the mean heart rate recorded at the 
time of the CMR scan. RV parameters were indexed to body surface area (BSA) which was 
derived using the Mosteller formula [Mosteller 1987]. Myocardial T2* was measured from a 
single full thickness region of interest in the septum of the mid-ventricular slice using semi-
automated software (Thalassemia-tools, Cardiovascular Imaging Solutions, London, UK). 
For the analysis of T2*, mean signal intensity was plotted against the echo time for each 
image in the series. The T2* value was calculated as previously described from the resulting 
exponential decay curve after truncating the curve to correct for background noise [He 
2008b].  
 
9.2.4 Haemoglobin measurements 
Pre-transfusion haemoglobin measurements were compared with right ventricular parameters. 
Where the interval between the haemoglobin measurement and the index CMR scan 
exceeded 1 week, patients were excluded from this part of the analysis.   
 
9.2.5 Statistical analysis 
All continuous parameters were found to be normally distributed and are therefore presented 
as mean ± standard deviation (SD). An unpaired two-tailed t-test was used to compare TM 
patients with the healthy non-anaemic volunteers. Separate analysis was performed for males 
and females due to known gender-specific differences for left and right ventricular 
parameters. Pearson correlation was used to compare haemoglobin measurements with the 
RV volumes and function measurements. Statistical significance was set at p < 0.05. All 
statistical analysis was performed using Stata 10.1 software (StataCorp, Texas, USA). 
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9.3 RESULTS 
9.3.1 Patient population 
A summary of the demographics for the patients and the control population is given in table 
9.1. Both groups were well matched for age and sex. The body mass index was equivalent in 
females but was slightly higher in the male control population than the TM patients. 
However, both male and female TM patients had significantly lower weight, height and body 
surface area than the non-anaemic controls. Resting heart rate in TM patients was also 
significantly higher than in the healthy controls. 
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Table 9.1. Demographics for TM patients and controls.  
 TM patients 
Mean ± SD 
Controls 
Mean ± SD 
P value 
Males    
Age (years) 30 ± 8 30 ± 5 0.94 
Height (m) 1.65 ± 0.1 1.80 ± 0.09 <0.0001 
Weight (kg) 59.1 ± 8.9 75.8 ± 9.9 <0.0001 
BMI (kg/m2) 21.9 ± 3.1 23.6 ± 3.1 0.048 
BSA (m2) 1.64 ± 0.16 1.94 ± 0.15 <0.0001 
Heart rate (min-1) 72.7 ± 10.4 64.0 ± 9.5 0.0024 
Females 
 
   
Age (years) 30 ± 8 30 ± 5 0.88 
Height (m) 1.54 ± 8.9 1.67 ± 9.2 <0.0001 
Weight (kg) 53.3 ± 10.1 61.4 ± 11.3 0.0064 
BMI (kg/m2) 22.5 ± 4.5 22.0 ± 2.8 0.68 
BSA (m2) 1.50 ± 0.15 1.68 ± 0.18 0.0001 
Heart rate (min-1) 78.8 ± 10.1 64.8 ± 13.6 <0.0001 
 
BSA – body surface area, BMI – body mass index. 
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9.3.2 Right ventricular parameters  
The right ventricular parameters are detailed in table 9.2, and represented graphically in 
figures 9.1 and 9.2. The mean and upper limit of end-diastolic RV volume were higher in TM 
patients than controls for males, but this was borderline significant for females (p = 0.027 for 
males, p = 0.093 for females). RV stroke volume and RV ejection fraction were higher in TM 
patients for both males (p = 0.0015 for stroke volume, p = 0.0009 for RV EF) and females (p 
= 0.0030 for stroke volume, p = 0.017 for RV EF). The lower limit of RV EF was higher in 
TM patients (males 58.0% vs 50.0%, females 56.4% vs 50.1%). The cardiac output was 
higher in the TM cohort than controls (p = 0.014 for males, p = 0.0033 for females) and this 
finding was confirmed when cardiac output was indexed for BSA (cardiac index, p < 0.0001). 
No significant difference was found however between TM patients and controls for either RV 
end-systolic volume index or RV mass index (p = 0.11 to 0.77). 
 
9.3.3 Correlation with haemoglobin levels  
Haemoglobin results which coincided with CMR scans (blood tests within one week of the 
scan) were obtained in 59% of the patients investigated. There was no difference in any of the 
RV parameters between those patients with haemoglobin results and those in whom the 
results were unavailable. Mean haemoglobin level was 9.7 ± 1.8g/dL for males (n = 20) and 
10.5 ± 1.4g/dL for females (n = 27). In the female TM patients, no significant correlations 
existed between haemoglobin concentration and any of the RV parameters. In male TM 
patients, an inverse correlation was found between cardiac index and haemoglobin (r = -0.47, 
p = 0.04). No other significant correlation was found. 
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Table 9.2. Right ventricular parameters for males and females. 
 TM patients 
(mean ± SD) 
[95% CI] 
Controls 





   
RVEDVI (mL/m2) 
98.1 ± 17.3 
[64.2 – 132.0] 
88.4 ± 11.2 
[66.5 – 110.4] 
0.027 
RVESVI (mL/m2) 
33.2 ± 8.0 
[17.5 – 48.8] 
33.8 ± 5.0 





64.7 ± 11.2 
[42.7 – 86.6] 
54.7 ± 10.3 
[34.6 – 74.8] 
0.0015 
RVEF (%) 
66.2 ± 4.1 
[58.0 – 74.3] 
61.6 ± 6.0 
[50.0 – 73.3] 
0.0009 
RVMI (g/m2) 
38.8 ± 7.9 
[23.3 – 54.4] 
36.4 ± 7.8 
[21.1 – 51.7] 
0.27 
CO (L/min) 
7.9 ± 1.9 
[4.16 – 11.5] 
6.6 ± 1.6 
[3.4 – 9.8] 
0.014 
CI (L/min/m2) 
4.8 ± 1.0 
[2.9 – 6.7] 
3.4 ± 0.7 




   
RVEDVI (mL/m2) 
86.5 ± 13.6 
[59.8 – 113.2] 
80.3 ± 12.8 





29.2 ± 7.2 
[15.1 – 43.2] 
30.3 ± 8.6 





57.4 ± 9.2 
[39.4 – 75.5] 
50.0 ± 7.8 
[34.7 – 65.2] 
0.0030 
RVEF (%) 
66.3 ± 5.1 
[56.4 – 76.2] 
62.6 ± 6.4 
[50.1 – 75.0] 
0.017 
RVMI (g/m2) 
34.0 ± 7.7 
[18.8 – 49.1] 
30.8 ± 5.3 
[20.5 – 41.1] 
0.11 
CO (L/min) 
6.8 ± 1.7 
[3.5 – 10.1] 
5.5 ± 1.5 





4.5 ± 0.8 
[2.9 – 6.2] 
3.2 ± 0.8 
[1.7 – 4.8] 
<0.0001 
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All values are quoted as mean ± SD with 95% confidence intervals in square brackets. The 
table is divided into TM patients with no evidence of cardiac iron overload and age-matched 
healthy controls. 
RVEDVI = right ventricular end-diastolic volume index, RVESVI = right ventricular end-
systolic volume index, RVSVI = right ventricular stroke volume index, RVEF = right 
ventricular ejection fraction, RVMI = right ventricular mass index, CO = cardiac output, CI = 
cardiac index  
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Figure 9.1. Right ventricular volumes and ejection fraction in male TM patients and controls. 
RVEDVI = right ventricular end-diastolic volume index, RVESVI = right ventricular end-
systolic volume index, RVSVI = right ventricular stroke volume index, RVEF = right 
ventricular ejection fraction, RVMI = right ventricular mass index.  
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Figure 9.2. Right ventricular volumes and ejection fraction in female TM patients and 
controls. RVEDVI = right ventricular end-diastolic volume index, RVESVI = right 
ventricular end-systolic volume index, RVSVI = right ventricular stroke volume index, 




Chapter 9 Page 174 Normal RV ranges in TM 
 
9.4 DISCUSSION 
Cardiac complications due to myocardial siderosis remain a serious problem for TM patients. 
Until recently, more than 50% of TM patients died before the age of 35 from cardiac failure 
[Modell 2000]. The monitoring of cardiac iron using T2* CMR has had a major impact on 
saving the lives of patients by identifying cardiac iron overload prior to the occurrence of 
heart failure which therefore allows tailored cardiac chelation [Modell 2008a]. However, 
cardiac T2* is not available in all centres and non-cardiac measures of iron loading are not 
satisfactory for assessing the risk of heart failure in comparison with cardiac T2* [Kirk 
2009]. An indirect approach to assessment of cardiac iron loading is to measure cardiac 
volumes and function. Although the literature establishing the value of this approach is rather 
sparse [Davis 2004], it has the merit that techniques for assessment of cardiac function such 
as echocardiography are widely available and its application is included in some clinical 
guidelines [Yardumian 2008]. In favour of the use of functional heart measurements is the 
clear evidence of a correlation with cardiac iron loading that is not present for cross-sectional 
measures of blood iron (ferritin) or liver iron [Anderson 2001]. Any such approach however, 
requires that normal values for TM patients who do not have cardiac iron loading are 
established. Previous data has shown that left ventricular volumes and function in non cardiac 
iron loaded TM patients are significantly different from healthy non-anaemic controls 
[Westwood 2007], but there is no data on the normal values of RV volumes and function in 
non cardiac iron loaded patients with TM. The right ventricle has consistently been 
underestimated as an important factor in heart disease and its power to predict adverse 
cardiac outcomes, which is independent and additional to LV function, has often been 
overlooked in the past. The balance has been addressed in a number of relatively recent 
studies of the RV in association with outcomes in heart failure syndromes related to dilated 
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cardiomyopathy [La Vecchia 2001], chronic systolic dysfunction [Meyer 2010], and ischemia 
[Di Salvo 1995, de Groote 1998, Ghio 2001],
 
and also in patients with congenital heart 
disease [Roos-Hesselink 2004, Graham 2000, Gatzoulis 1995]. This suggests that RV 
function may be a significant contributor to the clinical manifestation of heart failure seen in 
myocardial iron overload. Therefore in this study, we evaluated RV parameters using CMR 
in a population of regularly transfused TM patients with no cardiac iron loading or pulmonary 
hypertension or other cardiac morbidity and have compared the findings to those of healthy 
non-anaemic subjects to established reference ranges that would prove useful to assess the 
functional effects on the heart of iron overload. Many TM patients have growth retardation 
with short stature and low body weight. The direct comparison of raw RV indices between 
TM patients and a cohort of healthy non-anemic subjects therefore requires indexing the RV 
volumes to body surface area.  
 
Our results show that compared with healthy non-anaemic controls, TM patients have a 
higher RV stroke volume and heart rate, which results in a higher cardiac output. The RV EF 
is also increased mainly as a result of an increased end-diastolic volume. These results are 
similar to the observations of LV parameters in TM but the differences in RV parameters 
appear to be less pronounced than those found for the LV [Westwood 2007]. Our results 
stress that if functional measurements of the heart are to be made and used clinically to 
indirectly assess cardiac iron loading, then it is vital to use reference ranges from TM patients 
with no cardiac iron loading as presented from this study in order to prevent underdiagnosis 
of cardiac siderosis when using the EF, or its overdiagnosis when using the end-diastolic 
volume.  
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No correlation between haemoglobin level and RV parameters was identified in female TM 
patients but in males, there was an inverse correlation between haemoglobin and cardiac 
index. It is not evident why male and female patients differ but the result mirrors previous 
observations [Westwood 2007]. An inverse relationship between haemoglobin and cardiac 
index is predictable, and indicates a higher output state with a greater degree of anaemia. 
There was no correlation between haemoglobin and RV EF for either sex, a finding supported 
by a previous study which found no difference in LV EF using radionuclide ventriculography 
both before and 24 hours after blood transfusion [Davis 2004]. Pulmonary hypertension 
(which may depress RV function and cause right heart failure) has been described in 
thalassaemia patients but although it is prominent in those with thalassaemia intermedia, it is 
uncommon in well treated TM patients [Aessopos 2004, 2005a and 2005b]. Not only have we 
purposely excluded patients with pulmonary hypertension from this study, but we also found 
no significant difference in RV mass between cases and controls, a sensitive and specific 
measure for the diagnosis of pulmonary hypertension using CMR [Saba 2002]. Therefore we 
believe there is no confounding of our results from pulmonary hypertension.  
 
The right ventricle has a complex anatomical structure in comparison to the LV. Whereas the 
LV is approximately circular in cross-section, the RV is crescentic, wrapping around the LV 
with separate inflow and outflow portions, the tricuspid and the pulmonary valves being 
physically separated by a muscular subpulmonary infundibulum. The RV is thin walled with 
many trabeculations and there is a moderator band of myocardial tissue towards the apex. All 
of these features create challenges for modeling RV volumes, making it more difficult to 
perform reliable measurements using standard echocardiographic techniques. CMR is able to 
overcome most of these issues and is currently considered the gold standard for the 
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measurement of cardiac volumes and function [Grothues 2004], with well defined normalized 
values for the RV [Maceira 2006]. The relative accuracy of echocardiography in relation to 




There is previously published data regarding RV function in patients with established heart 
failure due to myocardial siderosis and other studies have reported RV parameters in TM 
patients across a wide range of iron loading [Hahalis 2002, Mavrogeni 2008, Pepe 2006a]. 
However, our study focuses only on RV volumes and function in TM patients without 
evidence of cardiac iron loading.  
 
9.4.1 Limitations 
We have restricted our investigation to CMR parameters of RV function and comparisons 
with RV measurements from other imaging modalities should be interpreted with caution. 
While RV EF is the most widely available method for assessing RV function, it may not 
adequately reflect RV contractility and other techniques for the assessment of the RV may 
provide additional insights. For the haemoglobin correlation, we only used results in a subset 
of the patients for which the time between the CMR scan and the haemoglobin estimation 
was less than 1 week. Subset analysis showed no significant differences in any of the RV 
parameters between patients with and those without haemoglobin results. We did not have 
reliable information regarding the date of the most recent transfusion prior to the CMR 
assessment in the TM cohort. While transfusion could potentially affect RV parameters 
including RV EF, there is only limited data regarding the effects of transfusion on ventricular 
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function. For the LV, no significant difference in LV EF is observed between measurements 
taken before or 24 hours after blood transfusion [Davis 2004].  
 
9.5 CONCLUSION 
Our findings show that the normal ranges for RV parameters differ between TM patients 
without cardiac iron loading and normal, non-anaemic controls. The lower limit of RVEF in 
TM patients without cardiac iron loading is significantly higher than the lower limit of the 
normal range in controls which could lead to under-diagnosis of iron-loading cardiomyopathy 
if this is not appreciated. It is important to use reference ranges which are specific to non-
cardiac iron loaded TM patients when assessing cardiac volumes and function as a surrogate 
for cardiac iron loading.  
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Of more than 300,000 children born each year with a haemoglobinopathy, some 50,000 have 
a major thalassaemia, of which, 30,000 need regular transfusion to survive beyond infancy. 
Most are born in low-income countries and it is estimated that almost 90% of these patients 
worldwide do not have access to regular blood transfusions. Of those that do receive 
transfusion, less than half obtain adequate chelation therapy to prevent cardiac siderosis and 
approximately 3000 die each year due to uncontrolled iron overload in their mid-20s [Modell 
2008b]. Myocardial iron overload (due to both excess gastrointestinal uptake and multiple 
transfusions) leads to heart failure and remains one of the leading causes of premature death. 
Cardiovascular magnetic resonance (CMR) is routinely used in many countries for 
monitoring chelation therapy and, as has already been mentioned, CMR T2* is a better 
indicator of myocardial iron loading than any of the ‘classical’ indices such as serum ferritin, 
liver iron, endomyocardial biopsy, ventricular ejection fraction and transthoracic echo tissue 
Doppler parameters [Anderson 2001, Telfer 2000, Leonardi 2008, Fitchett 1980, Olson 
1989]. 
 
Although worldwide survival is still poor [Telfer 2009], life expectancy is approaching 
normal in some higher income countries with regular blood transfusion and well-managed 
iron chelation therapy [Borgna-Pignatti 2004, Telfer 2006]. In most cases, cardiac siderosis is 
both preventable and reversible with modern chelation regimes [Miskin 2003, Anderson 
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2004]. A dramatic 71% decrease in deaths has been observed in the UK thalassaemia cohort 
since the introduction of improved chelation and the routine use of CMR T2* [Olivieri 1994, 
Modell 2000, Modell 2008a]. Whilst cardiac T2* has a strong prognostic value in the UK 
cohort [Kirk 2009], there is limited data on the burden of cardiac iron loading or the 
application of CMR T2* in different parts of the world. We therefore decided to perform a 
worldwide survey of centres that regularly use T2* to assess its clinical application and the 
degree of iron loading.  
 
10.2 METHODS 
10.2.1 Recruitment of sites 
The Royal Brompton CMR unit has assisted many centres around the world develop 
independent T2* measurement for thalassaemia patients. Sites were identified from the list of 
centres where our unit has helped to install the T2* sequence and others were identified from 
specialist international meetings in the field of cardiology and haematology. The lead 
clinician in each centre was approached by email. 65 worldwide centres were invited to 
participate and 60 replies were received, of which, 13 declined the invitation for a variety of 
reasons (such as difficulty in collating the information required, incomplete data or 
insufficient numbers of TM patients). In total, of the 47 centres which showed an interest in 
taking part, 34 completed surveys were returned with full information (representing a 
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10.2.2 Baseline data collection 
Each centre was asked for baseline data regarding total numbers of TM patients who had 
undergone T2* CMR scans. For the first scan, the distribution of severity of iron loading was 
evaluated using tertiles of T2* values as follows: 1) T2* between 0 and10ms; 2) T2* between 
10 and 20ms; and 3) T2* greater than 20ms. We also asked for further information about 
patients at the time of their first scan namely, a) the proportion of patients who were taking 
iron chelation, b) the proportion who had been on iron chelation for greater than 5 years and 
c) the total number of patients who were in heart failure at the time of this first scan. For the 
purposes of this study, cardiac failure was defined as symptoms (such as breathlessness) or 
signs of cardiac failure associated with objective evidence of ventricular dysfunction at rest 
(defined as reduced left ventricular ejection fraction <56% measured by CMR). This cutoff 
value was derived from the lower limit of the normal range for LV ejection fraction in TM 
patients [Westwood 2007]. 
 
10.2.3 Cardiovascular outcomes 
To assess the usefulness of T2* measurements in predicting patients who went on to develop 
cardiovascular complications, we asked each centre to identify those patients who had either 
died of cardiac causes or who had subsequently developed heart failure (using the criteria 
defined above). We related date of death or onset of heart failure to the date of the most 
recent T2* scan. 
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10.2.4 CMR parameters 
Myocardial T2* decay was derived from a multi-echo gradient echo sequence with a range of 
echo times (TE). It has previously been shown that this measurement is robust and 
transferable between scanners and across multiple different vendor platforms (including 
Siemens, Philips and GE) [Kirk 2010]. However, the absolute CMR sequence parameters 
(such as exact TE spacing and minimum achievable TE) varied between scanners and sites 
due to differences in gradient strength, slew rate and hardware capability. All T2* 
measurements were performed by experienced operators at each of the sites using a single 
mid-ventricular short axis slice with a region of interest (ROI) in the septum as previously 
described. To derive T2*, signal intensity was plotted for each TE and a decay curve 
generated of the form SI = SIo · exp (-TE/T2*) where SI = signal intensity, SIo = signal 
intensity at time zero and TE = echo time. A curve truncation model was used to correct for 
background noise [He 2008a]. In each case, left ventricular ejection fraction was calculated 
using a standardised protocol from a stack of equally spaced short-axis cine slices [Maceira 
2006a]. 
 
The study protocol was reviewed by the local research ethics committee. A waiver of 
informed consent was approved for the anonymous data collection associated with this 
project. Local institutional review board approval was granted at each of the centres involved. 
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10.2.5 Statistics 
All data were analysed using STATA version 10.1 (StataCorp, Texas, USA). Regional 
differences in iron loading were assessed using one way ANOVA and Kruskal Wallis tests. 
Linear regression analysis was performed to assess association between variables. A value of 
P < 0.05 was used to define a significant difference. 
 
10.3 RESULTS 
10.3.1 Worldwide use of T2* 
Data were analysed from all centres that returned completed survey results (34 in total). The 
results presented include a total of 3410 TM patients from Europe, the Middle East, North 
America, South America, North Africa, Australia and Asia. A full list of sites and patient 
numbers is given in table 10.1. All patients were included in the analysis of baseline T2* 
values but, for two of the sites, there was insufficient clinical outcome data available 
regarding heart failure and deaths. Therefore, patients from these sites were excluded from 
this part of the analysis. 
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Table 10.1. List of participating centres 
Continent Country Hospital and City 
Number of 
patients 
Africa Egypt Cairo University Hospital 111 
 Egypt Ain Shams University Hospital, Cairo 107 
Australasia Australia Royal Prince Alfred Hospital, Sydney 17 
Europe UK  Royal Brompton Hospital, London* 640 
 Italy Ospedali Galliera di Genova 92 
 Italy Ospedale Regionale Microcitemie, Cagliari 315 
 Greece Aghia Sophia Children’s Hospital, Athens 318 
 Greece General Hospital of Piraeus, Athens, Greece 112 
 Greece Hippokration General Hospital, Thessaloniki 121 
 Corfu General Hospital of Corfu 30 
 Portugal University Hospital Santa Maria, Lisbon 53 
 Bulgaria National Centre of Haematology, Sofia 29 
 Italy University of Milan 129 
 Cyprus Makarios III Hospital, Nicosia 54 
 France Hôpital d'enfants de la Timone, Marseille 55 
Middle East Saudi Arabia King Fahad Armed Forces Hospital, Jeddah 20 
 Oman Sultan Qaboos University, Muscat 104 
 UAE Thalassemia Center, Al Wasl Hospital, Dubai 66 
 Israel Sheba Medical Center, Tel Hashomer 34 
North America Canada Hospital for Sick Kids, Toronto 19 
 USA St Jude’s Hospital, Memphis 11 
 USA Children’s Memorial Hospital, Chicago 58 
 USA Children’s Hospital of Philadelphia 47 
South America Brazil University of Campinas 61 
 Brazil Albert Einstein Hospital, São Paolo 141 
South-East Asia Hong-Kong Prince of Wales Hospital, Shatin 52 
 Hong Kong University of Hong Kong, Queen Mary Hospital 180 
 Malaysia Ampang Hospital, Kuala Lumpur 9 
 Malaysia University Malaya Medical Centre, Kuala Lumpur 45 
 Indonesia University of Indonesia, Jakarta 10 
 Taiwan National Taiwan University Hospital, Taipei 34 
 Singapore KK Women’s and Children’s Hospital, Singapore 156 
Western Asia Turkey Ege Univeristy Medical Faculty, Izmir 147 
 Turkey Hacettepe Medical University, Ankara 33 
 
*Includes referrals from 21 UK haematology centres. UK – United Kingdom, UAE – United 
Arab Emirates, USA – United States of America, KK - Kandang Kerbau.  
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10.3.2 Baseline findings at first scan 
The baseline T2* values revealed that 57.5% of patients had no significant iron loading (T2* 
> 20ms), 22.6% had moderate cardiac iron (10ms < T2* ≤ 20ms) and 19.9% had severe 
cardiac iron loading (T2* ≤ 10ms) (figure 10.1). Overall therefore, 42.5% of patients had a 
T2* value below 20ms. The prevalence of moderate myocardial iron loading (T2* < 20ms) 
varied significantly between regions with the lowest level being found in patients from Egypt 
(Cairo) and the highest in South-East Asia (P = 0.033). A similar distribution was found with 
regards to the prevalence of severe iron loading (T2* <10ms), again with significant regional 
differences (P = 0.013). A full breakdown of regional variation is shown in table 10.2 and 
figures 10.2 and 10.3. A very high percentage (96.8%) of patients undergoing their first T2* 
scan were taking regular iron chelation medication and 93.2% had been taking chelation 
therapy for over 5 years. 
 
Figure 10.1. Baseline T2* values. The pie chart shows the proportion of patients with T2* 
values below 10ms (red, 19.9%), between 10 and 20ms (orange, 22.6%) and greater than 
20ms (green, 57.5%). 42.5% of the 3410 patients have a T2* value of below 20ms. 
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Figure 10.2. Iron loading by region. Percentage of patients with moderate (blue bars, 
T2*<20ms) and severe (red bars, T2*<10ms) cardiac siderosis at baseline scan. Data are 
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Table 10.2. Regional differences in iron loading. 
Region 
Percentage of patients with T2* <20ms 
(%) 
Percentage of patients with T2* <10ms 
(%) 
N Africa (Egypt) 24.8 9.6 
N America 30.4 13.3 
S America 32.2 18.3 
Australia 35.3 11.8 
Europe 43.5 19.1 
W Asia (Turkey) 43.9 23.9 
Mid East 46.3 20.0 
SE Asia 52.7 29.2 
P value* 0.033 0.013 
 
*One-way ANOVA was used to compare regional differences for T2* values <20ms but due 
to unequal variances, a Kruskal Wallis test was used to compare differences for values 
<10ms. 
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Figure 10.3. World map showing severity of myocardial iron loading at first scan. The colour 
scale represents the percentage of patients in each region who have severe myocardial iron 
loading with T2* values <10ms. 
 
 
10.3.3 Prevalence of heart failure at first scan and T2* distribution 
For 214 of the 3410 patients, there was inadequate information available from the clinical 
records to allow the centres to make an accurate diagnosis of heart failure. Therefore, these 
patients were excluded from the heart failure analysis. For the remaining 3196 patients, 105 
(3.1%) had confirmed heart failure at the time of the first scan with NYHA class II or above 
symptoms and evidence of ventricular dysfunction at rest (LV ejection fraction <56% by 
CMR). The majority of these patients (76.2%) had T2* values below 10ms with almost all 
patients (98.0%) having T2* values less than 20ms. See figure 10.4a. 
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10.3.4 New onset heart failure 
In the cohort of patients who did not have heart failure at the first scan (n=3091), there were 
115 (3.7%) who subsequently developed heart failure. A high majority of these patients 
(92.0%) had T2* values below 10ms. All patients who went on to develop heart failure had a 
myocardial T2* of below 20ms (figure 10.4b). There was no relationship between myocardial 
T2* and time to onset of heart failure (R
2
 = 0.01, p = 0.34). 
 
10.3.5 Deaths 
There were 38 deaths in total. The distribution of T2* values showed that the majority 
(79.0%) were once again less than 10ms with 95.0% below 20ms. There were two outliers 
with high T2* values (23.6ms and 24.1ms). In each case, it was confirmed that the primary 
cause of death was cardiac failure and the scan images were reviewed to check the T2* 
measurement. No problems with T2* measurement were identified. See figure 10.4c. There 
was no relationship between T2* and time to death (R
2
 = 0.002, p = 0.78). 
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Figure 10.4. Distribution of T2* values. a) Histogram of T2* values for patients with heart 
failure at first scan. b) Histogram of T2* values for patients who have developed new onset 
heart failure subsequent to their initial CMR scan. c) Histogram of T2* values for patients 
who died of cardiac causes. In each case, the broken red line represents a T2* value of 10ms. 
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10.4 DISCUSSION 
We have surveyed a total of 3410 patients which represents 9% of the WHO estimate of the 
37866 patients worldwide who receive chelation therapy [Modell 2008b]. This is a highly 
selected population of TM patients and represents just the tip of the iceberg of the worldwide 
burden of disease. Thalassaemia occurs in a broad belt across the world from the 
Mediterranean to South East Asia where the prevalence is particularly high but low numbers 
have access to transfusion and adequate iron chelation according to WHO data (see 
Introduction, table 2.2). This is reflected in our findings which reveal a high proportion of 
patients in South East Asia with high cardiac iron loading according to baseline CMR T2* 
results. Therefore, even in this well-treated cohort with access to advanced cardiac imaging 
using CMR, there is a high prevalence of moderate and severe cardiac iron loading and the 
results might be extrapolated to the wider population.  
 
It has been shown that T2* is strongly prognostic for the development of heart failure, 
particularly with T2* values below 10ms [Kirk 2009]. This observation is supported by the 
data we have presented here but in the ‘real-world’ situation, the arbitrary cut-off of 10ms is 
not as strongly demarcated and there are patients who both develop cardiac failure and die 
from cardiac causes with T2* values above this level. Genetic difference in the susceptibility 
to myocardial damage that results from iron overload could be one reason for this with 
certain populations being relatively protected. There may also be differences between sites in 
attributing symptoms of breathlessness to cardiac failure. Many TM patients experience a 
degree of breathlessness due to their anaemia in the immediate pre-transfusion period which 
then resolves following transfusion. In this study, there were only a small number of deaths 
(1.1% of the total population surveyed) and once again, the majority of patients who died had 
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T2* values below 10ms but there were 3 notable exceptions who had T2* values of over 
20ms. These deaths from cardiac causes in patients with no demonstrable cardiac iron by T2* 
could potentially be explained by another underlying cause of cardiac failure such as 
fulminant myocarditis which is known to contribute to the development of heart failure in 
thalassaemia [Kremastinos 1995]. 
 
In 2006, the WHO declared thalassaemia a public health priority but inequalities in provision 
and access to treatment still exist. In one recent study of 135 TM patients in India, over one 
third were not either in education or paid employment and only one patient was over the age 
of 45 [Mallik 2010]. Most families were spending up to 20% of their yearly income on 
treatment for thalassaemia and although blood was mostly available free of charge, 
expenditure associated with transfusion alone included hospital fees, medical equipment and 
travel costs. Although the CMR manufacturers have begun to introduce basic machines with 
lower installation and running costs (such as the Siemens Essenza), this investigation still 
remains out of reach of the majority of the patients with TM. 
 
These findings provide an invaluable insight into the burden of disease and the effects of 
cardiac iron overload worldwide. With the best available medical therapy and management, it 
is possible to prolong survival with a good quality of life, allowing each TM patient to 
contribute fully to society. However, improving survival in TM on a worldwide scale will 
require a major coordinated effort, particularly in low-income countries to provide better 
equality of access to expert medical care, transfusion, affordable chelation therapy and 
monitoring. 
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10.4.1 Limitations 
The main limitation of this study involved the clinical confirmation of heart failure. In some 
centres, there was not enough clinical data available to allow accurate diagnosis of heart 
failure and therefore, it was not possible to analyse the T2* values with respect to heart 
failure in these patients. This resulted in the exclusion of 214 patients from this part of the 
analysis. Due to the large numbers involved, we were unable to obtain the T2* scan results 
and dates for all 3410 patients and therefore, we have been unable to perform a full survival 
analysis. The patients are from a mixture of ethnic backgrounds and it is possible that genetic 
differences may contribute to varying levels of cardiac iron and different degrees of risk 
associated with myocardial siderosis. As well as this, there may be a degree of selection bias 
based on the fact that not all patients have access to CMR and that those who do are likely to 
be highly motivated and well managed. All of the T2* measurements were made by 
individual observers in each of the centres surveyed. Only if there were inconsistencies did 
we ask for anonymised DICOM data in each case to review the scan quality and assessment 
of T2*. Therefore, it is possible that there may have been some systematic errors in the 
measurement of T2*. Having said this, the technique is known to be highly robust with an 
excellent interobserver, interstudy, interscanner and intercentre reproducibility [Anderson 
2001, Westwood 2003a, 2003b, Tanner 2006b, Kirk 2010]. We have restricted our T2* 
measurements to a region of interest in the interventricular septum of a mid-ventricular slice. 
This is the most widely accepted technique although other groups have suggested that there is 
some heterogeneity of iron loading, especially in the setting of previous Hepatitis C infection 
[Pepe 2006b]. Where T2* is not restricted to a septal ROI, artefact can markedly affect the 
measurements obtained [Anderson 2001, Wacker 1999]. 
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10.5 CONCLUSION 
From the data which we have presented, it is clear that there is a substantial degree of severe 
cardiac iron loading even in TM patients who are regularly transfused and on iron chelation 
therapy. As already mentioned, this represents only the privileged few and there are likely to 
be many thousands of patients who do not have access to even basic levels of medical care.  
 
10.5.1 Acknowledgements 
This work was supported by the National Institutes for Health Research Cardiovascular 
Biomedical Research Unit of Royal Brompton and Harefield NHS Trust and Imperial College 
London. 
 
We would like to thank the following for their participation at the different sites involved in 
this study: Taigang He, Paul Kirk, Winston Banya (Royal Brompton and Harefield NHS 
Foundation Trust and National Heart and Lung Institute, Imperial College London), Lisa J 
Anderson (St George’s Hospital NHS Trust, London), John B Porter and J Malcolm Walker 
(University College Hospitals NHS Trust, London), Renzo Galanello and Fabrice Danjou
 
(Ospedale Regionale Microcitemie, Cagliari, Italy), Gianluca Forni
 
(Ospedali Galliera di 
Genova, Genoa, Italy), Antonis Kattamis and Vassilis Ladis (Aghia Sophia Children’s 
Hospital, Athens, Greece), Marouso Drossou and Demetra Vini (General Hospital of 
Piraeus, Athens, Greece), Andreas Michos (General Hospital of Corfu, Corfu), Vassilios 
Perifanis (Hippokration General Hospital, Thessaloniki, Greece), Tuncay Hazirolan 
(Hacettepe Medical University, Ankara, Turkey), Ana Almeida (University Hospital Santa 
Maria, Lisbon, Portugal), Yesim Aydinok (Ege Univeristy Medical Faculty, Izmir, Turkey), 
Chapter 10 Page 195 Worldwide Survey 
 
Mirella Rangelova (National Centre of Haematology, Sofia), Amal El-Beshlawy (Cairo 
University Hospital), Mohsen Elalfy (Ain Shams University Hospital, Cairo), Ibrahim Al-
Nasser (King Fahad Armed Forces Hospital, Jeddah), Wing Au and Shau-Yin Ha (University 
of Hong Kong, Queen Mary Hospital), Chi-Kong Li (Prince of Wales Hospital, Shatin), Lee-
Lee Chan (University Malaya Medical Centre, Kuala Lumpur), Meng-Yao Lu (National 
Taiwan University Hospital, Taipei), Lia Wahidiyat (University of Indonesia, Jakarta, 
Indonesia), Manuela Merelles-Pulcini (Hospital for Sick Kids, Toronto), Juliano de Lara 
Fernandes (University of Campinas, Brazil), Fernando Kay (Albert Einstein Hospital, São 
Paolo, Brazil), Joy Ho (Royal Prince Alfred Hospital, Sydney), Jane Hankins (St Jude’s 
Hospital, Memphis, USA), Maria Cappellini (University of Milan, Italy), Shahina Daar 
(Sultan Qaboos University, Muscat, Oman), Jameela Sathar (Ampang Hospital, Kuala 
Lumpur), George Kontoghiorges (Makarios III Hospital, Nicosia), Khawla Belhoul 
(Thalassemia Center, Al Wasl Hospital, Dubai, UAE), Alexis Thompson (Children’s 
Memorial Hospital, Chicago), Eli Konen (Sheba Medical Center, Tel Hashomer, Israel), 
Janet Kwiatkowski (Children’s Hospital of Philadelphia, USA), Ru-San Tan (KK Women’s 
and Children’s Hospital, Singapore), Isabelle Thuret and Catherine Badens (Hôpital 
d'enfants de la Timone, Marseille). 
 
This data has been presented at the SCMR / EuroCMR Joint Scientific Sessions 2011: 
Carpenter JP, He T, Kirk P, Anderson L, Porter JB, Walker JM, Galanello R, Danjou F, Forni 
G, Kattamis A, Ladis V, Drossou M, Vini D, Michos A, Perifanis V, Hazirolan T, Almeida 
A, Aydinok Y, Rangelova M, El-Beshlawy A, Elalfy M, Alnasser I, Daar S, de Lara 
Fernandes J, Pennell DJ. Worldwide survey of T2* cardiovascular magnetic resonance in 
Thalassaemia. J Cardiovasc Magn Reson 2011; 13(Suppl1): O15 (oral presentation). 
Chapter 11 Page 196 Conclusions 
 
CHAPTER 11: CONCLUSIONS 
11.1 OVERVIEW OF THESIS 
The aim of this thesis was to provide a detailed investigation of the pattern and effects of 
myocardial iron loading. The studies have approached this systematically under three main 
subheadings, firstly looking at the distribution of iron and magnetic resonance relaxation 
parameters in post-mortem hearts, then the effects of iron on the right ventricle and 
concluding with a worldwide multicentre assessment of the T2* technique. 
 
11.1.1 Cardiac Iron Distribution 
Although there have been studies looking at myocardial iron loading in transfusion-
dependent anaemia, none have given a detailed account of iron distribution throughout the 
heart. This has important consequences for a technique such as CMR T2* which relies on a 
measurement taken from a region of interest in a mid-septal slice to give an estimation of 
global myocardial iron. Chapter 5 demonstrated that iron is deposited with a homogeneous 
distribution throughout the left ventricle, although there is a transmural gradient that is not 
important clinically provided that full-thickness regions of interest are used for measurement 
of T2*. Moreover, the iron concentration measured in a mid-septal slice is highly 
representative of whole-heart iron concentration. 
 
11.1.2 Measurement of Cardiac Iron using CMR 
Until now, the use of CMR T2* for the non-invasive measurement of myocardial iron has 
been based solely on first principles and clinical observation. There is an increasing number 
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of iron chelation trials which use CMR T2* as a surrogate endpoint for cardiovascular 
outcome based on its ease of use, robust nature and strong prognostic value [Kirk 2009]. For 
example, in a randomised controlled trial, deferiprone has been shown to be more effective at 
removing cardiac iron than deferoxamine [Pennell 2006]. Chapter 6 provided a detailed 
calibration of T2* against biochemically derived myocardial iron concentration. Combined 
with the fact that both mid-septal iron and mid-septal T2* are highly representative of their 
respective global values, this validates the technique in current clinical use. Previously, the 
use of T2 for the assessment of myocardial iron has proved challenging but recent 
developments in CMR sequences have allowed reliable, reproducible in vivo T2 
measurement [He 2006, 2008c].  As described in Chapter 7, we found a direct relationship 
between T2 and tissue iron concentration. Although myocardial T2* does not appear to be 
significantly affected by formalin fixation, the calibration we have quoted for T2 needs to be 
interpreted with caution as T2 shortens slightly with time. The situation with T1 is altogether 
different as it is significantly altered by formalin fixation. Therefore, although there was a 
weak relationship between T1 and tissue iron in hearts which had been in formalin for under 
10 weeks, the measurement of T1 in post-mortem hearts was deemed unreliable and a 
definitive calibration could not be given. 
 
11.1.3  The Effects of Iron on the Right Ventricle  
The consequences of myocardial siderosis for the left ventricle have been well studied. It is 
known that increasing iron loading is associated with a progressive decline in ejection 
fraction [Anderson 2001] and that the normal expected ranges for LV volumes and function 
in patients with transfusion-dependent anaemia differ from the healthy, non-transfused 
population [Westwood 2007]. Chapter 8 described the relationship between iron loading and 
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ventricular function for the right ventricle. In a much larger cohort than the original study 
looking at the LV, we found a parallel between LV and RV parameters with both ventricles 
being affected in the same way by increasing myocardial iron concentrations (as measured by 
CMR T2*). The decline in RV function with increasing iron has the potential to be used for 
further studies of iron chelators looking at the relation between T2* measured in the mid 
septum and right ventricular function, an area which has not previously been addressed. 
Chapter 9 confirmed the clinical impression that RV volumes, ejection fraction and other 
cardiac indices would be different in the population of patients with transfusion-dependent 
TM when compared to normal, healthy volunteers. Although the differences are not as 
pronounced as for the LV, the findings have important implications for monitoring and 
follow-up of transfusion-dependent patients. 
 
11.1.4 Worldwide use of CMR T2* 
The worldwide multicentre survey of T2* use revealed some important findings. In Chapter 
10, the results of T2* scans in a large cohort of 3410 TM patients were presented. A striking 
42.5% of patients showed evidence of myocardial siderosis and low T2* values were 
associated with heart failure and death, confirming UK findings. Although the WHO 
designated β-thalassaemia major as a world health priority, many patients have no access 
even to transfusion, let alone chelation therapy or advanced monitoring techniques such as 
CMR. This makes it even more important to redouble efforts towards producing low-cost 
treatment and monitoring options which have the potential to save many thousands of lives 
and prolong survival. 
 
Chapter 11 Page 199 Conclusions 
 
11.2 CONCLUSION 
The study of iron and its effects on the heart has come a long way from the initial autopsy 
studies through to the development of the T2* technique. The initial MR observation that the 
liver and bone marrow appeared dark in patients with TM started the search for a quantitative 
method of non-invasive iron measurement. With progressive refinements and the 
development of improved scanner hardware, the acquisition of a T2* sequence can now be 
completed in a short breath-hold and analysis takes a few seconds to perform. T2* has been 
shown to be highly reliable and reproducible between different observers and across different 
scanner platforms throughout the world. We have now validated the technique and have 
shown that T2* is a true representation of myocardial tissue iron. In conclusion, CMR T2* is 
a prime example of translational research which has developed from the initial studies based 
on the first principles of the physical properties of iron, through clinical observation and 
rigorous research to a fully implemented, proven technique with a highly beneficial impact on 
patient survival. 
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CHAPTER 12: FUTURE DIRECTIONS 
12.1 FUTURE AREAS OF RESEARCH 
12.1.1 Genetic determinants of iron loading 
Since the first study of myocardial T2*, it has been noted that while some patients have 
severe iron loading in the liver with no iron in the heart, others have the opposite with severe 
cardiac and no liver iron. Using an extremes-of-phenotype model, patients will be recruited 
from UK Thalassaemia centres to investigate the underlying genetic determinants for this 
difference in iron loading. Genetic analysis will be performed to see if any mutations or 
single nucleotide polymorphisms (SNPs) are associated with the iron loading phenotypes. 
State-of-the-art techniques including exon capture and massively parallel high-throughput 
next generation sequencing will be used. The required gene sequencing equipment is in place 
as part of the Cardiovascular Biomedical Research Unit (BRU) at the Royal Brompton 
Hospital and over 80 patients have been recruited so far. Bioinformatic support is available 
through Imperial College with the recent appointment of a dedicated bioinformatician in the 
BRU. Once potential disease-causing mutations have been identified, the findings will be 
checked in a replication cohort. Collaboration has been agreed between our centre and 
investigators in Italy and USA. 
 
12.1.2 Validation of T2* at 3 Tesla 
Many centres throughout the world are now using magnetic resonance scanners with the 
higher field strength of 3 Tesla. The calibration we have performed and the clinical T2* 
measurements only apply for a field strength of 1.5T. There are differences in T2* decay at 
higher field strengths and work is required to validate measurements at 3T. A new 3T 
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Siemens Skyra CMR scanner is being installed in the BRU at the Royal Brompton Hospital. 
We therefore have the ideal opportunity to recruit patients when they attend for routine 
clinical assessment and parallel scans can be performed at both field strengths. 
 
12.1.3 Short bore CMR systems and T2* 
Manufacturers have started to produce simpler CMR systems (such as the Siemens Essenza) 
which have lower installation and running costs. These scanners have a shorter magnet bore 
and as a result, there is a smaller central region where the magnetic field is at its most 
homogeneous. T2* decay is very sensitive to magnetic field inhomogeneity and this feature is 
exploited for the measurement of cardiac and hepatic iron. Such short bore systems will need 
to be evaluated before they can be recommended for clinical T2* scanning and a project in 
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AV – atrioventricular 
BRU – biomedical research unit 
BSA – body surface area 
CMR – Cardiovascular magnetic resonance 
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ECG – electrocardiograph 
EDV – end diastolic volume 
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EMB – endomyocardial biopsy 
ESV – end systolic volume 
FID – free induction decay 
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